

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2018368541 B2**

- (54) Title  
**Potentiating the effect of ATP release**
- (51) International Patent Classification(s)  
**C07K 16/40** (2006.01)      **A61P 35/00** (2006.01)  
**A61K 31/282** (2006.01)      **C07K 16/28** (2006.01)  
**A61K 39/395** (2006.01)
- (21) Application No: **2018368541**      (22) Date of Filing: **2018.11.15**
- (87) WIPO No: **WO19/096900**
- (30) Priority Data
- |                   |                   |              |
|-------------------|-------------------|--------------|
| (31) Number       | (32) Date         | (33) Country |
| <b>62/733,175</b> | <b>2018.09.19</b> | <b>US</b>    |
| <b>62/586,224</b> | <b>2017.11.15</b> | <b>US</b>    |
| <b>62/686,149</b> | <b>2018.06.18</b> | <b>US</b>    |
- (43) Publication Date: **2019.05.23**  
(44) Accepted Journal Date: **2025.06.12**
- (71) Applicant(s)  
**Orega Biotech SAS;Innate Pharma**
- (72) Inventor(s)  
**CHANTEUX, Stéphanie;GOURDIN, Nicolas;PATUREL, Carine;PERROT, Ivan;ROSSI, Benjamin**
- (74) Agent / Attorney  
**Blue Penguin IP Ltd, C/- Connected Accountants Limited Level 1, South British Building 326 Lambton Quay, Wellington, 6011, NZ**
- (56) Related Art  
**WO 2017/089334 A1**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau



(10) International Publication Number

WO 2019/096900 A1

(43) International Publication Date  
23 May 2019 (23.05.2019)

(51) International Patent Classification:

*A61K 39/395* (2006.01) *C07K 16/40* (2006.01)  
*A61K 31/282* (2006.01) *A61P 35/00* (2006.01)  
*C07K 16/28* (2006.01)

13008 Marseille (FR). **PATUREL, Carine**; 411 Allée du Bois, 69280 Marcy l'Etoile (FR). **PERRON, Ivan**; Impasse des Brayes Résidence les Brayes, bâtiment la Chaconne, 13260 Cassis (FR). **ROSSI, Benjamin**; 70 Avenue d'Haifa Résidence la Palmeraie, Bt C, 13008 MARSEILLE (FR).

(21) International Application Number:

PCT/EP2018/081364

(74) Agent: **VOLLMY, Lukas**; INNATE PHARMA, 117 Avenue de Luminy, 13009 MARSEILLE (FR).

(22) International Filing Date:

15 November 2018 (15.11.2018)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/586,224 15 November 2017 (15.11.2017) US  
62/686,149 18 June 2018 (18.06.2018) US  
62/733,175 19 September 2018 (19.09.2018) US


(71) Applicant: INNATE PHARMA [FR/FR]; 117 Avenue de Luminy, 13009 Marseille (FR).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: POTENTIATING THE EFFECT OF ATP RELEASE

Figure 13

Oxa Repeated Injections d5, d12



(57) Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.

WO 2019/096900 A1

[Continued on next page]



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

## POTENTIATING THE EFFECT OF ATP RELEASE

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos. 62/586,224 filed 15 November 2017, US 62/686,149 filed 18 June 2018 and US 62/733,175 filed 19 September 2018; all of which are incorporated herein by reference in their entireties; including any drawings.

### REFERENCE TO SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled "CD39-8\_ST25", created 14 November 2018, which is 64 KB in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

### FIELD OF THE INVENTION

This invention relates to the use of CD39 neutralizing agents for the treatment of cancer.

### BACKGROUND OF THE INVENTION

NTPDase 1 (ectonucleoside triphosphate diphosphohydrolase1), also known as CD39/ENTPD1 or vascular CD39, functions together with another enzyme, CD73 (ecto-5'-nucleotidase), to hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system. The generation of adenosine via the CD73/CD39 pathway is recognized as a major mechanism of regulatory T cell (Treg) immunosuppressive function. CD39 has two transmembrane domains near the N- and C-terminal ends, short cytoplasmic N- and C-terminal segments, and a large extracellular domain containing the active site. However, while CD39 is typically anchored to the membrane by the two transmembrane domains at the two ends of the molecule, it has recently also been reported that a soluble catalytically active form of CD39 can be found in circulation in human and mice (Yegutkin et al., (2012) FASEB J. 26(9): 3875-3883).

Radiotherapy and some chemotherapeutic agents have been shown to induce specific immune responses resulting in immunogenic cancer cell death (Martins et al. 2009 Cell Cycle 8(22): 3723-3728). An anti-tumor immune response induced by such treatments

depends on the capacity of dendritic cells (DC) to present antigen from dying cancer cells and to prime tumor-specific cytotoxic T lymphocytes (CTL). To mount a CTL response, DC must incorporate antigens from stressed or dying cells, acquire the competence of antigen processing in a maturation step and present antigenic peptides bound to MHC molecules in the context of costimulatory signals and cytokines that stimulate the differentiation/activation of specific CTL.

There remains, however, a need to improve the efficacy of current therapies designed to eliminate cancer cells, including radiotherapy and chemotherapeutic agents.

### SUMMARY OF THE INVENTION

The present invention arises, *inter alia*, from the discovery that antibodies that neutralize the ATPase activity of the CD39 protein in the presence of significant concentrations of ATP are able to reverse the immunosuppressive effect of CD39 in dendritic cells (DCs) in the presence of exogenously added ATP. The antibodies are furthermore able to induce or increase the proliferation of T cells co-cultured with the DCs. The ability to reduce the CD39-mediated inhibition of DC activation provides an advantageous use of antibodies in combination with agents or treatments that induce the extracellular release of ATP from tumor cells, notably agents or treatments that induce immunogenic cancer cell death, e.g., agents or treatments that induce the death of tumor cells (*inter alia*, chemotherapeutic agents, radiotherapy). While the ATP release has the potential to be immunogenic and promote DC activation, it can also be subject to catabolism by CD39, in turn suppressing the immunogenic effect of the extracellular ATP. Furthermore, during chemotherapy increased levels of ATP are associated with higher expression of CD39 on DCs. Within an ATP-enriched tumor microenvironment, infiltrating DCs may contribute to ATP degradation by modulating CD39 expression, in turn decreasing the chemotherapy-induced immunogenic tumor cell death. Combined use with the anti-CD39 antibodies thus permits the potentiation of the immunogenic effect of agents or treatments that induce the death (e.g., apoptosis or necrosis) of tumor cells.

Accordingly, in one aspect the present invention relates to method of treating a tumor in a human individual, the treatment comprising administering to the individual an effective amount of each of: (a) an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of ATP, wherein the antibody comprises a HCDR1 comprising an amino acid sequence DYNMH (SEQ ID NO: 5); a HCDR2 comprising an amino acid sequence YIVPLNGGSTFNQKFKG (SEQ ID NO: 6); a HCDR3 comprising an amino acid sequence GGTRFAY (SEQ ID NO: 7); a LCDR1 comprising an amino acid sequence RASESVDNFGVSMY (SEQ ID NO: 8); a LCDR2 region comprising an amino

acid sequence GASNQGS (SEQ ID NO: 9); and a LCDR3 region comprising an amino acid sequence QQTKEVPYT (SEQ ID NO: 10), and (b) a platinum agent, wherein the antibody and the platinum agent are each administered for at least one administration cycle, the administration cycle comprising at least a first and second administrations of the antibody and the platinum agent.

In another aspect the invention relates to the use of (a) an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of ATP, wherein the antibody comprises a HCDR1 comprising an amino acid sequence DYNMH (SEQ ID NO: 5); a HCDR2 comprising an amino acid sequence YIVPLNGGSTFNQKFKG (SEQ ID NO: 6); a HCDR3 comprising an amino acid sequence GGTRFAY (SEQ ID NO: 7); a LCDR1 comprising an amino acid sequence RASESVDNFGVFSFMY (SEQ ID NO: 8); a LCDR2 region comprising an amino acid sequence GASNQGS (SEQ ID NO: 9); and a LCDR3 region comprising an amino acid sequence QQTKEVPYT (SEQ ID NO: 10), and (b) a platinum agent, in the manufacture of a medicament for treating a tumor in a human individual, wherein the antibody and the platinum agent are each administered for at least one administration cycle, the administration cycle comprising at least a first and second administrations of the antibody and the platinum agent.

Certain statements that appear below are broader than what appears in the statements of the invention above. These statements are provided in the interests of providing the reader with a better understanding of the invention and its practice. The reader is directed to the accompanying claim set which defines the scope of the invention.

Disclosed herein are improved methods of enhancing an anti-tumor immune response, via the use of antibodies that bind and neutralize CD39 in the presence of ATP, in combination with an agent or treatment that induces the death of tumor cells, e.g., an agent or treatment that is capable of inducing the extracellular release of ATP from tumor cells, an agent or treatment that induces immunogenic cancer cell death. Also described herein are improved methods of enhancing an anti-tumor immune response, via the use of antibodies that are capable of binding and neutralizing CD39 in the presence of ATP, in combination with a means for inducing the death of tumor cells, e.g., a means for inducing apoptosis and/or the extracellular release of ATP from tumor cells. In one embodiment, the agent or treatment (or means) that is capable of inducing the extracellular release of ATP from tumor cells comprises an anthracycline, an oxaliplatin, a cisplatin, X-rays, a PARP inhibitor, a taxane, an anthracycline, a DNA damaging agent, a camptothecin, an epothilone, a mytomycin, a combretastatin, a vinca alkaloid, a nitrogen mustard, a maytansinoid, a calicheamycin, a duocarmycin, a tubulysin, a dolastatin, an auristatin, an enediyne, an amatoxin, a pyrrolobenzodiazepine, an ethylenimine, a radioisotope, a therapeutic protein or

2018368541 26 May 2025

peptide toxin, or an antibody that binds an antigen expressed by a tumor cell and that mediates ADCC. In one embodiment, the antibody that is capable of binding and neutralizing CD39 is capable of neutralizing the activity of both soluble extracellular domain CD39 protein (sCD39) and membrane-bound CD39 protein (memCD39). As shown herein, the antibodies that are able to reverse the immunosuppressive effect of CD39 in dendritic cells (DCs) in the presence of exogenously added ATP are also characterized by being capable of neutralizing the activity of both soluble extracellular domain CD39 protein (sCD39) and membrane-bound CD39 protein (memCD39). Notably, antibody BY40 which is unable to reverse the immunosuppressive effect of CD39 in dendritic cells (DCs) in the presence of exogenously ATP is also unable to neutralize the ATPase activity of soluble extracellular domain CD39 protein (sCD39) and has a lower maximal inhibition of membrane-bound CD39 protein (memCD39) ATPase activity.

Without wishing to be bound by theory, it is believed that antibodies that neutralize membrane-bound CD39 at the cell surface operate by inhibiting the domain motion of membrane-bound CD39 (memCD39), however without similarly affecting the activity of the soluble CD39 protein (sCD39). It has been reported that memCD39 occurs as homo-multimers (e.g., tetramers and/or other multimers, in addition to monomeric forms) while sCD39 is a monomer, and moreover that the transmembrane domains in memCD39 undergo dynamic motions that underlie a functional relationship with the active site (Schulte am Esch et al. 1999 Biochem. 38(8):2248-58). Antibodies that block only memCD39 may recognize CD39 outside of the enzyme active site and prevent multimerization without blocking the monomeric form of CD39. Blockade of multimerization may reduce enzyme activity, and it has been reported that CD39 multimerization substantially augments ATPase activity. In contrast, antibodies that also block sCD39 may interfere with CD39 substrate and inhibit monomeric form of the enzyme. Such antibodies may also prevent multimerization of memCD39, thus providing a second mechanism of inhibition of the enzymatic activity of CD39. In the presence of ATP (e.g., as in the tumor environment), partial inhibition of CD39 by prevention of multimerization without blockade of sCD39 may lead to sufficient residual AMP to prevent any detectable additive effect on activation of DC. Consequently, antibodies that bind and inhibit the ATPase activity of monomeric and/or soluble CD39 (e.g., monomeric sCD39) can be used advantageously to achieve greater neutralization of CD39 activity in an individual by neutralizing both membrane-bound and soluble CD39 protein (an extracellular domain protein in solution).

In one aspect, provided herein is an agent that binds CD39 and inhibits the enzymatic (ATPase activity) activity of human CD39 protein, for use in the treatment of cancer, wherein the agent that binds CD39 is administered in combination with an agent that

induces the extracellular release of ATP from tumor cells, optionally an agent that induces the death of tumor cells, optionally inducing apoptosis and/or necrosis. In another aspect, provided herein is an agent that induces the extracellular release of ATP from tumor cells, optionally an agent that induces the death of tumor cells, optionally inducing apoptosis and/or necrosis, for use in the treatment of cancer, wherein the agent that induces the extracellular release of ATP from tumor cells is administered in combination with an agent that binds CD39 and inhibits the enzymatic (ATPase activity) activity of human CD39 protein.

In one embodiment, provided is a method for treating or preventing a cancer in an individual, the method comprising administering to an individual: (a) an agent that binds and that inhibits the ATPase activity of a CD39 protein, and (b) an agent that is capable of inducing the extracellular release of ATP from tumor cells.

In one embodiment, provided is a method of potentiating the anti-tumor effect of an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of exogenously added ATP, the method comprising administering to the individual an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.

In one embodiment, provided is a method of treating cancer in an individual having a poor response, or prognostic for response, to treatment with an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells (in the absence of combined treatment with anti-CD39 antibody), the method comprising administering to the individual an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of exogenously added ATP.

In one embodiment, the agent that is capable of inducing the extracellular release of ATP from tumor cells directly induces apoptosis of tumor cells. In one embodiment, the agent that is capable of inducing the extracellular release of ATP from tumor cells directly induces necrosis of tumor cells. In one embodiment, the agent comprises a cytotoxic agent that directly causes the death of tumor cells, optionally a chemotherapeutic agent used in the treatment of cancer. In one embodiment, the agent comprises a depleting antibody. In one embodiment, the agent comprises an immunoconjugate comprising an antibody that specifically binds a protein expressed by a tumor cell and a cytotoxic agent. In one embodiment, the agent comprises an antibody that specifically binds a protein expressed by a tumor cell and that is not conjugated to a cytotoxic agent (e.g., a naked antibody). Optionally the antibody is capable of directly inducing the apoptosis of tumor cells.

In one embodiment, the agent that binds CD39 and inhibits the ATPase activity of human CD39 protein is capable of neutralizing the ATPase activity of CD39 in the presence of exogenously added ATP.

In one embodiment, the agent that binds CD39 and inhibits the ATPase activity of human CD39 protein is capable of neutralizing the ATPase activity of a soluble extracellular domain human CD39 protein. Optionally the agent is capable of neutralizing the ATPase activity of the soluble extracellular domain human CD39 protein in the presence of exogenously added ATP, optionally wherein added ATP at a concentration of 20  $\mu$ M. Assays can be for example as shown in the Examples herein, e.g., anti-CD39 antibody is incubated in plates with soluble recombinant human CD39 protein for 1h at 37°C, 20  $\mu$ M ATP is added to the plates for 30 additional minutes at 37°C before addition of CTG (Cell Titer Glo) reagent, and emitted light is quantified using an Enspire™ luminometer after a short incubation period of 5 min in the dark.

Optionally, the antibody is capable of causing a decrease in the ATPase activity of the human extracellular domain CD39 protein in solution by more than 50%, optionally more than 60%, 70%, 75% or 80%.

In one embodiment, an agent that binds CD39 will provide an at least 50%, 60%, 70%, 75%, 80% or 90% reduction in the ATPase activity of a soluble human CD39 protein (e.g., as assessed by the methods disclosed herein), optionally further at a concentration compatible with administration of an antibody to a human.

In one embodiment, the agent that binds CD39 and inhibits the ATPase activity of human CD39 protein is capable of causing an increase in expression of a cell surface marker of activation in monocyte-derived dendritic cells, when such moDC are incubated *in vitro* with the antibody and ATP, optionally wherein exogenously added ATP is provided at 0.125 mM, 0.25 mM or 0.5mM.

In one embodiment, the agent that binds CD39 and inhibits the ATPase activity of human CD39 protein is capable of binding and neutralizing the ATPase activity of human CD39 at the surface of a cell. In one embodiment, the agent is capable of increasing the activation of dendritic cells in the presence of ATP. In one embodiment, the agent is capable of causing an increase in expression of a cell surface marker of activation in monocyte-derived dendritic cells, when such moDC are incubated *in vitro* with the antibody and ATP. Optionally, ATP is exogenously added ATP provided at 0.125 mM, 0.25 mM or 0.5mM. Optionally, an increase in expression of a cell surface marker of activation is assessed by incubating moDC in presence of ATP for 24 hours and analyzing cell surface expression of CD80, CD83 and/or HLA-DR on moDC by flow cytometry. Optionally, the increase in expression of a cell surface marker is at least 40%, 50%, 75% or 80%, compared to a negative control (e.g., medium).

In one aspect of any embodiment herein, the agent that inhibits or neutralizes the ATPase activity of a CD39 protein is or comprises an antibody or antibody fragment that binds CD39 protein (e.g., a monospecific antibody, a bispecific or multispecific antibody).

The combined use of the agents will be useful in promoting an adaptive immune response against a tumor by increasing the pool of available ATP in the tumor microenvironment. These antibodies will therefore be useful in reversing the immunosuppressive effect of CD39 on the activity of DCs and/or T cells. In one embodiment, the methods of the disclosure are useful for increasing or enhancing anti-tumor immunity, for reducing immunosuppression, for enhancing an adaptive anti-tumor immune response, or for activating and/or potentiating the activity of a DC, a T cell, a tumor-infiltrating and/or tumor-specific T cell, in an individual.

In one aspect of any embodiment herein, the sCD39 protein can be characterized as lacking the two transmembrane domains (i.e. the transmembrane domains near the N- and C-terminal ends) found in membrane bound CD39. In one embodiment, sCD39 is a non-membrane bound sCD39 protein found in circulation, e.g., in a human individual. In one embodiment, sCD39 comprises or consists of the amino acid sequence of SEQ ID NO: 2 (optionally further comprising a C-terminal tag or another non-CD39-derived amino acid sequence), for example a sCD39 protein as produced in the Examples herein. In one embodiment, the protein, antibody or antibody fragment inhibits or neutralizes the ATPase activity of sCD39 when incubated with sCD39 in solution, e.g., according to the methods disclosed herein. In one embodiment, the protein, antibody or antibody fragment specifically binds the human CD39 protein, both in soluble (extracellular domain protein) and in membrane-bound form.

In one aspect of any embodiment herein, the individual can be specified to be a human.

In one embodiment, the anti-CD39 antibody is administered in a therapeutically effective amount.

In one embodiment, the anti-CD39 antibody is administered to an individual having a cancer in an amount and frequency sufficient to neutralize the activity of CD39 (sCD39 and/or memCD39) in the periphery and/or in the tumor microenvironment. In one embodiment, the antibody is administered in an amount and frequency sufficient to decrease the catabolism of ATP in the tumor microenvironment. Optionally, the antibody is administered in an amount and frequency sufficient to provide continued inhibition of the activity of CD39 (sCD39 and/or memCD39) in the periphery and/or in the tumor microenvironment, and/or continued decrease the catabolism of ATP in the tumor

microenvironment, for the duration of time between two successive administration of the agent capable of inducing the extracellular release of ATP from tumor cells.

In one embodiment, the agent capable of inducing the extracellular release of ATP from tumor cells is administered in a therapeutically effective amount. In one embodiment, the agent capable of inducing the extracellular release of ATP from tumor cells is administered to an individual having a cancer in an amount and frequency sufficient to induce the death, apoptosis and/or necrosis of tumor cells. In one embodiment, the agent capable of inducing the extracellular release of ATP from tumor cells is administered to an individual having a cancer in an amount and frequency sufficient to induce the extracellular release of ATP in the tumor microenvironment.

In one embodiment, the anti-CD39 antibody and agent capable of inducing the extracellular release of ATP from tumor cells is each administered for at least one administration cycle, the administration cycle comprising at least a first and second (and optionally a 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup>, 6<sup>th</sup>, 7<sup>th</sup> and/or 8<sup>th</sup> or further) administration of the anti-CD39 antibody and agent capable of inducing the extracellular release of ATP from tumor cells.

In one embodiment, the cancer is a leukemia, a glioma or glioblastoma, or a cancer of the bladder, breast, colon, esophagus, kidney, liver, lung, ovary, uterus, prostate, pancreas, stomach, cervix, thyroid, head and neck (head and neck squamous cell carcinoma, and skin (e.g., melanoma). In one embodiment the cancer is an advanced and/or refractory solid tumor. In one embodiment the cancer is an advanced and/or refractory solid tumor. In one non-limiting embodiment, the cancer (e.g., the advanced refractory solid tumor) is selected from the group consisting of non-small cell lung cancer (NSCLC), kidney cancer, pancreatic or esophagus adenocarcinoma, breast cancer, renal cell carcinoma (RCC), melanoma, colorectal cancer, and ovarian cancer (and optionally a further cancer type described herein).

In certain optional aspects an anti-CD39 agent can be used to treat a cancer in an individual having a cancer or tumor characterized by immunosuppression, optionally lack of or insufficient immune infiltrate in tumors, optionally lack of or insufficient anti-tumor immunity.

In certain optional aspects the treatments disclosed herein can be used to treat a cancer in an individual having a poor disease prognosis, notably a poor prognosis for response to treatment with an anti-cancer agent, e.g., an agent capable of inducing the extracellular release of ATP from tumor cells, a cytotoxic agent, a chemotherapeutic agent, or an agent that inhibits the enzymatic activity of CD39. An individual having a poor disease prognosis is, for example, at a higher risk of progression, based on one or more predictive factors. In one embodiment, a predictive factor(s) comprises presence or absence of a

mutation in one or more genes. In one embodiment, the predictive factor(s) comprises level(s) of expression of one or more genes or proteins, or example inhibitory or activating receptors on immune effector cells. In one embodiment, a predictive factor(s) comprises presence (e.g., numbers) of cells in circulation or in the tumor environment expressing CD39, and/or expression levels of CD39 on the surface of cells in circulation or in the tumor environment; in one embodiment, the cells are tumor cells; in one embodiment the cells are leukocytes, e.g., B cells, regulatory T cells (Treg); in one embodiment the cells are dendritic cells. Presence of elevated expression of CD39, and/or elevated numbers of CD39 expressing cells can indicate an individual has a poor prognosis for response to treatment with an antibody that neutralizes CD39.

In any aspect herein, an individual may be an individual who is a non-responder, or who has experienced a partial or an incomplete response to treatment with an agent capable of inducing the extracellular release of ATP from tumor cells, or whose disease has relapsed or progressed following treatment with an agent capable of inducing the extracellular release of ATP from tumor cells.

In one aspect, provided is an anti-CD39 agent for use in the treatment a cancer in an individual who is a non-responder, or who has experienced a partial or an incomplete response to treatment with an agent capable of inducing the extracellular release of ATP from tumor cells, or whose disease has relapsed or progressed following treatment with an agent capable of inducing the extracellular release of ATP from tumor cells. In one embodiment, the anti-CD39 agent is administered in combination with a treatment (e.g., an agent) capable of inducing the extracellular release of ATP from tumor cells. Optionally, the anti-CD39 agent is capable of binding and inhibiting the ATPase activity of CD39 in the presence of ATP and/or capable of binding and inhibiting the ATPase activity of a soluble extracellular domain human CD39 protein.

In one embodiment, the anti-CD39 agent competes for binding to an epitope or determinant on CD39 with the antibody I-394, I-395, I-396, I-397, I-398 or I-399. In one embodiment, the anti-CD39 agent competes for binding to CD39 with an antibody having the heavy and light chains of SEQ ID NOS: 37 and 38 respectively. The agent can be, e.g., a human or humanized anti-CD39 antibody. In one embodiment, the anti-CD39 antibody is an antibody comprising the heavy chain CDRs of the heavy chain of SEQ ID NOS: 37 and the light chain CDRs of the light chain of SEQ ID NO: 37 respectively. In one embodiment, the anti-CD39 antibody comprises a heavy chain comprising an amino acid sequence at least 60%, 70%, 75%, 80%, 85% or 90% identical to the heavy chain amino acid sequence of SEQ ID NO: 37 and a light chain comprising an amino acid sequence at least 60%, 70%,

75%, 80%, 85% or 90% identical the light chain amino acid sequence of SEQ ID NO: 38 respectively.

In certain optional aspects, individuals can be identified for treatment with a CD39-neutralizing agent and an agent capable of inducing the extracellular release of ATP from tumor cells by assessing whether the patient is a poor responder (has a poor prognosis for response) for an anti-cancer agent (e.g., a composition comprising a cytotoxic compound, a chemotherapeutic agent, a depleting antibody). A poor responder can be treated with a combination of a CD39-neutralizing agent and the agent capable of inducing the extracellular release of ATP from tumor cells.

In certain optional aspects, patients can be identified for treatment with a CD39-neutralizing agent by assessing the presence of extracellular ATP in a tumor sample (e.g., tumor tissue and/or tumor adjacent tissue), optionally wherein a pre-determined concentration of ATP indicates an individual is suitable for treatment with the anti-CD39 agent, optionally wherein the concentration of extracellular ATP is at least 0.01 mM, 0.02 mM, 0.05 mM, 0.125 mM, 0.25 mM or 0.5 mM.

In other embodiments, the treatment methods described herein can be used in combination with any other suitable treatments. In one embodiment, the treatment methods described herein further comprise administering to the individual an agent, optionally an antibody, that neutralizes the inhibitory activity of human PD-1. In one embodiment, the treatment methods described herein further comprise administering to the individual an agent, optionally an antibody, that neutralizes the 5'-ectonucleotidase activity of human CD73 protein.

In other embodiments, pharmaceutical compositions and kits are provided, as well as methods for using them. In one embodiment, provided is a pharmaceutical composition comprising a compound that neutralizes the ATPase activity of a human CD39 polypeptide and an agent capable of inducing the extracellular release of ATP from tumor cells. In one embodiment, provided is a kit comprising a compound that neutralizes the inhibitory activity of a human CD39 polypeptide and an agent capable of inducing the extracellular release of ATP from tumor cells.

In other embodiments, provided are methods for predicting or assessing the efficacy or suitability of an anti-cancer agent for combined use with an antibody that is capable of binding and inhibiting the ATPase activity of a soluble extracellular domain human CD39 protein, the method comprising determining or assessing (e.g., *in vitro*) whether the anti-cancer agent induces the extracellular release of ATP from cells (e.g. tumor cells), wherein a determination that the anti-cancer agent induces the extracellular release of ATP from cells (e.g. tumor cells) indicates that the agent can be used for treatment of cancer

in combination with said antibody that is capable of binding and inhibiting the ATPase activity of a soluble extracellular domain human CD39 protein. Determining or assessing whether the anti-cancer agent induces the extracellular release of ATP from tumor cells can comprise, for example, bringing cells (e.g. tumor cells) into contact with the agent in vitro and assessing extracellular release of ATP.

These aspects are more fully described in, and additional aspects, features, and advantages will be apparent from, the description of the invention provided herein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a representative screening result, showing antibodies I-397, I-398 and I-399 compared to positive control I-394 antibody.

Figure 2A shows that antibodies BY40, I-394, I-395 and I-396 inhibit cell-membrane bound CD39, with both I-394 and I-395 showing greater potency at all concentrations as well as greater maximal inhibition of cellular CD39 compared to BY40. Figure 2B shows that antibodies I-395 and I-396 both inhibit soluble CD39 in comparison to negative control (BY40) and positive control (I-394) antibodies.

Figure 3A shows the position of residues mutated in mutants 5 (M5), 15 (M15) and 19 (M19) on the surface of the CD39 protein. Figure 3B shows results of binding to mutants 5, 15 and 19 for different antibodies.

Figure 4 shows binding of antibody I-394 to cells expressing human CD39, as assessed by flow cytometry. I-394 binds cells expressing human CD39 (CHO-huCD39), cells expressing cynomolgus CD39 (CHO-cyCD39) and to Ramos lymphoma cells, but not to cells expressing murine CD39 (CHO-moCD39).

Figure 5 shows antibody I-394 is highly potent at blocking CD39 enzymatic activity in tumor (Ramos) cells, in cells expressing human CD39 (CHO-huCD39), and in cells expressing cynomolgus CD39 (CHO-cyCD39), as assessed by quantifying luminescence units which are proportional to the amount of ATP present.

Figure 6 shows antibody I-394 is highly potent at blocking the enzymatic activity of soluble recombinant human CD39 protein, as assessed by quantifying luminescence units which are proportional to the amount of ATP present.

Figure 7 shows antibody I-394 binds to human CD39 but not to any of the human isoforms CD39-L1, -L2, -L3 or -L4, as assessed in an ELISA assay.

Figure 8 shows the experimental procedure for assessing the effect of ATP-mediated DC activation on CD4 T cells activation, ATP-activated DC were washed and then incubated with allogenic CD4 T cells (ratio 1 MoDC / 4 T cells) for a mixed lymphocytes reaction (MLR)

30 during 5 days. T cells activation and proliferation were analyzed through CD25 expression and Cell Trace Violet dilution by flow cytometry.

35 Figure 9 shows HLA-DR expression on moDC and Figure 10 shows CD83 expression on moDC. These figures show that the anti-CD39 blocking antibody I-394 and chemical inhibitors of CD39 lead to moDC activation at each of 0.125 mM, 0.25 mM or 0.5mM. However, anti-CD39 antibody BY40 or anti-CD73 antibodies were not able to favor ATP-induced activation of dendritic cell (DC), suggesting that antibodies are not able to block enzymatic activity sufficiently to avoid ATP catabolism. The legends, top to bottom, correspond to the bars in the graph, from left to right.

40 Figure 11 shows CD25 expression, showing that MoDC activated in presence of ATP were able to induce T cell activation and proliferation in a MLR assay; the enhancement of ATP-mediated MoDC activation by anti-CD39 blocking antibody I-394 resulted in higher T cell proliferation and activation. The legends, top to bottom, correspond to the bars in the graph, from left to right.

45 Figure 12 shows tumor growth and survival in mice treated at day 5 post tumor cell engraftment with either control (1 group) PBS, or oxaliplatin chemotherapy (2 groups). In parallel, one group of mice treated with oxaliplatin was injected twice a week with anti-CD39 antibody, with the anti-CD39 antibody treatment starting just one day before oxaliplatin treatment (at day 4). This ensured that oxaliplatin induced ATP release in a tumor environment where CD39 was already and fully inhibited, and thus providing optimal prevention of ATP degradation by intratumoral CD39.

50 Figure 13 shows tumor growth and survival in mice treated at day 5 post tumor cell engraftment with either control (1 group) PBS, anti-CD39 antibody, oxaliplatin, or combination of oxaliplatin and anti-CD39 antibody. The oxaliplatin injection was repeated one week after the first oxaliplatin injection, again just one day after the treatment with I-394 antibody, to provide optimal inhibition of ATP degradation.

## DETAILED DESCRIPTION

### Definitions

55 As used in the specification, "a" or "an" may mean one or more. As used in the claim(s), when used in conjunction with the word "comprising", the words "a" or "an" may mean one or more than one. As used herein "another" may mean at least a second or more.

60 Where "comprising" is used, this can optionally be replaced by "consisting essentially of" or by "consisting of".

65 Human CD39, also known as NTPdase1, ENTPD1, ATPDase and vascular ATP diphosphohydrolase, exhibits ATPase activity. CD39 is a membrane bound protein that

hydrolyzes extracellular ATP and ADP to AMP, which is further converted to adenosine by another enzyme, 5-prime nucleotidase. The amino acid sequence of the human CD39 mature polypeptide chain is shown in Genbank under accession number P49961, the entire disclosure of which is incorporated herein by reference, and as follows:

MEDTKESNVK TFCSKNILAI LGFSSIIAVI ALLAVGLTQN KALPENVKYG IVLDAGSSHT  
SLYIYKWPME KENDTGVVHQ VEECRVKPGP ISKFWQKVNE IGYIYLTDCME RAREVIPRSQ  
HQETPVYLGA TAGMRLLRME SEELADRVLD VVERSLSNYP FDFQGARIIT GQEEGAYGWI  
TINYLLGKFS QKTRWFSIVP YETNNQETFG ALDLGGASTQ VTFVPQNQTI ESPDNALQFR  
LYGKDYNVYT HSFLCYGKDQ ALWQKLAQDI QVASNEILRD PCFHPGYKKV VNVSDLYKTP  
CTKRFEMTLP FQQFEIQGIG NYQQCHQSIL ELFNTSYCPY SQCAFNGIFL PPLQGDFGAF  
SAFYFVMKFL NLTSEKVSQE KVTEMMKKFC AQPWEEIKTS YAGVKEKYL EYCFSGTYIL  
SLLLQGYHFT ADSWEHIHFI GKIQGSDAGW TLGYMLNLTN MIPAEQPLST PLSHSTYVFL  
MVLFLSLVLFT VAIIGLLIFH KPSYFWKDMV

(SEQ ID NO: 1).

In the context herein, "inhibit", "inhibiting", "neutralize" or "neutralizing" when referring to the CD39 polypeptide (e.g., "neutralize CD39", "neutralize the activity of CD39" or "neutralize the enzymatic activity of CD39", etc.), refers to a process in which the ATP hydrolysis (ATPase) activity of CD39 is inhibited. This comprises, notably the inhibition of CD39-mediated generation of AMP and/or ADP, i.e., the inhibition of CD39-mediated catabolism of ATP to AMP and/or ADP. This can be measured for example in a cellular assay that measures the capacity of a test compound to inhibit the conversion of ATP to AMP and/or ADP, either directly or indirectly. For example, disappearance of ATP and/or generation of AMP can be assessed, as described herein. In one embodiment, an antibody preparation causes at least a 60% decrease in the conversion of ATP to AMP, at least a 70% decrease in the conversion of ATP to AMP, or at least an 80% or 90% decrease in the conversion of ATP to AMP, referring, for example, to the assays described herein (e.g., disappearance of ATP and/or generation of AMP).

"EC<sub>50</sub>" with respect to an agent and a particular activity (e.g., binding to a cell, inhibition of enzymatic activity, activation or inhibition of an immune cell), refers to the efficient concentration of the agent which produces 50% of its maximum response or effect with respect to such activity. "EC<sub>100</sub>" with respect to an agent and a particular activity refers to the efficient concentration of the agent which produces its substantially maximum response with respect to such activity.

The term "antibody," as used herein, refers to polyclonal and monoclonal antibodies. Depending on the type of constant domain in the heavy chains, antibodies are assigned to one of five major classes: IgA, IgD, IgE, IgG, and IgM. Several of these are further divided into subclasses or isotypes, such as IgG1, IgG2, IgG3, IgG4, and the like. An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and

one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains respectively. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are termed "alpha," "delta," "epsilon," "gamma" and "mu," respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. IgG are the exemplary classes of antibodies employed herein because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting. Optionally the antibody is a monoclonal antibody. Particular examples of antibodies are humanized, chimeric, human, or otherwise-human-suitable antibodies. "Antibodies" also includes any fragment or derivative of any of the herein described antibodies.

The term "specifically binds to" means that an antibody can bind preferably in a competitive binding assay to the binding partner, e.g., CD39, as assessed using either recombinant forms of the proteins, epitopes therein, or native proteins present on the surface of isolated target cells. Competitive binding assays and other methods for determining specific binding are well known in the art. For example binding can be detected via radiolabels, physical methods such as mass spectrometry, or direct or indirect fluorescent labels detected using, e.g., cytofluorometric analysis (e.g., FACScan). Binding above the amount seen with a control, non-specific agent indicates that the agent binds to the target.

When an antibody is said to "compete with" a particular monoclonal antibody, it means that the antibody competes with the monoclonal antibody in a binding assay using either recombinant molecules (e.g., CD39) or surface expressed molecules (e.g., CD39). For example, if a test antibody reduces the binding of an antibody having a heavy chain of SEQ ID NO: 3 and a light chain of SEQ ID NO: 4 to a CD39 polypeptide or CD39-expressing cell in a binding assay, the antibody is said to "compete" respectively with such antibody.

The term "affinity", as used herein, means the strength of the binding of an antibody to an epitope. The affinity of an antibody is given by the dissociation constant  $K_d$ , defined as  $[Ab] \times [Ag] / [Ab-Ag]$ , where  $[Ab-Ag]$  is the molar concentration of the antibody-antigen complex,  $[Ab]$  is the molar concentration of the unbound antibody and  $[Ag]$  is the molar concentration of the unbound antigen. The affinity constant  $K_a$  is defined by  $1/K_d$ . Methods for determining the affinity of mAbs can be found in Harlow, et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988), Coligan et al., eds., *Current Protocols in Immunology*, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), and Muller, *Meth. Enzymol.* 92:589-601 (1983), which references are entirely incorporated herein by reference. One standard method well known

in the art for determining the affinity of mAbs is the use of surface plasmon resonance (SPR) screening (such as by analysis with a BIAcore™ SPR analytical device).

Within the context herein a “determinant” designates a site of interaction or binding on a polypeptide.

The term “epitope” refers to an antigenic determinant, and is the area or region on an antigen to which an antibody binds. A protein epitope may comprise amino acid residues directly involved in the binding as well as amino acid residues which are effectively blocked by the specific antigen binding antibody or peptide, *i.e.*, amino acid residues within the “footprint” of the antibody. It is the simplest form or smallest structural area on a complex antigen molecule that can combine with *e.g.*, an antibody or a receptor. Epitopes can be linear or conformational/structural. The term “linear epitope” is defined as an epitope composed of amino acid residues that are contiguous on the linear sequence of amino acids (primary structure). The term “conformational or structural epitope” is defined as an epitope composed of amino acid residues that are not all contiguous and thus represent separated parts of the linear sequence of amino acids that are brought into proximity to one another by folding of the molecule (secondary, tertiary and/or quaternary structures). A conformational epitope is dependent on the 3-dimensional structure. The term “conformational” is therefore often used interchangeably with “structural”.

The term “deplete” or “depleting”, with respect to tumor cells, means a process, method, or compound that results in killing, elimination, lysis or induction of such killing, elimination or lysis, so as to negatively affect the number of such tumor cells present in a sample or in a subject.

The term “internalization”, used interchangeably with “intracellular internalization”, refers to the molecular, biochemical and cellular events associated with the process of translocating a molecule from the extracellular surface of a cell to the intracellular surface of a cell. The processes responsible for intracellular internalization of molecules are well-known and can involve, *inter alia*, the internalization of extracellular molecules (such as hormones, antibodies, and small organic molecules); membrane-associated molecules (such as cell-surface receptors); and complexes of membrane-associated molecules bound to extracellular molecules (for example, a ligand bound to a transmembrane receptor or an antibody bound to a membrane-associated molecule). Thus, “inducing and/or increasing internalization” comprises events wherein intracellular internalization is initiated and/or the rate and/or extent of intracellular internalization is increased.

The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. The term “therapeutic agent” refers to an agent that has biological activity.

For the purposes herein, a "humanized" or "human" antibody refers to an antibody in which the constant and variable framework region of one or more human immunoglobulins is fused with the binding region, e.g., the CDR, of an animal immunoglobulin. Such antibodies are designed to maintain the binding specificity of the non-human antibody from which the binding regions are derived, but to avoid an immune reaction against the non-human antibody. Such antibodies can be obtained from transgenic mice or other animals that have been "engineered" to produce specific human antibodies in response to antigenic challenge (see, e.g., Green et al. (1994) *Nature Genet* 7:13; Lonberg et al. (1994) *Nature* 368:856; Taylor et al. (1994) *Int Immun* 6:579, the entire teachings of which are herein incorporated by reference). A fully human antibody also can be constructed by genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art (see, e.g., McCafferty et al. (1990) *Nature* 348:552-553). Human antibodies may also be generated by in vitro activated B cells (see, e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275, which are incorporated in their entirety by reference).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues from a "complementarity-determining region" or "CDR" (e.g., residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light-chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy-chain variable domain; Kabat et al. 1991) and/or those residues from a "hypervariable loop" (e.g., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light-chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy-chain variable domain; Chothia and Lesk, *J. Mol. Biol.* 1987;196:901-917), or a similar system for determining essential amino acids responsible for antigen binding. Typically, the numbering of amino acid residues in this region is performed by the method described in Kabat et al., *supra*. Phrases such as "Kabat position", "variable domain residue numbering as in Kabat" and "according to Kabat" herein refer to this numbering system for heavy chain variable domains or light chain variable domains. Using the Kabat numbering system, the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable

domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of CDR H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.

By "framework" or "FR" residues as used herein is meant the region of an antibody variable domain exclusive of those regions defined as CDRs. Each antibody variable domain framework can be further subdivided into the contiguous regions separated by the CDRs (FR1, FR2, FR3 and FR4).

The terms "Fc domain," "Fc portion," and "Fc region" refer to a C-terminal fragment of an antibody heavy chain, e.g., from about amino acid (aa) 230 to about aa 450 of human  $\gamma$  (gamma) heavy chain or its counterpart sequence in other types of antibody heavy chains (e.g.,  $\alpha$ ,  $\delta$ ,  $\epsilon$  and  $\mu$  for human antibodies), or a naturally occurring allotype thereof. Unless otherwise specified, the commonly accepted Kabat amino acid numbering for immunoglobulins is used throughout this disclosure (see Kabat et al. (1991) Sequences of Protein of Immunological Interest, 5th ed., United States Public Health Service, National Institute of Health, Bethesda, MD).

The terms "isolated", "purified" or "biologically pure" refer to material that is substantially or essentially free from components which normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified.

25 The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

30 The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (nonrecombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

Within the context herein, the term antibody that "binds" a polypeptide or epitope designates an antibody that binds said determinant with specificity and/or affinity.

The term "identity" or "identical", when used in a relationship between the sequences of two or more polypeptides, refers to the degree of sequence relatedness between polypeptides, as determined by the number of matches between strings of two or more amino acid residues. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., "algorithms"). Identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).

Methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 12, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol. 215, 403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al., *supra*). The well-known Smith Waterman algorithm may also be used to determine identity.

### 25 Agents that inhibit CD39

The agent that binds and inhibits CD39 for use in accordance herein can be an antigen binding domain or a protein comprising such, optionally an antibody or antibody fragment, that binds to and inhibits or neutralizes the ATPase activity of a CD39 protein, e.g., a soluble CD39 protein (sCD39), a monomeric CD39 protein, a membrane bound CD39 protein (memCD39), e.g., expressed at the surface of a cell.

35 In one embodiment a sCD39 protein is a CD39 protein lacking the two transmembrane domains (i.e. the transmembrane domains near the N- and C-terminal ends) found in membrane bound CD39. In one embodiment, sCD39 is a non-membrane bound

sCD39 protein found in circulation, e.g., in a human individual. In one embodiment, sCD39 comprises or consists of the amino acid sequence of SEQ ID NO: 2 (optionally further comprising a C-terminal tag or another non-CD39-derived amino acid sequence). In one embodiment, the protein, antibody or antibody fragment inhibits the ATPase activity of sCD39 when incubated with sCD39 in solution, e.g., according to the methods disclosed herein. In one embodiment, the protein, antibody or antibody fragment specifically binds the human CD39 protein, both in soluble (extracellular domain protein) and in membrane-bound form.

In one embodiment, the anti-CD39 antibody does not increase or induce intracellular internalization of, or more generally down-modulation of, cell surface-expressed CD39 and/or does not depend thereupon for its CD39 inhibitory activity.

In one aspect, an anti-CD39 antibody is capable of: (a) inhibiting the enzymatic activity of membrane-bound CD39 protein (e.g., comprising an amino acid sequence of SEQ ID NO: 1) expressed at the surface of cells, and (b) inhibiting the enzymatic activity of soluble CD39 protein (e.g., a CD39 protein having an amino acid sequence of SEQ ID NO: 2, a CD39 protein lacking its transmembrane domains).

In one embodiment, an anti-CD39 antibody does not substantially bind (e.g., via its Fc domain) to human Fc<sub>Y</sub> receptors (e.g., CD16, CD32a, CD32b, CD64) and/or C1q, and/or do not substantially direct ADCC and/or CDC toward a CD39-expressing cell. Optionally, the antibody retains an Fc domain (e.g., of human IgG isotype) and retains binding to human FcRn.

In one embodiment, the CD39 neutralizing antibodies can be characterized by being capable of causing a decrease in the ATPase activity of a sCD39 polypeptide and/or of a monomeric CD39 polypeptide, optionally causing a decrease of AMP generation by a soluble monomeric human CD39 protein, e.g., a CD39 protein consisting of the amino acid sequence of SEQ ID NO: 2, by at least 50%, 60%, 70%, 80% or 90%.

In one embodiment, the CD39 neutralizing antibodies can be characterized by being capable of causing a decrease in cells' ATPase activity of CD39, optionally causing a decrease of AMP generation by a CD39-expressing cell, by at least 50%, 60%, 70%, 80% or 90%. In one embodiment, the CD39-neutralizing antibodies can be characterized by an EC<sub>50</sub> for inhibition of ATPase activity (e.g., EC<sub>50</sub> for inhibition of AMP generation by a CD39-expressing cell) of CD39 expressed by a cell of no more than 1 µg/ml, optionally no more than 0.5 µg/ml, optionally no more than 0.2 µg/ml.

In one embodiment, the CD39 neutralizing antibodies can be characterized by being capable of causing an increase in expression of a cell surface marker of activation in human monocyte-derived dendritic cells (moDC), when such moDC are incubated *in vitro* with the

antibody and ATP, optionally wherein ATP is exogenously added ATP, optionally further wherein the added ATP is provided at 0.125 mM, 0.25 mM or 0.5mM.

An antigen-binding compound can be produced as further described herein, and at any desired stage be assessed for its ability to inhibit the enzymatic activity of CD39, notably to block the ATPase activity of sCD39 and to reduce the production of ADP and AMP (and, together with CD73, adenosine) by soluble CD39 protein and optionally further by a CD39-expressing cell, and in turn restore the ATP-mediated activation of dendritic cell activity and/or T cell proliferation.

The inhibitory activity (e.g., immune enhancing potential) of an antibody can also be assessed for example, in an assay to detect the disappearance (hydrolysis) of ATP and/or the generation of AMP.

The ability of an antibody to inhibit soluble recombinant human CD39 protein can be tested by detecting ATP after incubating test antibody with soluble CD39 protein (e.g., the CD39 protein having the amino acid sequence of SEQ ID NO: 2, as produced in Example 1, optionally further comprising a purification tag or other functional or non-functional non-CD39-derived amino acid sequence). See, e.g., the Examples. Briefly, ATP can be quantified using the Cell Titer Glo™ (Promega), in an assay in which dose ranges of test antibody are incubated with soluble recombinant human CD39 protein described in the Examples, for 1 hour at 37°C. 20 µM ATP are added to the plates for 30 additional minutes at 37°C before addition of CTG reagent. Emitted light is quantified using an Enspire™ luminometer after a short incubation period of 5 min in the dark.

The ability of an antibody to inhibit cells expressing CD39 protein can be tested by detecting ATP after incubating test antibody with cells (e.g., Ramos cells, cells transfected with CD39, etc.). See, e.g., Examples. Cells can be incubated for 1 hour at 37°C with test antibody. Cells are then incubated with 20 µM ATP for 1 additional hour at 37°C. Plates are centrifuged for 2 min at 400g and cell supernatant are transferred in a luminescence microplate (white wells). CTG is added to the supernatant and emitted light is quantified after a 5 min incubation in the dark using an Enspire™ luminometer. Anti-CD39 antibody efficacy is determined by comparing emitted light in presence of antibody with ATP alone (maximal light emission) and ATP together with cells (minimal light emission).

A decrease in hydrolysis of ATP into AMP, and/or an increase of ATP and/or a decrease in generation of AMP, in the presence of antibody indicate the antibody inhibits CD39. In one embodiment, an antibody preparation is capable of causing at least a 60% decrease in the enzymatic activity of a CD39 polypeptide expressed by a cell, preferably the antibody causes at least a 70%, 80% or 90% decrease in the enzymatic activity of a CD39 polypeptide in a cell, as assessed by detecting ATP using the Cell Titer Glo™ (Promega)

after incubating cells expressing CD39 polypeptide (e.g., Ramos cells) with a test antibody, e.g., as in Example 1.

In one embodiment, an antibody preparation is capable of causing at least a 60% decrease in the enzymatic activity of a soluble recombinant CD39 polypeptide, preferably at least a 70%, 80% or 90% decrease in the enzymatic activity of a soluble recombinant CD39 polypeptide, as assessed by detecting ATP using the Cell Titer Glo™ (Promega) after incubating soluble recombinant CD39 polypeptide with a test antibody, e.g., as in Example 1.

In one example, provided is an in vitro method for producing or identifying an anti-CD39 antibody or antigen binding domain capable of use in the methods of the disclosure (e.g., for use combination with an agent that induces release of ATP from tumor cells), the method comprising the steps of:

- (a) providing a plurality of antibodies that bind a human CD39 polypeptide,
- (b) bringing each of the antibodies into contact with human monocyte-derived dendritic cells (moDC), in the presence of ATP, optionally wherein ATP is exogenously added ATP, and
- (c) selecting an antibody of step (b) that results in an increase in expression of a cell surface marker of activation in the moDC.

Optionally, in any embodiment herein, a neutralizing anti-CD39 antibody binds an antigenic determinant present on both sCD39 and CD39 expressed at the cell surface (memCD39).

Optionally, in any embodiment herein, a neutralizing anti-CD39 antibody competes for binding to an epitope on CD39 bound by antibody I-394, (e.g., that competes for binding to an epitope on a CD39 polypeptide with an antibody having the heavy and light chain CDRs or variable regions of any of I-394).

25        Optionally, in any embodiment herein, a neutralizing anti-CD39 antibody binds the same epitope and/or competes for binding to a CD39 polypeptide with monoclonal antibody I-394 (e.g., that competes for binding to a CD39 polypeptide with an antibody having the heavy and light chain CDRs or variable regions of I-394. In one embodiment, a neutralizing anti-CD39 antibody binds the same epitope and/or competes for binding to a CD39 polypeptide with an antibody having respectively a VH and VL region of SEQ ID NOS: 3 and 4.

30        Optionally, in any embodiment herein, an anti-CD39 antibody binds an epitope comprising one, two or three amino acid residues selected from the group consisting of the amino acid residues on CD39 bound by I-394.

35        Optionally, in any embodiment herein, the binding molecule (e.g., anti-CD39 antibody) comprises the variable heavy chain domain (V<sub>H</sub>) comprising a light chain CDR1, 2

and 3 as described herein, and a variable light chain domain (V<sub>L</sub>) comprising a heavy chain CDR1, 2 and 3 as described herein, or an amino acid sequence in which the CDR (or set of heavy and/or light chain CDRs) has at least 60%, 70%, 80%, 90% or 95% amino acid identity to said CDR (or said set of heavy and/or light chain CDRs). In one aspect of any of the embodiments herein, the antibody may comprise a heavy chain comprising the three CDRs of the heavy chain variable region (VH) of antibody I-394 and a light chain comprising the three CDRs of the light chain variable region (VL) of antibody I-394.

Optionally, in any embodiment herein, anti-CD39 antibody comprises an Fc domain that is modified (compared to a wild-type Fc domain of the same isotype) to reduce binding between the Fc domain and human CD16A, CD16B, CD32A, CD32B and/or CD64 polypeptides, optionally wherein the antibody comprises: (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 3 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 4. In one aspect, the Fc domain is modified (compared to a wild-type Fc domain of the same isotype) to reduce binding between the Fc domain and human C1q polypeptide. In one embodiment, the antibody comprises an amino acid substitution in a heavy chain constant region at any one, two, three, four, five or more of residues selected from the group consisting of: 220, 226, 229, 233, 234, 235, 236, 237, 238, 243, 264, 268, 297, 298, 299, 309, 310, 318, 320, 322, 327, 330 and 331 (Kabat EU numbering). In one embodiment, the antibody has an amino acid substitution in a heavy chain constant region at any three, four, five or more of residues selected from the group consisting of: 234, 235, 237, 322, 330 and 331. In one embodiment, the antibody comprises an Fc domain comprising an amino acid sequence shown below.

In one embodiment, an antibody comprises a heavy chain constant region or Fc domain comprising the amino acid sequence below, or an amino acid sequence at least 90%, 95% or 99% identical thereto but retaining the amino acid residues at Kabat positions 234, 235 and 331 (underlined):

A S T K G P S V F P L A P S S K S T S G G T A A L G C L V K D Y F P  
E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V  
30 V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K R V E P K S  
C D K T H T C P P C P A P E A E G G P S V F L F P P K P K D T L M I  
S R T P E V T C V V V D V S H E D P E V K F N W Y V D G V E V H N A  
K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K C  
K V S N K A L P A S I E K T I S K A K G Q P R E P Q V Y T L P P S R  
35 E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N

N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F  
S C S V M H E A L H N H Y T Q K S L S L S P G K (SEQ ID NO :44)

In one embodiment, an antibody comprises a heavy chain constant region or Fc domain comprising the amino acid sequence below, or an amino acid sequence at least 90%, 95% or 99% identical thereto but retaining the amino acid residues at Kabat positions 234, 235 and 331 (underlined):

A S T K G P S V F P L A P S S K S T S G G T A A L G C L V K D Y F P  
E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V  
V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K R V E P K S  
C D K T H T C P P C P A P E F E G G P S V F L F P P K P K D T L M I  
S R T P E V T C V V V D V S H E D P E V K F N W Y V D G V E V H N A  
K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K C  
K V S N K A L P A S I E K T I S K A K G Q P R E P Q V Y T L P P S R  
E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N  
N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F  
S C S V M H E A L H N H Y T Q K S L S L S P G K (SEQ ID NO :45)

In one embodiment, an antibody comprises a heavy chain constant region or Fc domain comprising the amino acid sequence below, or an amino acid sequence at least 90%, 95% or 99% identical thereto but retaining the amino acid residues at Kabat positions 234, 235, 237, 330 and 331 (underlined):

A S T K G P S V F P L A P S S K S T S G G T A A L G C L V K D Y F P  
E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V  
V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K R V E P K S  
C D K T H T C P P C P A P E A E G A P S V F L F P P K P K D T L M I  
25 S R T P E V T C V V V D V S H E D P E V K F N W Y V D G V E V H N A  
K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K C  
K V S N K A L P S S I E K T I S K A K G Q P R E P Q V Y T L P P S R  
E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N  
N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F  
30 S C S V M H E A L H N H Y T Q K S L S L S P G K (SEQ ID NO :46)

In one embodiment, an antibody comprises a heavy chain constant region or Fc domain comprising the amino acid sequence below, or a sequence at least 90%, 95% or 99% identical thereto but retaining the amino acid residues at Kabat positions 234, 235, 237 and 331 (underlined):

35 A S T K G P S V F P L A P S S K S T S G G T A A L G C L V K D Y F P  
E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V

V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K R V E P K S  
C D K T H T C P P C P A P E **A** **E** G **A** P S V F L F P P K P K D T L M I  
S R T P E V T C V V V D V S H E D P E V K F N W Y V D G V E V H N A  
K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K C  
K V S N K A L P A **S** I E K T I S K A K G Q P R E P Q V Y T L P P S R  
E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N  
N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F  
S C S V M H E A L H N H Y T Q K S L S L S P G K (SEQ ID NO : 47)

In one aspect, the anti-CD39 antibody binds the same epitope as antibody I-394, I-395, I-396, I-397, I-398 or I-399. In one embodiment, the antibodies bind to an epitope of CD39 that at least partially overlaps with, or includes at least one residue in, the epitope bound by antibody I-394, I-395, I-396, I-397, I-398 or I-399. The residues bound by the antibody can be specified as being present on the surface of the CD39 polypeptide, e.g., in a CD39 polypeptide expressed on the surface of a cell.

Binding of anti-CD39 antibody to cells transfected with CD39 mutants can be measured and compared to the ability of anti-CD39 antibody to bind wild-type CD39 polypeptide (e.g., SEQ ID NO: 1). A reduction in binding between an anti-CD39 antibody and a mutant CD39 polypeptide (e.g., a mutant of Table 1) means that there is a reduction in binding affinity (e.g., as measured by known methods such FACS testing of cells expressing a particular mutant, or by Biacore testing of binding to mutant polypeptides) and/or a reduction in the total binding capacity of the anti- CD39 antibody (e.g., as evidenced by a decrease in Bmax in a plot of anti-CD39 antibody concentration versus polypeptide concentration). A significant reduction in binding indicates that the mutated residue is directly involved in binding to the anti-CD39 antibody or is in close proximity to the binding protein when the anti-CD39 antibody is bound to CD39.

In some embodiments, a significant reduction in binding means that the binding affinity and/or capacity between an anti-CD39 antibody and a mutant CD39 polypeptide is reduced by greater than 40 %, greater than 50 %, greater than 55 %, greater than 60 %, greater than 65 %, greater than 70 %, greater than 75 %, greater than 80 %, greater than 85 %, greater than 90% or greater than 95% relative to binding between the antibody and a wild type CD39 polypeptide. In certain embodiments, binding is reduced below detectable limits. In some embodiments, a significant reduction in binding is evidenced when binding of an anti-CD39 antibody to a mutant CD39 polypeptide is less than 50% (e.g., less than 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10%) of the binding observed between the anti-CD39 antibody and a wild-type CD39 polypeptide.

In some embodiments, anti-CD39 antibodies exhibit significantly lower binding for a mutant CD39 polypeptide in which a residue in a segment comprising an amino acid residue bound by antibody I-394, I-395, I-396, I-397, I-398 or I-399 is substituted with a different amino acid.

In some embodiments, anti-CD39 antibodies (e.g., other than I-394) are provided that bind the epitope on CD39 bound by antibody I-394, I-395, I-396, I-397, I-398 or I-399.

In one aspect, the antibody binds an epitope on CD39 comprising an amino acid residue (e.g., one, two or three of the residues) selected from the group consisting of R138, M139 and E142 (with reference to SEQ ID NO: 1).

In one aspect, an anti-CD39 antibody exhibits reduced binding (e.g. substantially complete loss of binding) to a CD39 polypeptide having a mutation at one, two or three of the residues selected from the group consisting of: R138, M139 and E142 (with reference to SEQ ID NO: 1), compared to a wild-type CD39 polypeptide (a CD39 polypeptide of SEQ ID NO: 1); optionally, the mutant CD39 polypeptide has the mutations: R138A, M139A and E142K. In one optional aspect, the antibody does not have a loss of binding to any of the mutant CD39 polypeptide of Table 1 other than mutant 19. In another optional aspect, the anti-CD39 antibody exhibits reduced binding (optionally reduced but not a substantially complete loss of binding; or optionally a substantially complete loss of binding) to a CD39 polypeptide having a mutation at one, two, three or four of the residues selected from the group consisting of: Q96, N99, E143 and R147 (with reference to SEQ ID NO: 1), compared to a wild-type CD39 polypeptide (a CD39 polypeptide of SEQ ID NO: 1); optionally, the mutant CD39 polypeptide has the mutations: Q96A, N99A, E143A and R147E.

In one aspect, the antibody binds an epitope on CD39 comprising an amino acid residue (e.g., one, two, three or four of the residues) selected from the group consisting of Q96, N99, E143 and R147 (with reference to SEQ ID NO: 1). In one aspect, the antibody has reduced binding (e.g. substantially complete loss of binding) to a mutant CD39 polypeptide comprising a mutation at 1, 2, 3 or 4 residues selected from the group consisting of Q96, N99, E143 and R147 (with reference to SEQ ID NO: 1), in each case relative to binding between the antibody and a wild-type CD39 polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

In one aspect, the antibody binds an epitope on CD39 comprising (a) an amino acid residue (e.g., one, two or three of the residues) selected from the group consisting of R138, M139 and E142 (with reference to SEQ ID NO: 1), and (b) an amino acid residue (e.g., one, two, three or four of the residues) selected from the group consisting of Q96, N99, E143 and R147.

In one aspect, an anti-CD39 antibody exhibits reduced (e.g. substantially complete

loss of) binding to both (a) a CD39 polypeptide having a mutation at one, two, three or four of the residues selected from the group consisting of: Q96, N99, E143 and R147 (with reference to SEQ ID NO: 1), and (b) a CD39 polypeptide having a mutation at one, two, or three of the residues selected from the group consisting of: R138, M139 and E142 (with reference to SEQ ID NO: 1), in each case compared to a wild-type CD39 polypeptide (a CD39 polypeptide of SEQ ID NO: 1). Optionally, the mutant CD39 polypeptide of (a) has the mutations: Q96A, N99A, E143A and R147E. Optionally, the mutant CD39 polypeptide of (b) has the mutations: R138A, M139A and E142K. Optionally the antibody does not have a loss of binding to any of the mutant CD39 polypeptide of Table 1 other than mutants 5 and 19.

In one aspect, the antibody binds an epitope on CD39 comprising an amino acid residue (e.g., one, two, three or four of the residues) selected from the group consisting of K87, E100 and D107 (with reference to SEQ ID NO: 1).

In one aspect, an anti-CD39 antibody exhibits reduced binding (e.g. substantially complete loss of binding) to a CD39 polypeptide having a mutation at one, two, three or four of the residues selected from the group consisting of: K87, E100 and D107 (with reference to SEQ ID NO: 1), compared to a wild-type CD39 polypeptide (a CD39 polypeptide of SEQ ID NO: 1); optionally, the mutant CD39 polypeptide has the mutations: K87A, E100A and D107A. Optionally the antibody does not have a loss of binding to any of the mutant CD39 polypeptide of Table 1 other than mutant 15.

In one aspect, the antibody binds an epitope on CD39 comprising an amino acid residue (e.g., one, two, three or four of the residues) selected from the group consisting of N371, L372, E375, K376 and V377 (with reference to SEQ ID NO: 1).

In one aspect, an anti-CD39 antibody exhibits reduced (e.g. substantially complete loss of) binding to a CD39 polypeptide having a mutation at one, two, three, four or five of the residues selected from the group consisting of: N371, L372, E375, K376 and V377 (with reference to SEQ ID NO: 1), compared to a wild-type CD39 polypeptide (a CD39 polypeptide of SEQ ID NO: 1); optionally, the mutant CD39 polypeptide has the mutations: N371K, L372K, E375A, K376G and V377S, and an insertion of a valine between residues 376 and 377. Optionally the antibody does not have a loss of binding to any of the mutant CD39 polypeptide of Table 1 other than mutant 11.

An anti-CD39 antibody may for example comprise: a HCDR1 comprising an amino acid sequence: DYNMH (SEQ ID NO: 5), or a sequence of at least 4 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR2 comprising an amino acid sequence: YIVPLNGGSTFNQKFKG (SEQ ID NO: 6), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may

be substituted by a different amino acid;; a HCDR3 comprising an amino acid sequence: GGTRFAY (SEQ ID NO: 7), or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR1 comprising an amino acid sequence: RASESVDNFGVFSFMY (SEQ ID NO: 8), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR2 region comprising an amino acid sequence: GASNQGS (SEQ ID NO: 9) or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; and/or a LCDR3 region of I-394 comprising an amino acid sequence: QQTKEVPYT (SEQ ID NO: 10), or a sequence of at least 4, 5, 6, 7 or 8 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be deleted or substituted by a different amino acid. CDR positions may be according to Kabat numbering.

An exemplary anti-CD39 VH and VL pair of an antibody that inhibits the enzymatic activity of human sCD39 protein is that of antibody I-394, the amino acid sequence of the heavy chain variable region of which is listed below (SEQ ID NO: 3), and the amino acid sequence of the light chain variable region of which is listed below (SEQ ID NO: 4). The CDRs according to Kabat numbering are underlined in SEQ ID NOS: 3 and 4. Optionally, the VH and VL comprise (e.g., are modified to incorporate) human acceptor frameworks. In one embodiment, an anti-CD39 antibody of the disclosure comprises the VH CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the heavy chain variable region having the amino acid sequence of SEQ ID NO: 3. In one embodiment, an anti-CD39 antibody of the disclosure comprise the VL CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the light chain variable region having the amino acid sequence of SEQ ID NO: 4.

I-394 VH:

EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGRTLEWIGYIVPLNGGSTF  
NQKFKGRATLTVNTSSRTAYMELRSLTSEDSAAYYCARGGTRFAYWGQGTLTVSA (SEQ ID NO: 3).

I-394 VL:

DIVLTQSPASLA VSLGQRATISCRASESVDNFGVFSFMYWFQQKPGQPPNLLIYGASNQGSG  
VPARFRGSGSGTDFSLNIHPMEADDTAMYFCQQTKEVPYTFGGGTKLEIK (SEQ ID NO: 4).

Another exemplary anti-CD39 VH and VL pair according to the disclosure is that of antibody I-395, the amino acid sequence of the heavy chain variable region of which is listed below (SEQ ID NO: 11), and the amino acid sequence of the light chain variable region of which is listed below (SEQ ID NO: 12). The CDRs according to Kabat numbering are underlined in SEQ ID NOS: 11 and 12. Optionally, the VH and VL comprise (e.g., are modified to incorporate) human acceptor frameworks. In one embodiment, an anti-CD39 antibody of the disclosure comprises the VH CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the heavy chain variable region having the amino acid sequence of SEQ ID NO: 11. In one embodiment, an anti-CD39 antibody of the disclosure comprise the VL CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the light chain variable region having the amino acid sequence of SEQ ID NO: 12.

I-395 VH:

EVQLQQSGPELVKPGASVRMSCKASGYTFTDYNMHWVKKNHGKGLEWIGYINPNNGTT  
YNQKFKKGKATLTVNTSSKTAYMELRSLTSEDSAVYYCTRGGTRFASWGQGTLTVSA  
(SEQ ID NO: 11).

I-395 VL:

NIVLTQSPASLA VSLGQRATISCRASESVDNYGISFMYWFQQKPGQPPKLLIYAASTQGS  
VPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSK EVPFTFGSGTKLEIK  
(SEQ ID NO: 12).

An anti-CD39 antibody may for example comprise: a HCDR1 of I-395 comprising an amino acid sequence: DYNMH (SEQ ID NO: 13), or a sequence of at least 4 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR2 of I-395 comprising an amino acid sequence: YINPNNGTTYNQKFKG (SEQ ID NO: 14), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR3 of I-395 comprising an amino acid sequence: GGTRFAS (SEQ ID NO: 15), or a sequence of at least 4, 5, 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR1 of I-395 comprising an amino acid sequence: RASESVDNYGISFMY (SEQ ID NO: 16), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR2 region of I-395 comprising an amino acid sequence: AASTQGS (SEQ ID NO: 17) or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid.

substituted by a different amino acid; and/or a LCDR3 region of I-395 comprising an amino acid sequence: QQSK EVPFT (SEQ ID NO: 18), or a sequence of at least 4, 5, 6, 7 or 8 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be deleted or substituted by a different amino acid. CDR positions may be according to Kabat numbering.

Another exemplary anti-CD39 VH and VL pair according to the disclosure is that of antibody I-396, the amino acid sequence of the heavy chain variable region of which is listed below (SEQ ID NO: 19), and the amino acid sequence of the light chain variable region of which is listed below (SEQ ID NO: 20). The CDRs according to Kabat numbering are underlined in SEQ ID NOS: 19 and 20. Optionally, the VH and VL comprise (e.g., are modified to incorporate) human acceptor frameworks. In one embodiment, an anti-CD39 antibody of the disclosure comprises the VH CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the heavy chain variable region having the amino acid sequence of SEQ ID NO: 19. In one embodiment, an anti-CD39 antibody of the disclosure comprise the VL CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the light chain variable region having the amino acid sequence of SEQ ID NO: 20.

I-396 VH:

EVQLQQSGAELVKPGASVKLSCIVSGFNIKDTYINWVKQRPEQGLEWIGRIDPANGNTKYD  
PKFQGKATMTSDTSSNTAYLHLSSLTSDDSAVYYCARWGYDDEEADYFDSWGQGTTLV  
SS

(SEQ ID NO: 19).

I-396 VL:

DIVLTQSPASLA VSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSG  
VPARFSGSGSGTDFSLNILPMEEVDAAMYFCHHQSKEVPWTFGGGTKLEIK  
(SEQ ID NO: 20).

An anti-CD39 antibody may for example comprise: a HCDR1 comprising an amino acid sequence: DTYIN (SEQ ID NO: 21), or a sequence of at least 4 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR2 comprising an amino acid sequence: RIDPANGNTKYDPKFQG (SEQ ID NO: 22), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR3 comprising an amino acid sequence: WGYDDEEADYFDS (SEQ ID NO: 23), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may

be substituted by a different amino acid; a LCDR1 comprising an amino acid sequence: RASESVDNYGISFMN (SEQ ID NO: 24), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR2 region comprising an amino acid sequence: AASNQGS (SEQ ID NO: 25) or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; and/or a LCDR3 region of I-396 comprising an amino acid sequence: HQSKEVPWT (SEQ ID NO: 26), or a sequence of at least 4, 5, 6, 7 or 8 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be deleted or substituted by a different amino acid. CDR positions may be according to Kabat numbering.

Another exemplary anti-CD39 VH and VL pair according to the disclosure is that of antibody I-399, the amino acid sequence of the heavy chain variable region of which is listed below (SEQ ID NO: 27), and the amino acid sequence of the light chain variable region of which is listed below (SEQ ID NO: 28). The CDRs according to Kabat numbering are underlined in SEQ ID NOS: 27 and 28. Optionally, the VH and VL comprise (e.g., are modified to incorporate) human acceptor frameworks. In one embodiment, an anti-CD39 antibody of the disclosure comprises the VH CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the heavy chain variable region having the amino acid sequence of SEQ ID NO: 27. In one embodiment, an anti-CD39 antibody of the disclosure comprise the VL CDR1, CDR2 and/or CDR3 (e.g., according to Kabat numbering) of the light chain variable region having the amino acid sequence of SEQ ID NO: 28.

I-399 VH:

25 PVQLQQPGAEVVMPGASVKLSCKASGYTFTSFWMNWMRQRPGQGLEWIGEIDPSDFYTN  
SNQRFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARGDFGWYFDVWGTGTSVTVSS  
(SEQ ID NO: 27).

I-399 VL:

30 EIVLTQSPTTMTSSPGEKITFTCSASSSINSNYLHWYQQKPGFSPKLLIYRTSNLASGVPTRF  
SGSGSGTYSLTIGTMEAEDVATYYCQQGSSLPRTFGGGTKLEIK  
(SEQ ID NO: 28).

An anti-CD39 antibody may for example comprise: a HCDR1 comprising an amino acid sequence: SFWMN (SEQ ID NO: 29), or a sequence of at least 4 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR2 comprising an amino acid sequence:

EIDPSDFYTNSNQRFKG (SEQ ID NO: 30), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a HCDR3 comprising an amino acid sequence: GDFGWFYFDV (SEQ ID NO: 31), or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR1 comprising an amino acid sequence: SASSSINSNYLH (SEQ ID NO: 32), or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; a LCDR2 region comprising an amino acid sequence: RTSNLAS (SEQ ID NO: 33) or a sequence of at least 4, 5 or 6 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be substituted by a different amino acid; and/or a LCDR3 region of I-399 comprising an amino acid sequence: QQGSSLPRT (SEQ ID NO: 34), or a sequence of at least 4, 5, 6, 7 or 8 contiguous amino acids thereof, optionally wherein one or more of these amino acids may be deleted or substituted by a different amino acid. CDR positions may be according to Kabat numbering.

In any of the I-394, I-395, I-396 and I-399 antibodies, the HCDR1, 2, 3 and LCDR1, 2, 3 sequences (each CDR independently, or all CDRs) can be specified as being those of the Kabat numbering system, (as indicated in the VH and VL sequences by underlining), those of the Chothia numbering system, or, those of the IMGT numbering system, or any other suitable numbering system.

In any aspect, the specified variable region, FR and/or CDR sequences may comprise one or more sequence modifications, e.g., a substitution (1, 2, 3, 4, 5, 6, 7, 8 or more sequence modifications). In one embodiment the substitution is a conservative modification.

25 In another aspect, the anti-CD39 compound comprises a VH domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity, to the VH domain of an antibody disclosed herein. In another aspect, the anti-CD39 antibody comprises a VL domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity, to the VL domain of an antibody disclosed herein.

30 35 Optionally, in any embodiment herein, an anti-CD39 antibody can be characterized as being a function-conservative variant of any of the antibodies, heavy and/or light chains, CDRs or variable regions thereof described herein. "Function-conservative variants" are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example,

polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A “function-conservative variant” also includes a polypeptide which has at least 60% amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75%, more preferably at least 85%, still preferably at least 90%, and even more preferably at least 95%, and which has the same or substantially similar properties or functions as the native or parent protein (e.g. heavy or light chains, or CDRs or variable regions thereof) to which it is compared. In one embodiment, the antibody comprises a heavy chain variable region that is a function-conservative variant of the heavy chain variable region of antibody I-394, I-395, I-396, I-397, I-398 or I-399, and a light chain variable region that is a function-conservative variant of the light chain variable region of the respective I-394, I-395, I-396, I-397, I-398 or I-399 antibody. In one embodiment, the antibody comprises a heavy chain that is a function-conservative variant of the heavy chain variable region of antibody I-394, I-395, I-396, I-397, I-398 or I-399 fused to a human heavy chain constant region disclosed herein, optionally a constant region of any of SEQ ID NOS: 44-47, and a light chain that is a function-conservative variant of the light chain variable region of the respective I-394, I-395, I-396, I-397, I-398 or I-399 antibody fused to a human Cκappa light chain constant region.

#### *Production of antibodies*

Anti-CD39 antibodies may be produced by any of a variety of techniques known in the art. Typically, they are produced by immunization of a non-human animal, for example a mouse, with an immunogen comprising a CD39 polypeptide, respectively, or by screening a library of candidate binding domains with a CD39 polypeptide. The CD39 polypeptide may comprise the full length sequence of a human CD39 polypeptide, respectively, or a fragment or derivative thereof, typically an immunogenic fragment, i.e., a portion of the polypeptide comprising an epitope exposed on the surface of cells expressing a CD39 polypeptide. Such fragments typically contain at least about 7 consecutive amino acids of the mature polypeptide sequence, even more preferably at least about 10 consecutive amino acids thereof. Fragments typically are essentially derived from the extra-cellular domain of the receptor. In one embodiment, the immunogen comprises a wild-type human CD39 polypeptide in a lipid membrane, typically at the surface of a cell. In a specific embodiment,

the immunogen comprises intact cells, particularly intact human cells, optionally treated or lysed. In another embodiment, the polypeptide is a recombinant CD39 polypeptide.

The step of immunizing a non-human mammal with an antigen may be carried out in any manner well known in the art for stimulating the production of antibodies in a mouse (see, for example, E. Harlow and D. Lane, *Antibodies: A Laboratory Manual.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988), the entire disclosure of which is herein incorporated by reference). The immunogen is suspended or dissolved in a buffer, optionally with an adjuvant, such as complete or incomplete Freund's adjuvant. Methods for determining the amount of immunogen, types of buffers and amounts of adjuvant are well known to those of skill in the art and are not limiting in any way. These parameters may be different for different immunogens, but are easily elucidated.

Similarly, the location and frequency of immunization sufficient to stimulate the production of antibodies is also well known in the art. In a typical immunization protocol, the non-human animals are injected intraperitoneally with antigen on day 1 and again about a week later. This is followed by recall injections of the antigen around day 20, optionally with an adjuvant such as incomplete Freund's adjuvant. The recall injections are performed intravenously and may be repeated for several consecutive days. This is followed by a booster injection at day 40, either intravenously or intraperitoneally, typically without adjuvant. This protocol results in the production of antigen-specific antibody-producing B cells after about 40 days. Other protocols may also be used as long as they result in the production of B cells expressing an antibody directed to the antigen used in immunization.

For monoclonal antibodies, splenocytes are isolated from the immunized non-human mammal and the subsequent fusion of those splenocytes with an immortalized cell in order to form an antibody-producing hybridoma. The isolation of splenocytes from a non-human mammal is well-known in the art and typically involves removing the spleen from an anesthetized non-human mammal, cutting it into small pieces and squeezing the splenocytes from the splenic capsule through a nylon mesh of a cell strainer into an appropriate buffer so as to produce a single cell suspension. The cells are washed, centrifuged and resuspended in a buffer that lyses any red blood cells. The solution is again centrifuged and remaining lymphocytes in the pellet are finally resuspended in fresh buffer.

Once isolated and present in single cell suspension, the lymphocytes can be fused to an immortal cell line. This is typically a mouse myeloma cell line, although many other immortal cell lines useful for creating hybridomas are known in the art. Murine myeloma lines include, but are not limited to, those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, U. S. A., X63 Ag8653 and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland U.

S. A. The fusion is effected using polyethylene glycol or the like. The resulting hybridomas are then grown in selective media that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Hybridomas are typically grown on a feeder layer of macrophages. The macrophages are preferably from littermates of the non-human mammal used to isolate splenocytes and are typically primed with incomplete Freund's adjuvant or the like several days before plating the hybridomas. Fusion methods are described in Goding, "Monoclonal Antibodies: Principles and Practice," pp. 59-103 (Academic Press, 1986), the disclosure of which is herein incorporated by reference.

The cells are allowed to grow in the selection media for sufficient time for colony formation and antibody production. This is usually between about 7 and about 14 days.

The hybridoma colonies are then assayed for the production of antibodies that specifically bind to CD39 polypeptide gene products. The assay is typically a colorimetric ELISA-type assay, although any assay may be employed that can be adapted to the wells that the hybridomas are grown in. Other assays include radioimmunoassays or fluorescence activated cell sorting. The wells positive for the desired antibody production are examined to determine if one or more distinct colonies are present. If more than one colony is present, the cells may be re-cloned and grown to ensure that only a single cell has given rise to the colony producing the desired antibody. Typically, the antibodies will also be tested for the ability to bind to CD39 polypeptides, e.g., CD39-expressing cells.

Hybridomas that are confirmed to produce a monoclonal antibody can be grown up in larger amounts in an appropriate medium, such as DMEM or RPMI-1640. Alternatively, the hybridoma cells can be grown *in vivo* as ascites tumors in an animal.

After sufficient growth to produce the desired monoclonal antibody, the growth media containing monoclonal antibody (or the ascites fluid) is separated away from the cells and the monoclonal antibody present therein is purified. Purification is typically achieved by gel electrophoresis, dialysis, chromatography using protein A or protein G-Sepharose, or an anti-mouse Ig linked to a solid support such as agarose or Sepharose beads (all described, for example, in the Antibody Purification Handbook, Biosciences, publication No. 18-1037-46, Edition AC, the disclosure of which is hereby incorporated by reference). The bound antibody is typically eluted from protein A/protein G columns by using low pH buffers (glycine

or acetate buffers of pH 3.0 or less) with immediate neutralization of antibody-containing fractions. These fractions are pooled, dialyzed, and concentrated as needed.

Positive wells with a single apparent colony are typically re-cloned and re-assayed to insure only one monoclonal antibody is being detected and produced.

Antibodies may also be produced by selection of combinatorial libraries of immunoglobulins, as disclosed for instance in (Ward et al. *Nature*, 341 (1989) p. 544, the entire disclosure of which is herein incorporated by reference).

The identification of one or more antibodies that bind(s) to the antigen of interest, i.e. CD39, particularly or essentially the same region, determinant or epitope as monoclonal antibody I-394, I-395, I-396 or I-399, can be readily determined using any one of a variety of immunological screening assays in which antibody competition can be assessed. Many such assays are routinely practiced and are well known in the art (see, e.g., U.S. Pat. No. 5,660,827, issued Aug. 26, 1997, which is specifically incorporated herein by reference).

For example, where the test antibodies to be examined are obtained from different source animals, or are even of a different Ig isotype, a simple competition assay may be employed in which the control (I-394, I-395, I-396 or I-399, for example) and test antibodies are admixed (or pre-adsorbed) and applied to a sample containing CD39 polypeptides. Protocols based upon western blotting and the use of BIACORE analysis are suitable for use in such competition studies.

In certain embodiments, one pre-mixes the control antibodies (e.g., I-394, I-395, I-396 or I-399, for example) with varying amounts of the test antibodies (e.g., about 1:10 or about 1:100) for a period of time prior to applying to the CD39 antigen sample. In other embodiments, the control and varying amounts of test antibodies can simply be admixed during exposure to the CD39 antigen sample. As long as one can distinguish bound from free antibodies (e.g., by using separation or washing techniques to eliminate unbound antibodies) and I-394 from the test antibodies (e.g., by using species-specific or isotype-specific secondary antibodies or by specifically labeling I-394, I-395, I-396 or I-399 with a detectable label) one can determine if the test antibodies reduce the binding of I-394, I-395, I-396 or I-399 to the antigens. The binding of the (labelled) control antibodies in the absence of a completely irrelevant antibody can serve as the control high value. The control low value can be obtained by incubating the labelled (I-394, I-395, I-396 or I-399) antibodies with unlabelled antibodies of exactly the same type (I-394, I-395, I-396 or I-399), where competition would occur and reduce binding of the labelled antibodies. In a test assay, a significant reduction in labelled antibody reactivity in the presence of a test antibody is indicative of a test antibody that "cross-reacts" or competes with the labelled (I-394, I-395, I-396 or I-399) antibody. Any test antibody that reduces the binding of I-394, I-395, I-396 or I-399 to the antigen can be used to identify the test antibody.

399 to CD39 antigens by at least about 50%, such as at least about 60%, or more preferably at least about 80% or 90% (e.g., about 65-100%), at any ratio of I-394, I-395, I-396 or I-399: test antibody between about 1:10 and about 1:100 can be selected. In one embodiment, such test antibody will reduce the binding of I-394, I-395, I-396 or I-399 to the CD39 antigen by at least about 90% (e.g., about 95%).

Competition can also be assessed by, for example, a flow cytometry test. In such a test, cells bearing a given CD39 polypeptide can be incubated first with I-394, for example, and then with the test antibody labelled with a fluorochrome or biotin. The antibody is said to compete with I-394 if the binding obtained upon preincubation with a saturating amount of I-394 is about 80%, preferably about 50%, about 40% or less (e.g., about 30%, 20% or 10%) of the binding (as measured by mean of fluorescence) obtained by the antibody without preincubation with I-394. Alternatively, an antibody is said to compete with I-394 if the binding obtained with a labelled I-394 antibody (by a fluorochrome or biotin) on cells preincubated with a saturating amount of test antibody is about 80%, preferably about 50%, about 40%, or less (e.g., about 30%, 20% or 10%) of the binding obtained without preincubation with the test antibody.

Determination of whether an antibody binds within an epitope region can be carried out in ways known to the person skilled in the art. As one example of such mapping/characterization methods, an epitope region for an anti-CD39 antibody may be determined by epitope "foot-printing" using chemical modification of the exposed amines/carboxyls in the respective CD39 protein. One specific example of such a foot-printing technique is the use of HXMS (hydrogen-deuterium exchange detected by mass spectrometry) wherein a hydrogen/deuterium exchange of receptor and ligand protein amide protons, binding, and back exchange occurs, wherein the backbone amide groups participating in protein binding are protected from back exchange and therefore will remain deuterated. Relevant regions can be identified at this point by peptic proteolysis, fast microbore high-performance liquid chromatography separation, and/or electrospray ionization mass spectrometry. See, e.g., Ehring H, Analytical Biochemistry, Vol. 267 (2) pp. 252-259 (1999) Engen, J. R. and Smith, D. L. (2001) Anal. Chem. 73, 256A-265A. Another example of a suitable epitope identification technique is nuclear magnetic resonance epitope mapping (NMR), where typically the position of the signals in two-dimensional NMR spectra of the free antigen and the antigen complexed with the antigen binding peptide, such as an antibody, are compared. The antigen typically is selectively isotopically labeled with <sup>15</sup>N so that only signals corresponding to the antigen and no signals from the antigen binding peptide are seen in the NMR-spectrum. Antigen signals originating from amino acids involved in the interaction with the antigen binding peptide typically will shift position in the

spectrum of the complex compared to the spectrum of the free antigen, and the amino acids involved in the binding can be identified that way. See, e.g., Ernst Schering Res Found Workshop. 2004; (44): 149-67; Huang et al., Journal of Molecular Biology, Vol. 281 (1) pp. 61-67 (1998); and Saito and Patterson, Methods. 1996 Jun; 9 (3): 516-24.

Epitope mapping/characterization also can be performed using mass spectrometry methods. See, e.g., Downard, J Mass Spectrom. 2000 Apr; 35 (4): 493-503 and Kiselar and Downard, Anal Chem. 1999 May 1; 71 (9): 1792-1801. Protease digestion techniques also can be useful in the context of epitope mapping and identification. Antigenic determinant-relevant regions/sequences can be determined by protease digestion, e.g., by using trypsin in a ratio of about 1:50 to CD39 or o/n digestion at and pH 7-8, followed by mass spectrometry (MS) analysis for peptide identification. The peptides protected from trypsin cleavage by the anti-CD39 binder can subsequently be identified by comparison of samples subjected to trypsin digestion and samples incubated with antibody and then subjected to digestion by e.g., trypsin (thereby revealing a footprint for the binder). Other enzymes like chymotrypsin, pepsin, etc., also or alternatively can be used in similar epitope characterization methods. Moreover, enzymatic digestion can provide a quick method for analyzing whether a potential antigenic determinant sequence is within a region of the CD39 polypeptide that is not surface exposed and, accordingly, most likely not relevant in terms of immunogenicity/antigenicity.

Site-directed mutagenesis is another technique useful for elucidation of a binding epitope. For example, in “alanine-scanning”, each residue within a protein segment is replaced with an alanine residue, and the consequences for binding affinity measured. If the mutation leads to a significant reduction in binding affinity, it is most likely involved in binding. Monoclonal antibodies specific for structural epitopes (i.e., antibodies which do not bind the unfolded protein) can be used to verify that the alanine-replacement does not influence over-all fold of the protein. See, e.g., Clackson and Wells, Science 1995; 267:383-386; and Wells, Proc Natl Acad Sci USA 1996; 93:1-6.

Electron microscopy can also be used for epitope “foot-printing”. For example, Wang et al., Nature 1992; 355:275-278 used coordinated application of cryoelectron microscopy, three-dimensional image reconstruction, and X-ray crystallography to determine the physical footprint of a Fab-fragment on the capsid surface of native cowpea mosaic virus.

Other forms of “label-free” assay for epitope evaluation include surface plasmon resonance (SPR, BIACORE) and reflectometric interference spectroscopy (RifS). See, e.g., Fägerstam et al., Journal Of Molecular Recognition 1990;3:208-14; Nice et al., J. Chromatogr. 1993; 646:159-168; Leipert et al., Angew. Chem. Int. Ed. 1998; 37:3308-3311; Kröger et al., Biosensors and Bioelectronics 2002; 17:937-944.

It should also be noted that an antibody binding the same or substantially the same epitope as an antibody can be identified in one or more of the exemplary competition assays described herein.

Typically, an anti-CD39 antibody provided herein has an affinity for a respective CD39 polypeptide in the range of about  $10^4$  to about  $10^{11}$  M<sup>-1</sup> (e.g., about  $10^8$  to about  $10^{10}$  M<sup>-1</sup>). For example, in a particular aspect the anti-CD39 antibody that have an average disassociation constant (K<sub>D</sub>) of less than  $1 \times 10^{-9}$  M with respect to CD39, respectively, as determined by, e.g., surface plasmon resonance (SPR) screening (such as by analysis with a BIAcore™ SPR analytical device). In a more particular exemplary aspect, the anti-CD39 antibodies that have a KD of about  $1 \times 10^{-8}$  M to about  $1 \times 10^{-10}$  M, or about  $1 \times 10^{-9}$  M to about  $1 \times 10^{-11}$  M, for CD39, respectively. In one embodiment, binding is monovalent binding. In one embodiment, binding is bivalent binding.

Antibodies can be characterized for example by a mean KD of no more than about (i.e. better affinity than) 100, 60, 10, 5, or 1 nanomolar, preferably sub-nanomolar or optionally no more than about 500, 200, 100 or 10 picomolar. KD can be determined for example for example by immobilizing recombinantly produced human CD39 proteins on a chip surface, followed by application of the antibody to be tested in solution. In one embodiment, the method further comprises a step of selecting antibodies from (b) that are capable of competing for binding to CD39 with antibody I-394.

In one aspect of any of the embodiments, the antibodies prepared according to the present methods are monoclonal antibodies. In another aspect, the non-human animal used to produce antibodies according to the methods herein is a mammal, such as a rodent, bovine, porcine, fowl, camelid, horse, rabbit, goat, or sheep.

25 DNA encoding an antibody that binds an epitope present on a CD39 polypeptide is isolated from a hybridoma and placed in an appropriate expression vector for transfection into an appropriate host. The host is then used for the recombinant production of the antibody, or variants thereof, such as a humanized version of that monoclonal antibody, active fragments of the antibody, chimeric antibodies comprising the antigen recognition portion of the antibody, or versions comprising a detectable moiety.

30 DNA encoding the monoclonal antibodies of the disclosure, e.g., antibody I-394, can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the

recombinant host cells. As described elsewhere in the present specification, such DNA sequences can be modified for any of a large number of purposes, e.g., for humanizing antibodies, producing fragments or derivatives, or for modifying the sequence of the antibody, e.g., in the antigen binding site in order to optimize the binding specificity of the antibody. In one embodiment, provided is an isolated nucleic acid sequence encoding a light chain and/or a heavy chain of an antibody, as well as a recombinant host cell comprising (e.g., in its genome) such nucleic acid. Recombinant expression in bacteria of DNA encoding the antibody is well known in the art (see, for example, Skerra et al., *Curr. Opinion in Immunol.*, 5, pp. 256 (1993); and Pluckthun, *Immunol.* 130, p. 151 (1992)).

Fragments and derivatives of antibodies (which are encompassed by the term "antibody" or "antibodies" as used in this application, unless otherwise stated or clearly contradicted by context) can be produced by techniques that are known in the art. "Fragments" comprise a portion of the intact antibody, generally the antigen binding site or variable region. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')2, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (referred to herein as a "single-chain antibody fragment" or "single chain polypeptide"), including without limitation (1) single-chain Fv molecules (2) single chain polypeptides containing only one light chain variable domain, or a fragment thereof that contains the three CDRs of the light chain variable domain, without an associated heavy chain moiety and (3) single chain polypeptides containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multispecific (e.g., bispecific) antibodies formed from antibody fragments. Included, *inter alia*, are a nanobody, domain antibody, single domain antibody or a "dAb".

In one aspect, the agent is an antibody selected from a fully human antibody, a humanized antibody, and a chimeric antibody.

In one aspect, the agent is a fragment of an antibody comprising a constant domain selected from IgG1, IgG2, IgG3 and IgG4. In one aspect, the agent is an antibody fragment selected from a Fab fragment, a Fab' fragment, a Fab'-SH fragment, a F(ab)2 fragment, a F(ab')2 fragment, an Fv fragment, a Heavy chain Ig (a llama or camel Ig), a V<sub>HH</sub> fragment, a single domain FV, and a single-chain antibody fragment. In one aspect, the agent is a synthetic or semisynthetic antibody-derived molecule selected from a scFV, a dsFV, a minibody, a diabody, a triabody, a kappa body, an IgNAR; and a multispecific antibody. In one aspect, the antibody is in at least partially purified form. In one aspect, the antibody is in essentially isolated form.

An anti-CD39 such as an antibody can be incorporated in a pharmaceutical formulation comprising in a concentration from 1 mg/ml to 500 mg/ml, wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants. In one embodiment, the pharmaceutical formulation is an aqueous formulation, i.e., formulation comprising water. Such formulation is typically a solution or a suspension. In a further embodiment, the pharmaceutical formulation is an aqueous solution. The term "aqueous formulation" is defined as a formulation comprising at least 50 %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50 %w/w water.

In another embodiment, the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds solvents and/or diluents prior to use.

In another embodiment, the pharmaceutical formulation is a dried formulation (e.g., freeze-dried or spray-dried) ready for use without any prior dissolution.

In a further aspect, the pharmaceutical formulation comprises an aqueous solution of such an antibody, and a buffer, wherein the antibody is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.

In a another embodiment, the pH of the formulation is in the range selected from the list consisting of from about 2.0 to about 10.0, about 3.0 to about 9.0, about 4.0 to about 8.5, about 5.0 to about 8.0, and about 5.5 to about 7.5.

In a further embodiment, the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment contemplated herein.

In a further embodiment, the formulation further comprises a pharmaceutically acceptable preservative. In a further embodiment, the formulation further comprises an isotonic agent. In a further embodiment, the formulation also comprises a chelating agent. In a further embodiment described herein the formulation further comprises a stabilizer. In a further embodiment, the formulation further comprises a surfactant. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19<sup>th</sup> edition, 1995.

It is possible that other ingredients may be present in the peptide pharmaceutical formulation described herein. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatine or proteins) and a

zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical formulation described herein.

Administration of pharmaceutical compositions as described herein may be through several routes of administration, for example, intravenous. Suitable antibody formulations can also be determined by examining experiences with other already developed therapeutic monoclonal antibodies. Several monoclonal antibodies have been shown to be efficient in clinical situations, such as Rituxan (Rituximab), Herceptin (Trastuzumab) Xolair (Omalizumab), Bexxar (Tositumomab), Campath (Alemtuzumab), Zevalin, Oncolym and similar formulations may be used with the antibodies as described herein.

Also provided are kits which include a pharmaceutical composition containing an anti-CD39 antibody, and an agent that induces ATP release from tumor cells, and a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods. The kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having cancer (e.g., a solid tumor). The kit also can include a syringe.

Optionally, the kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the anti- CD39 or an agent that induces ATP release from tumor cells for a single administration in accordance with the methods provided above. Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits. For instance, a kit may provide one or more pre-filled syringes containing an amount of the anti-CD39 and agent that induces ATP release from tumor cells.

25 In one embodiment, described herein is a kit for treating a cancer in a human patient, the kit comprising:

(a) a dose of an anti-CD39 antibody that neutralizes the activity of sCD39, optionally wherein the antibody comprises the hypervariable region (e.g., CDR1, CDR2 and CDR3 domains) of a heavy chain variable region of antibody I-394, and the hypervariable region (e.g., CDR1, CDR2 and CDR3 domains) of a light chain variable region of antibody I-394;

30 (b) a dose of an agent that induces ATP release from tumor cells; and

(c) optionally, instructions for using the anti-CD39 antibody and agent that induces ATP release from tumor cells in any of the methods described herein.

### Diagnostics, prognostics, and treatment of malignancies

Described herein are methods useful in the diagnosis, prognosis, monitoring, treatment and prevention of a cancer in an individual through the use of anti-CD39 antibodies to potentiate the activity of an agent that induces the extracellular release of ATP from tumor cells.

Extracellular ATP is released from tumor cells in case of stress (mechanical, hypotonic or hypoxic) or in case of cell death. Necrosis favors the passive release of ATP through the release of total cellular content, whereas apoptosis favors the release of ATP by activation of caspases 3 and 9 which cleave and activate Panexin1 (ATP transporter). Examples of agents that induce the extracellular release of ATP from tumor cells can include chemotherapy, radiotherapy, and, more generally, agents that induce apoptosis and thereby favor ATP release. Agents that induce the extracellular release of ATP have been shown to induce immunogenic cell death. For example, substantial ATP release can be induced by anthracyclines, oxaliplatin, cisplatin and X-rays, PARP inhibitors, taxanes, anthracyclines, DNA damaging agents, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, nitrogen mustards, maytansinoids, calicheamycins, duocarmycins, tubulysins, dolastatins and auristatins, enediynes, amatoxins, pyrrolobenzodiazepines, ethylenimines, radioisotopes, therapeutic proteins and peptides, and toxins or fragments thereof.

ATP can also be released through administration with depleting antibodies that bind antigens expressed at the surface of cancer cells (e.g. tumor antigen), for example antibodies that are coupled to a chemotherapeutic agent that induces ATP release, antibodies that are capable of mediating apoptosis or antibodies that direct antibody-dependent cell-mediated cytotoxicity (ADCC) toward the cancer cells (for example wherein the antibody has an Fc domain of human IgG1 isotype so as to mediate ADCC).

Anthracyclines include, for example daunorubicin, doxorubicin, epirubicin or idarubicin, optionally liposomal formulations thereof, e.g. liposomal daunorubicin such as DaunoXome™ or Vyxeos™ or CPX-351 (a combination of cytarabine and daunorubicin). Anthracyclines are widely used to treat solid and hematological malignancies, including for example acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Doxorubicin and its derivative, epirubicin, are used in breast cancer, childhood solid tumors, soft tissue sarcomas, and aggressive lymphomas. Daunorubicin is used to treat acute lymphoblastic or myeloblastic leukemias, and its derivative, idarubicin is used in multiple myeloma, non-Hodgkin's lymphomas, and breast cancer. Nemorubicin is used for treatment of hepatocellular carcinoma, pixantrone, used as a second-line treatment of non-Hodgkin's lymphomas. Sabarubicin is used for non-small cell lung cancer, hormone refractory metastatic prostate

cancer, and platinum- or taxane-resistant ovarian cancer. Valrubicin is used for the topical treatment of bladder cancer.

Platinum agents include for example oxaliplatin, cisplatin, carboplatin, nedaplatin, Phenanthriplatin, picoplatin, satraplatin.

Taxanes, include, for example Paclitaxel (Taxol) and docetaxel (Taxotere).

DNA damaging agents, include for example DNA intercalating agents, e.g. an agent that inserts itself into the DNA structure of a cell and binds to the DNA, in turn causing DNA damage (e.g. daunorubicin). Compounds include topoisomerase inhibitors, chemical compounds that block the action of topoisomerase (topoisomerase I and II). Such compounds are used for a wide range of solid tumor and hematological malignancies, notably lymphomas. Topoisomerase I inhibitors include camptothecins, for example irinotecan (approved for treatment of colon cancer), topotecan (approved for treatment of ovarian and lung cancer), camptothecin, lamellarin D, indenoisoquinoline, indimitecan. Further camptothecins include sultecan, cositecan, exatecan, lurtotecan, gimatecan, belotecan, and rubitecan. Topoisomerase II inhibitors include for example etoposide (VP-16), teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticines, aurintricarboxylic acid, and HU-331, a quinolone synthesized from cannabidiol.

PARP inhibitors have been reported to tilt cell death from necrosis to caspase-independent apoptosis in cancer cells. Inhibition of PARP results in increase of intracellular ATP, which in turn is believed to result in extracellular release of ATP upon apoptosis. Poly(ADP-ribose) polymerase (PARP) family of enzymes transform NAD<sup>+</sup> to nicotinamide and ADP-ribose to form long and branched (ADP-ribose) polymers on glutamic acid residues of a number of acceptor proteins usually associated with chromatin. PARP-1, the most abundant PARP, is a nuclear enzyme that catalyzes the formation of poly (ADP-ribose) on its target proteins using NAD<sup>+</sup> as a substrate. PARP inhibitors typically contain as key pharmacophore benzoxazole or benzamide moieties, and various benzamide-derivatives have been reported. Example of approved PARP inhibitors that can be used in accordance with the disclosure include Olaparib (AZD-2281, Lynparza® by Astra Zeneca, approved in ovarian cancer, also effective for treatment of breast cancer, prostate cancer and colorectal cancer), Rucaparib (PF-01367338, Rubraca® by Clovis Oncology, approved in ovarian cancer), Niraparib (MK-4827, Zejula® by Tesaro, approved for epithelial, ovarian, fallopian tube, and primary peritoneal cancer). Further examples of PARP inhibitors that can be used in accordance with the disclosure include Talazoparib (BMN-673, BioMarin Pharmaceutical Inc., Pfizer) for hematological and advanced or recurrent solid tumors, Veliparib (ABT-888, developed by AbbVie) for ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC), melanoma, CEP 9722 for non-small-cell lung cancer (NSCLC),

E7016 (developed by Eisai) for melanoma, and Pamiparib (BGB-290) developed by Beigene for a variety of solid tumor malignancies.

Epothilones include for example, epothilone B and its various analogues, e.g. ixabepilone (BMS-247550) approved for treatment of breast cancer. Vinca alkaloids, include for example, vinblastine, vincristine, vindesine, and vinorelbine. Nitrogen mustards, include for example, cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan, and bendamustine. Maytansinoids, include for example, Ansamitocin, or mertansine (DM1) or DM4 developed by Immunogen Inc.

The agents can be in any suitable configuration or formulation, including for example as free compound or as part of a conjugate, nanoparticle-formulation, encapsulated (e.g. in a liposome), in each case optionally further in a combination with additional pharmaceutically active agents. Agents can conveniently be conjugated to a targeting moiety, such as in an immunoconjugate. The terms "immunoconjugate" and "antibody conjugate" are used interchangeably and refer to an antigen binding agent, e.g., an antibody binding protein or an antibody that is conjugated to another moiety (e.g., a cytotoxic agent, a chemotherapeutic agent that induces ATP release described herein). An immunoconjugate comprising an antigen binding agent conjugated to a cytotoxic agent can also be referred to as a "antibody drug conjugate" or an "ADC".

While the treatment regimens and methods described herein are particularly useful for the treatment of solid tumors, the treatment regimens and methods described herein can also be used for a variety of hematological cancers. The methods and compositions described herein are utilized for example the treatment of a variety of cancers and other proliferative diseases including, but not limited to: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, uterus, prostate, pancreas, stomach, cervix, thyroid, head and neck (head and neck squamous cell carcinoma, and skin (e.g., melanoma); hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkitts lymphoma, and multiple myeloma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, promyelocytic leukemia, and myelodysplastic syndrome; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyoscarcoma; other tumors, including melanoma, seminoma, terato-carcinoma, neuroblastoma and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyoscaroma, and osteosarcoma; and other tumors, including

melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, and thyroid follicular cancer.

Combination therapies for the treatment of cancer provided herein involve administration of a neutralizing anti-CD39 agent (e.g., an antibody) and an agent that induces the extracellular release of ATP, to treat subjects afflicted with cancer. In one embodiment, described herein is an anti-CD39 antibody and a treatment (e.g., an agent) that induces the extracellular release of ATP, for use in combination, to treat subjects having a solid tumor (e.g., a solid tumor, an advanced refractory solid tumor) or subjects having a hematological tumor. In one embodiment, the provided is an anti-CD39 antibody (e.g. having the further characteristics described herein), for use in treating an individual having a cancer, where the treatment comprises administration to the individual of the anti-CD39 antibody in combination with a means for inducing apoptosis in cancerous cells (e.g., so as to induce the extracellular release of ATP in cancerous cells). In one embodiment, the provided is an anti-CD39 antibody (e.g. having the further characteristics described herein), for use in treating an individual having a cancer, where the treatment comprises administration to the individual of the anti-CD39 antibody in combination with a pharmaceutical composition comprising (a) a means (e.g. an agent or treatment) for inducing the apoptosis of cancerous cells and (b) a pharmaceutically acceptable carrier. In one embodiment, the provided is an anti-CD39 antibody (e.g. having the further characteristics described herein), for use in treating an individual having a cancer, where the treatment comprises administration to the individual of the anti-CD39 antibody in combination with a pharmaceutical composition comprising (a) a means (e.g. and agent or treatment) for inducing the extracellular release of ATP in cancerous cells and (b) a pharmaceutically acceptable carrier.

In one embodiment, described herein is an anti-CD39 antibody for use in combination with a platinum agent (e.g. oxaliplatin, cisplatin, carboplatin, nedaplatin, phenanthriplatin, picoplatin, satraplatin, or a combination regimen comprising a platinum agent), to treat an individual having a solid tumor. In one embodiment, the solid tumor is a lung cancer, a squamous lung cancer, non-small cell lung cancer (NSCLC), an ovarian cancer, a carcinoma, a head and neck squamous cell carcinoma (HNSCC), a colorectal cancer, an urothelial cancer, a bladder cancer, a cervical cancer, a gastric cancer, an esophageal cancer or a breast cancer. In one embodiment, the combination regimen comprising a platinum agent is FOLFOX (folinic acid, 5-Fu and oxaliplatin). In one embodiment, the combination regimen comprising a platinum agent comprises carboplatin and a taxane (e.g. paclitaxel).

In one embodiment, described herein is an anti-CD39 antibody for use in combination with a taxane agent (e.g. Paclitaxel (Taxol™) or docetaxel (Taxotere™)), to treat an individual having a solid tumor, e.g. an ovarian cancer, a breast cancer.

In one embodiment, described herein is an anti-CD39 antibody for use in combination with gemcitabine to treat an individual having a solid tumor, e.g. an ovarian cancer.

In one embodiment, the provided is an anti-CD39 antibody for use in combination with an anthracycline agent (e.g. daunorubicin, doxorubicin, epirubicin or idarubicin), to treat an individual having a solid tumor, e.g. an ovarian cancer, a breast cancer, a non-small cell lung cancer, a colorectal cancer, a prostate cancer, a soft tissue sarcoma or a bladder cancer. In one embodiment, described herein is an anti-CD39 antibody for use in combination with an anthracycline agent (e.g. daunorubicin, doxorubicin, epirubicin or idarubicin), to treat an individual having a hematological tumor, e.g. an AML, an acute lymphocytic leukemia (ALL), a chronic myelogenous leukemia (CML), a lymphoma, an acute lymphoblastic, a myeloblastic leukemia, a multiple myeloma or a non-Hodgkin's lymphoma.

In one embodiment, described herein is an anti-CD39 antibody for use in combination with a PARP inhibitor agent (e.g. a PARP-1 inhibitor, olaparib, rucaparib, niraparib, talazoparib, veliparib, CEP 9722, E7016 or pamiparib), to treat an individual having a solid tumor, e.g. an epithelial cancer, an ovarian cancer, a breast cancer, a prostate cancer, a colorectal cancer, a fallopian tube cancer, a peritoneal cancer, a lung cancer, a non-small cell lung cancer (NSCLC) or a melanoma.

The combination treatments described herein can be particularly effective in the treatment of cancers characterized by high expression of CD39 (with or without a prior step of assessing expression or levels of CD39 in the individual), including in particular ovarian cancer, gastric cancer and esophageal cancer.

In one embodiment, provided is an anti-CD39 antibody for use in combination with a platinum agent (e.g. carboplatin), and optionally further in combination with gemcitabine, to treat an individual having an ovarian cancer.

In one embodiment, provided is an anti-CD39 antibody for use in combination with a platinum agent (e.g. oxaliplatin), optionally wherein the anti-CD39 antibody is used in combination with the FOLFOX regimen (folinic acid, 5-Fu and oxaliplatin), to treat an individual having a gastric cancer or an esophageal cancer.

In one embodiment, provided is an anti-CD39 antibody for use in combination with a platinum agent (e.g. carboplatin), and optionally further in combination with a taxane (e.g. paclitaxel), to treat an individual having a NSCLC, optionally wherein the NSCLC is a squamous cell lung cancer.

In one embodiment, provided is an anti-CD39 antibody for use in combination with FOLFOX.

In one embodiment, a solid tumor is an ovarian cancer and the individual is treated with anti-CD39 antibody in combination with oxaliplatin or carboplatin, optionally further in combination with gemcitabine. Optionally, in any embodiment herein, an ovarian cancer is a platinum-resistant ovarian cancer. An individual having a platinum-resistant ovarian cancer can for example be characterized as having cancer which has progressed, relapsed or not responded to prior treatment with a platinum-agent containing therapeutic regimen that does not include an anti-CD39 antibody. In another embodiment, an ovarian cancer can be characterized as a platinum-sensitive ovarian cancer.

The combination therapies involving an anti-CD39 antibody can be advantageously used to enhance the effect of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells. This can be useful, for example, in an individual having a cancer (e.g., a lung cancer, ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer) that is resistant to an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells. An individual having a cancer that is resistant to an agent or treatment can for example be characterized as having cancer which has progressed, relapsed or not responded to prior treatment with such agent or treatment (or a therapeutic regimen comprising such agent or treatment, wherein the regimen does not include an anti-CD39 antibody).

For example, an individual having a cancer (e.g., a breast cancer, ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer) that is resistant to a member of a particular class of agent or treatment that induces the extracellular release of ATP from tumor cells (e.g. taxane, platinum agent, PARP inhibitor, or combination regimen comprising such) can be treated with an anti-CD39 antibody in combination with an agent of the said class of agent or treatment that induces the extracellular release of ATP from tumor cells. For example, in one embodiment, an anti-CD39 antibody can be used in combination with a taxane, to treat an individual having a taxane-resistant cancer. In another example, an anti-CD39 antibody can be used in combination with a platinum agent, to treat an individual having a platinum agent-resistant cancer. In another example, an anti-CD39 antibody can be used in combination with a PARP inhibitor, to treat an individual having a PARP inhibitor-resistant cancer.

In another embodiment, an individual having a cancer that is resistant to a member of a particular class of agent or treatment that induces the extracellular release of ATP from tumor cells (e.g. taxane, platinum agent, PARP inhibitor, or combination regimen comprising such) can be treated with an anti-CD39 antibody in combination with an agent of a different

class of agent or treatment that induces the extracellular release of ATP from tumor cells. For example, in one embodiment, an anti-CD39 antibody can be used in combination with a taxane, to treat an individual having a platinum-resistant cancer. In another embodiment, an anti-CD39 antibody can be used in combination with a platinum agent, to treat an individual having a taxane-resistant cancer. In another embodiment, an anti-CD39 antibody can be used in combination with a PARP inhibitor, to treat an individual having a taxane-resistant and/or a platinum resistant cancer.

In one embodiment, provided is an antibody that is capable of binding and inhibiting the ATPase activity of a soluble extracellular domain human CD39 protein, for use in the treatment or prevention of a cancer in an individual, the treatment comprising:

- a) determining whether the individual has a poor prognosis for response to treatment with an agent that induces the extracellular release of ATP from tumor cells, and
- b) upon a determination that the individual has a poor prognosis for response to treatment with an agent that induces the extracellular release of ATP from tumor cells, administering to the individual an antibody that is capable of binding and inhibiting the ATPase activity of a human CD39 protein in the presence of exogenously added ATP. Optionally, the individual has a platinum-resistant cancer, a taxane-resistant cancer, or a PARP inhibitor-resistant cancer. Optionally, the step determining the individual has a poor prognosis for response to treatment with an agent that induces the extracellular release of ATP from tumor cells comprises assessing whether immune effector cells in a biological sample from the individual are characterized by one or markers of immune suppression and/or exhaustion, wherein the presence or and/or elevated levels of immune effector cells characterized by one or markers of immune suppression and/or exhaustion indicates a poor prognosis for response to treatment with an agent that induces the extracellular release of ATP from tumor cells.

The advantage of using an anti-CD39 antibody to enhance the effect of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells can also be employed to achieve improved results in an individual having a cancer (e.g., a lung cancer, ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer) that is sensitive (e.g. predicted or determined to be sensitive) to an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells. For example, in one embodiment, an anti-CD39 antibody can be used in combination with a taxane, to treat an individual having a taxane-sensitive cancer. In another example, an anti-CD39 antibody can be used in combination with a platinum agent, to treat an individual having a platinum agent-sensitive cancer. In another

example, an anti-CD39 antibody can be used in combination with a PARP inhibitor, to treat an individual having a PARP inhibitor-sensitive cancer.

As used herein, adjunctive or combined administration (co-administration) includes simultaneous administration of the compounds in the same or different dosage form, or separate administration of the compounds (e.g., sequential administration). Thus, the anti-CD39 and the agent that induces the extracellular release of ATP can be simultaneously administered in a single formulation. Alternatively, the anti-CD39 and the agent that induces the extracellular release of ATP can be formulated for separate administration and are administered concurrently or sequentially.

A patient having a cancer can be treated with the anti-CD39 agent and the agent that induces the extracellular release of ATP with or without a prior detection step to assess tumoral ATPase activity, tumoral ATP (e.g., intratumoral ATP concentration), and/or CD39 expression on cells. Optionally, the treatment methods can comprise a step of detecting a CD39 nucleic acid or polypeptide in a biological sample of a tumor (e.g., on a tumor or tumor-infiltrating cell) from an individual.

Optionally, the treatment methods can comprise a step of detecting a CD39 nucleic acid or polypeptide in a biological sample from an individual. Examples of biological samples include any suitable biological fluid (for example serum, lymph, blood), cell sample, or tissue sample. Any determination that cells in a biological sample (e.g., cancer cells, lymphocytes, e.g., TReg cells, B cells, T cells) express CD39 at a high level, or that a high number of cells in the sample are CD39-positive, or show high intensity of staining with an anti-CD39 antibody, compared to a reference) can indicate that the individual has a cancer that may have a strong benefit from treatment with an agent that inhibits CD39 in combination with an agent that induces ATP release from tumor cells. In one embodiment, the treatment methods can comprise a step of detecting a CD39 nucleic acid or polypeptide in a biological sample of a tumor (e.g., on a tumor-infiltrating cell) from an individual.

In the treatment methods, the anti-CD39 antibody and the agent or treatment that induces the extracellular release of ATP can be administered separately, together or sequentially, or in a cocktail (where appropriate). In some embodiments, the agent or treatment that induces the extracellular release of ATP is administered prior to the administration of the anti-CD39 antibody. In preferred embodiments, the anti-CD39 antibody is administered prior to or concurrently with the administration of the agent or treatment that induces the extracellular release of ATP. In one advantageous embodiment, the anti-CD39 antibody is administered concurrently with or 0 to 15 days prior to, a course or cycle of treatment with the agent or treatment that induces the extracellular release of ATP. For example, an anti-CD39 antibody can be administered approximately 0 to 15 days prior to the

administration of the agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered at least 1 hours, 12 hours, 24 hours or 48 hours prior to the administration of the agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered at least 1 hour, 12 hours, 24 hours or 48 hours prior to the administration of the agent or treatment that induces the extracellular release of ATP, but no more than 1 week prior to the administration of the agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered between 0 and 48 hours, or between 1 and 48 hours prior to the administration of the agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered from about 30 minutes to about 2 weeks, from about 30 minutes to about 1 week, from about 1 hour to about 2 weeks, from about 1 hour to about 1 week, from about 1 hour to about 2 hours, from about 2 hours to about 4 hours, from about 4 hours to about 6 hours, from about 6 hours to about 8 hours, from about 8 hours to 1 day, from about 24 or 48 hours to about 5, 6 or 7 days, from about 1 hour to about 5, 6 or 7 days, from about 1 hour to about 15 days, from about 24 or 48 hours to about 15 days, from about 3 to 7 days, or from about 1 to 5 days prior to the administration of the agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered concurrently with the administration of the agent or treatment that induces the extracellular release of ATP. In some advantageous embodiments, the agent or treatment that induces the extracellular release of ATP is administered at least twice within a period of 15 days or about two weeks following administration of the anti-CD39 antibody. In other embodiments, an anti-CD39 antibody is administered after the administration of agent or treatment that induces the extracellular release of ATP. In some embodiments, an anti-CD39 antibody is administered from about 30 minutes to about 2 weeks, from about 30 minutes to about 1 week, from about 1 hour to about 24, 36 or 48 hours, from about 1 hour to about 2 hours, from about 2 hours to about 4 hours, from about 4 hours to about 6 hours, from about 6 hours to about 8 hours, from about 8 hours to 1 day, or from about 1 day to about 2, 3, 4 or 5 days after the administration of the agent or treatment that induces the extracellular release of ATP.

The agent or treatment that induces the extracellular release of ATP can be administered in amounts and treatment regimens typically used for that agent or treatment in a monotherapy for the particular disease or condition being treated.

An example of a suitable amount of anti-CD39 antibody can be between 1 and 20 mg/kg body weight. In one embodiment, the amount is administered to an individual weekly, every two weeks, monthly or every two months.

In one embodiment provided is a method of treating a human individual having a cancer, comprising administering to the individual at least one administration cycle comprising an effective amount of an anti-CD39 antibody of the disclosure and an effective amount of an agent or treatment that induces the extracellular release of ATP. In one embodiment, the cycle is a period of eight weeks or less (e.g. 2 weeks, 4 weeks, 8 weeks). In one embodiment, for each of the at least one cycles, one, two, three or four doses of the anti-CD39 antibody are administered, optionally at a dose of 1-20 mg/kg body weight. In one embodiment, the anti-CD39 antibody is administered by intravenous infusion. In one embodiment, for each of the at least one cycles, one, two, three or four doses of the agent or treatment that induces the extracellular release of ATP are administered.

As shown herein, the strongest anti-tumor responses were observed when repeated administration of chemotherapeutic agent in presence of saturating concentrations of anti-CD39 antibody permitted ATP accumulation and adenosine (Ado) suppression to take place during the classical two-week period required to mount an efficient anti-tumor immune response. Accordingly, in one advantageous embodiment, treatment according to the present disclosure comprises at least two successive administrations of the agent or treatment that induces the extracellular release of ATP. In one embodiment, the agent or treatment that induces the extracellular release of ATP is administered at least twice within a period of 15 days or about two weeks following administration of the anti-CD39 antibody. The anti-CD39 antibody can be administered in an amount and/or schedule such that the concentrations of anti-CD39 antibody in circulation and/or tissue of interest (e.g. tumor tissue) inhibit the ATPase activity of CD39 (e.g. at a concentration that saturates CD39 protein) at each of the two successive administrations of the agent or treatment that induces the extracellular release of ATP. For example, in one advantageous therapeutic regimen, an anti-CD39 antibody is administered concurrently with, or at least 1-48 hours before, administration of the chemotherapeutic agent inducing ATP release. In one advantageous therapeutic regimen, an anti-CD39 antibody is administered at least 1, 2, 3, 4, 5, 6 or 7 days before administration of the chemotherapeutic agent inducing ATP release.

In one embodiment, provided is antibody that is capable of binding and inhibiting the ATPase activity of human CD39 (NTPDase1) protein, for use in treating a tumor in a human individual, the treatment comprising administering to the individual an effective amount of each of an anti-CD39 antibody and an agent or treatment that induces the extracellular release of ATP from tumor cells, wherein the agent or treatment that induces the extracellular release of ATP from tumor cells is administered at least twice (e.g. in a first and a second successive administration) and wherein the anti-CD39 antibody is administered in an amount and/or schedule effective to achieve and/or to maintain a saturating concentration

of anti-CD39 antibody between said two administrations of the agent or treatment that induces the extracellular release of ATP from tumor cells. The anti-CD39 antibody can be administered once or twice, for example. In one embodiment, the two administrations of the agent or treatment that induces the extracellular release of ATP from tumor cells are separated by two weeks or less (e.g. administered daily, weekly, two weekly). In one embodiment, the agent or treatment that induces the extracellular release of ATP from tumor cells is administered at least 2, 3 or 4 times during the two week period. In one embodiment, the anti-CD39 antibody can be administered in an amount that results in a concentration that is at least the minimum concentration required to substantially fully (e.g. 90%, 95%) occupy (saturate) CD39 protein. In one embodiment, the anti-CD39 antibody can be administered in an amount that results in a concentration that is at least the minimum concentration required to substantially fully (e.g. 90%, 95%) occupy (saturate) CD39 protein antibody between said two administrations of the agent or treatment that induces the extracellular release of ATP from tumor cells.

Exemplary treatment protocols for treating a human with an anti-CD39 antibody include, for example, administering to the patient an effective amount of each of anti-CD39 antibody and an agent or treatment that induces the extracellular release of ATP from tumor cells, wherein the method comprises at least one administration cycle in which at least one dose of the anti-CD39 antibody is administered and two doses of the agent or treatment that induces the extracellular release of ATP from tumor cells are administered, wherein the two doses of agent or treatment that induces the extracellular release of ATP are administered at an interval of two weeks or less. In one embodiment, the administration cycle is between 2 weeks and 8 weeks. In one embodiment, the anti-CD39 antibody can be administered in an amount and/or schedule such that the concentration of anti-CD39 antibody in circulation and/or tissue of interest (e.g. tumor tissue) inhibits the ATPase activity of CD39. Optionally, the anti-CD39 antibody is administered in an amount that provides a concentration that provides substantially full (e.g. 90%, 95%) occupation (saturation) of CD39. In one embodiment, the anti-CD39 antibody is administered concurrently with, or 1-48 hours prior to, the administration of the agent or treatment that induces the extracellular release of ATP from tumor cells.

In one embodiment, provided is antibody that is capable of binding and inhibiting the ATPase activity of human CD39 (NTPDase1) protein, for use in treating a tumor in a human individual, the treatment comprising administering to the individual: (a) an anti-CD39 antibody in an amount and schedule effective to achieve and/or to maintain a saturating concentration of anti-CD39 antibody for at least one week, optionally at least two weeks (e.g. two weeks, three weeks, four weeks, or more), and (b) an agent or treatment that induces

the extracellular release of ATP from tumor cells, wherein the anti-CD39 antibody is administered concurrently with, or 1-48 hours prior to, the administration of the agent or treatment that induces the extracellular release of ATP from tumor cells. Optionally, the agent or treatment that induces the extracellular release of ATP from tumor cells is administered at least two times within a two week period following the administration of the anti-CD39 antibody, for example the agent or treatment that induces the extracellular release of ATP from tumor cells can be administered at least once per week.

In any embodiment, the anti-CD39 antibody can be administered in an amount that results in a concentration that is at least the minimum concentration required to substantially fully (e.g. 90%, 95%) occupy (saturate) CD39 protein antibody for one week. In one embodiment, the anti-CD39 antibody can be administered in an amount that results in a concentration that is at least the minimum concentration required to substantially fully (e.g. 90%, 95%) occupy (saturate) CD39 protein antibody for two weeks.

The anti-CD39 antibody compositions, in combination with an agent or treatment that induces the extracellular release of ATP, may optionally be combined (further combined) treatments with one or more other treatment or therapeutic agents, including agents normally utilized for the particular therapeutic purpose for which the antibody is being administered. The additional therapeutic agent will normally be administered in amounts and treatment regimens typically used for that agent in a monotherapy for the particular disease or condition being treated. In one embodiment, the additional therapeutic agent is an agent (e.g., an antibody) that inhibits CTLA-4 or the PD-1 axis (i.e. inhibits PD-1 or PD-L1). Antibodies that bind CTLA-4, PD1 or PD-L1 can be used, for example, at the exemplary the doses and/or frequencies that such agents are used as monotherapy, e.g., as described below. In one embodiment, the additional therapeutic agent is an agent (e.g., an antibody) that binds and neutralizes the 5'-ectonucleotidase activity of human CD73 protein (e.g., a soluble CD73 protein, a CD73 protein expressed by a cell). Human CD73, also known as ecto-5'-nucleotidase and as 5-prime-ribonucleotide phosphohydrolase, EC 3.1.3.5, encoded by the NT5E gene, exhibits 5'-nucleotidase, notably AMP-, NAD-, and NMN-nucleosidase, activities. CD73 catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. The enzyme consists of a dimer of 2 identical 70-kD subunits bound by a glycosyl phosphatidyl inositol linkage to the external face of the plasma membrane. The amino acid sequence of Human CD73 preprotein (monomer), including a signal sequence at amino acids 1-26, is shown in Genbank under accession number NP\_002517, the entire disclosure of which is incorporated herein by reference, and as follows:

VARLFTKVQQ IRRAEPNVLL LDAGDQYQGT IWFTVYKGAE VAHFMNALRY DAMALGNHEF  
DNGVEGLIEP LLKEAKFPIL SANIKAKGPL ASQISGLYLP YKVLPGDEV VGIVGYSKE  
TPFLSNPGTN LVFEDEITAL QPEVDKLKTL NVNKIIALGH SGFEMDKLIA QKVRGVDVVV  
GGHSNTFLYT GNPPSKEVPA GKYPFIVTSD DGRKVPVVQA YAFGKYLGYL KIEFDERGNV  
ISSHGNPILL NSSIPEDPSI KADINKWRIK LDNYSTQELG KTIVYLDGSS QSCRFRNCNM  
GNLICDAMIN NNLRHTDEMF WNHVSMCILN GGGIRSPIDE RNNGTITWEN LAAVLPFGGT  
FDLVQLKGST LKKAFEHHSVH RYGQSTGEFL QVGGIHHVYD LSRKPGDRVV KLDVLCTKCR  
VPSYDPLKMD EVYKVILPNF LANGGDGFQM IKDELLRHDS GDQDINVVST YISKMKVIYP  
AVEGRIKFST GSHCHGSFSL IFLSLWAVIF VLYQ

(SEQ ID NO: 48).

In the context herein, “inhibit”, “inhibiting”, “neutralize” or “neutralizing” when referring to the CD73 polypeptide (e.g., “neutralize CD73”, “neutralize the activity of CD73” or “neutralize the enzymatic activity of CD73”, etc.), refers to a process in which the 5'-nucleotidase (5'-ectonucleotidase) activity of CD73 is inhibited. This comprises, notably the inhibition of CD73-mediated generation of adenosine, i.e. the inhibition of CD73-mediated catabolism of AMP to adenosine. This can be measured for example in a cell-free assay that measures the capacity of a test compound to inhibit the conversion of AMP to adenosine, either directly or indirectly. In one embodiment, an antibody preparation causes at least a 50% decrease in the conversion of AMP to adenosine, at least a 70% decrease in the conversion of AMP to adenosine, or at least an 80% decrease in the conversion of AMP to adenosine, referring, for example, to the assays described herein.

## Examples

### 25 Methods

#### *Generation of CD39 mutants*

CD39 mutants were generated by PCR. The sequences amplified were run on agarose gel and purified using the Macherey Nagel PCR Clean-Up Gel Extraction kit (reference 740609). The purified PCR products generated for each mutant were then ligated into an expression vector, with the ClonTech InFusion system. The vectors containing the mutated sequences were prepared as Miniprep and sequenced. After sequencing, the vectors containing the mutated sequences were prepared as Midiprep using the Promega PureYield™ Plasmid Midiprep System. HEK293T cells were grown in DMEM medium (Invitrogen), transfected with vectors using Invitrogen's Lipofectamine 2000 and incubated at 37°C in a CO2 incubator for 48 hours prior to testing for transgene expression. Mutants were

transfected in Hek-293T cells, as shown in the table below. The targeted amino acid mutations in the table 1 below are shown using numbering of SEQ ID NO: 1.

Table 1

<b><i>Mutant</i></b>	<b><i>Substitutions</i></b>					
<b>1</b>	V77G	H79Q	Q444K	G445D		
<b>2A</b>	V81S	E82A	R111A	V115A		
<b>2B</b>	E110A	R113T	E114A			
<b>3</b>	R118A	S119A	Q120K	Q122H	E123A	
<b>4</b>	D150A	E153S	R154A	S157K	N158A	L278F
<b>5</b>	Q96A	N99A	E143A	R147E		
<b>6</b>	K188R	Replacement of the residues 190 to 207 by KTPGGS				
<b>7</b>	A273S	N275A	I277S	R279A		
<b>8</b>	S294A	K298G	K303A	E306A	T308K	Q312A
<b>9</b>	K288E	K289A	V290A	E315R		
<b>10A</b>	Q354A	D356S	E435A	H436Q		
<b>10B</b>	H428A	T430A	A431D	D432A		
<b>11</b>	N371K	L372K	E375A	K376G	Insertion377V	V377S
<b>12</b>	K388N	Q392K	P393S	E396A		
<b>13</b>	A402P	G403A	K405A	E406A		
<b>15</b>	K87A	E100A	D107A			
<b>16</b>	Q323A	Q324A	Q327A	E331K		
<b>17</b>	N334A	S336A	Y337G	N346A		
<b>18</b>	Q228A	I230S	D234A	Q238A		
<b>19</b>	R138A	M139A	E142K			

*Cloning, production and purification of soluble huCD39*

*Molecular Biology*

The huCD39 protein was cloned from human PBMC cDNA using the following primers TACGACTCACAGCTTGGCCACCATGGAAGATACAAAGGAGTC (SEQ ID NO: 35) (Forward),

CCGCCCCGACTCTAGATCACTTGTCACTCGTCATCTTGTAATCGA

CATAGGTGGAGTGGGAGAG (SEQ ID NO: 36) (Reverse). The purified PCR product was then cloned into an expression vector using the InFusion cloning system. A M2 tag (FLAG

tag, underlined in SEQ ID NO: 39) was added in the C-terminal part of the protein for the purification step; it will be appreciated that a CD39 extracellular domain protein (e.g., of SEQ ID NO: 39) can in any embodiment optionally be specified to lack the M2 tag.

*Expression and purification of the huCD39 proteins*

After validation of the sequence cloned, CHO cells were nucleofected and the producing pool was then sub-cloned to obtain a cell clone producing the huCD39 protein. Supernatant from the huCD39 clone grown in roller was harvested and purified using M2 chromatography column and eluted using the M2 peptide. The purified proteins were then loaded onto a S200 size exclusion chromatography column. The purified protein corresponding to a monomer was formulated in a TBS PH7.5 buffer. The amino acid sequence of the CD39-M2 extracellular domain recombinant protein without M2 tag was as follows:

MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYGIVLDAGSSHTSLYIY  
KWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNEIGIYLTDCMERAREVIPRSQHQETPV  
YLGATAGMRLRMESEELADRVLDVVERSLSNYPFDQGARIITGQEEGAYGWITINYLLGK  
FSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVY  
THSFLCYGKDQALWQKLADIQVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKRFEMTLP  
FQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNL  
TSEKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYILSLLQGYHFTADS  
WEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYV

(SEQ ID NO: 2).

The final amino acid sequence of the CD39-M2 extracellular domain recombinant protein with the M2 tag was as follows:

MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYGIVLDAGSSHTSLYIY  
KWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNEIGIYLTDCMERAREVIPRSQHQETPV  
YLGATAGMRLRMESEELADRVLDVVERSLSNYPFDQGARIITGQEEGAYGWITINYLLGK  
FSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVY  
THSFLCYGKDQALWQKLADIQVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKRFEMTLP  
FQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNL  
TSEKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYILSLLQGYHFTADS  
WEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYVDYKDDDDK  
(SEQ ID NO: 39).

*Inhibition of the enzymatic activity of soluble CD39*

The inhibition by antibodies of the enzymatic activity of soluble CD39 protein produced was evaluated using Cell Titer Glo™ (Promega, reference G7571) that allows

assessment of ATP hydrolysis through use of a reagent that generates a luminescent signal proportional to the amount of ATP present. In this way, inhibition of the soluble-CD39-mediated ATP hydrolysis can be assessed. Briefly, dose ranges of anti-CD39 antibodies from 100  $\mu$ g/ml to  $6 \times 10^{-3}$   $\mu$ g/ml were incubated with 400 ng/ml of soluble recombinant human CD39 protein having the amino acid sequence described in the Methods section (SEQ ID NO: 39), for 1h at 37°C. 20  $\mu$ M ATP was added to the plates for 30 additional minutes at 37°C before addition of CTG (Cell Titer Glo) reagent. Emited light was quantified using an Enspire™ luminometer after a short incubation period of 5 min in the dark. Anti-CD39 antibody efficacy was determined by comparing emitted light in presence of antibody with ATP alone (maximal light emission) and ATP together with soluble CD39 protein (minimal light emission).

#### *Inhibition of the enzymatic activity of cellular CD39*

The inhibition of the CD39 enzymatic activity in CD39-expressing cells by antibodies was evaluated using Cell Titer Glo™ (Promega, reference G7571) that allows assessment of ATP hydrolysis through use of a reagent that generates a luminescent signal proportional to the amount of ATP present. The assay was thus designed to permit assessment of the inhibition of ATP hydrolyzed by CD39 in the cell culture supernatant. Briefly,  $5 \times 10^4$  Ramos human lymphoma cells,  $5 \times 10^3$  human CD39-, cynomolgus CD39 - and mouse CD39-expressing CHO cells, were incubated 1 hour at 37°C with anti-CD39 antibodies from 30  $\mu$ g/ml to  $5 \times 10^{-4}$   $\mu$ g/ml. Cells were then incubated with 20  $\mu$ M ATP for 1 additional hour at 37°C. Plates were centrifuged for 2 min at 400g and 50  $\mu$ l cell supernatant are transferred in a luminescence microplate (white wells). 50  $\mu$ l CellTiter-Glo® Reagent (CTG) was added to the supernatant and emitted light was quantified after a 5 min incubation in the dark using a 25 Enspire™ luminometer. Anti-CD39 antibody efficacy was determined by comparing emitted light in presence of antibody with ATP alone (maximal light emission) and ATP together with cells (minimal light emission).

#### *Generation of antibodies: Immunization and screening in mice*

To obtain anti-human CD39 antibodies, Balb/c mice were immunized with the recombinant human CD39-M2 extracellular domain recombinant protein described above. Mice received one primo-immunization with an emulsion of 50  $\mu$ g CD39 protein and Complete Freund Adjuvant, intraperitoneally, a 2nd immunization with an emulsion of 50  $\mu$ g CD39 protein and Incomplete Freund Adjuvant, intraperitoneally, and finally a boost with 10  $\mu$ g CD39 protein, intravenously. Immune spleen cells were fused 3 days after the boost with X63.Ag8.653 immortalized B cells, and cultured in the presence of irradiated spleen cells.

Hybridomas were plated in semi-solid methylcellulose-containing medium and growing clones were picked using a clonepix 2 apparatus (Molecular Devices).

#### **Example 1: Epitope mapping of known neutralizing CD39 mAbs**

In order to gain insight into how antibodies that are able to inhibit the enzymatic (ATPase) activity of cellular CD39, we investigated the epitopes bound by antibodies that have been reported to inhibit the ATPase activity of CD39 in cellular assays: BY40 disclosed in PCT publication no. WO2009/095478.

In order to define the epitopes of anti-CD39 antibodies, we designed CD39 mutants defined by substitutions of amino acids exposed at the molecular surface over the surface of CD39. Mutants were transfected in Hek-293T cells, as shown in Table 1, using numbering of SEQ ID NO: 1.

Dose-ranges of I-394 (10 – 2.5 – 0.625 – 0.1563 – 0.0391 – 0.0098 – 0.0024 – 0.0006 µg/ml) are tested on the 20 generated mutants by flow cytometry. BY40 antibodies both had complete loss of binding to cells expressing mutant 5 of CD39, without loss of binding to any other mutant. Mutant 5 contains amino acid substitutions at residues Q96, N99, E143 and R147. The position of Mutant 5 on the surface of CD39 is shown in **Figure 3A**.

#### **Example 2: Known neutralizing CD39 mAbs are unable to inhibit the ATPase activity of recombinant soluble CD39 protein**

The two antibodies that have been reported to inhibit the ATPase activity of CD39 in cellular assays (BY40 and BY12) were assessed to determine whether are able to inhibit the ATPase activity of recombinant soluble CD39 protein. The inhibition by antibodies of the enzymatic activity of soluble CD39 protein produced as described above was evaluated using Cell Titer Glo™ (Promega, reference G7571). The inhibition by antibodies of the enzymatic activity of cellular CD39 protein was evaluated as indicated above.

As expected, BY40 inhibited the ATPase activity of CD39 protein in cells. However, BY40 was unable to inhibit the enzymatic activity of soluble CD39 protein. **Figure 2B** shows a comparison of BY40 with the new antibodies identified herein.

#### **Example 3: Screening for new mAbs to block sCD39 activity**

A series of immunizations were carried out in order to seek antibodies that neutralize the ATPase activity of sCD39. To obtain anti-human CD39 antibodies, animals were immunized with the recombinant human CD39-M2 extracellular domain recombinant protein

described above. In total, 15 series of immunizations were carried out using different protocols and in different animals. Included were different mice strains, rats and rabbits.

In initial immunization protocols, the primary screen involved testing supernatant (SN) of growing clones by flow cytometry using wild type CHO and CHO expressing huCD39 cell lines. Cells were stained with 0.1 $\mu$ M and 0.005 $\mu$ M CFSE, respectively. For the flow cytometry screening, all cells were equally mixed and the presence of reacting antibodies in supernatants was revealed by Goat anti-mouse polyclonal antibody (pAb) labeled with APC. For antibodies that bound huCD39, supernatants were then screened for inhibition of the enzymatic activity of soluble CD39 using the screening assay developed and described above (Methods).

Results showed that while numerous specific CD39-binding antibodies could be obtained, none of the antibodies from any of these immunizations showed any inhibition of the enzymatic activity of soluble CD39. One possibility is that dominant epitopes on CD39 do not include any epitopes suitably positioned at or near that catalytic site of CD39. In view of the few antibodies available that inhibit cellular CD39 and the known difficulties in inhibiting the catalytic sites of enzymes using antibodies, the absence of antibodies that neutralize sCD39 may indicate that it is not possible to obtain antibodies that inhibit soluble (extracellular domain) CD39. Other possibilities relate to non-functional screening assays and/or improperly folded or functioning soluble CD39 protein, particularly since the lack of any antibody that can inhibit soluble CD39 hampers validation of sCD39 blockade assays.

In view of the absence of antibodies able to inhibit soluble CD39, a further immunization was carried out with a screening protocol designed to favor the generation of antibodies that bind the active site of CD39 as identified by the epitope of antibody BY40. Briefly, the primary screen involved testing supernatant (SN) of growing clones by flow cytometry using wild type CHO and CHO expressing huCD39 cell lines, as in the preceding immunizations, followed by screening for loss of binding Hek-293T cells expressing CD39 mutant 5, compared to wild-type CD39, as shown in Table 1. Mutant 5 has substitutions at residues Q96, N99, E143 and R147. However, again results showed that while numerous specific CD39-binding antibodies could be obtained that showed loss of binding to mutant 5, none of the antibodies from any of the initial immunizations showed any inhibition of the enzymatic activity of soluble CD39.

#### **Example 4: Identification of a first antibody that inhibits sCD39 activity as part of an epitope-directed screen**

We sought to identify anti-CD39 antibodies that do not bind the Q96, N99, E143 and R147 region (defined by mutant 5) in order to have antibodies that do not compete with

BY40-like antibodies. Such antibodies which need not have any ability to block the ATPase activity of CD39 can be useful for pharmacology studies of antibodies that inhibit cellular CD39 which bind to the BY40 binding site, e.g., to detect and quantify free CD39 proteins on cells in the presence of BY40 or BY40-like antibodies that inhibit cellular CD39.

Starting from the results of the immunization of Example 3 in which hybridomas were screened for loss of binding to CD39 mutant 5, a hybridoma was selected that was not among those that showed loss of binding to CD39 mutant 5. This hybridoma (I-394) was among the broader pool due to inconclusive data indicating possible partial decrease in binding to mutant 5, but did not lose binding to mutant 5 and was therefore not initially retained.

In the context of ongoing screening of supernatants from further immunizations for inhibition of the enzymatic activity of soluble CD39, the antibody I-394 that had been cloned and produced was included as a control. Surprisingly, despite antibody I-394 not being among the clones retained in the epitope-directed screen, this antibody showed strong inhibition of the enzymatic activity of soluble CD39 in the assay described above (Methods).

I-394 was produced with human constant regions of IgG1 isotype, with a modified Fc domain having the mutations L234A/L235E/G237A/A330S/P331S (Kabat EU numbering) which results in lack of binding to human Fc<sub>Y</sub> receptors CD16A, CD16B, CD32A, CD32B and CD64. Briefly, the VH and Vk sequences of the I-394 antibody (the VH and Vk variable regions shown in SEQ ID NOS: 3 and 4, respectively) were cloned into expression vectors containing the hulgG1 constant domains harboring the aforementioned mutations and the huCk constant domain respectively. The two obtained vectors were co-transfected into the CHO cell line. The established pool of cell was used to produce the antibody in the CHO medium. The antibody was then purified using protein A. The amino acid sequences of the respective heavy and light chain variable domains of I-394 are shown below (Kabat CDRs underlined).

25 I-394 heavy chain variable domain sequence:

EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGRTELWIGYIVPLNGGSTFNQKFKGRA  
TLTVNTSSRTAYMELRSLTSEDSAAYYCARGGTRFAYWGQGTLTVSA (SEQ ID NO: 3).

30 I-394 light chain variable domain sequence:

DIVLTQSPASLAVALGQRATISCRASESVDNFGVSFMYWFQQKPGQPPNLLIYGASNQGSGVPARFRG  
SGSGTDFSLNIHPMEADDTAMYFCQQTKEVPYTFGGGTKLEIK (SEQ ID NO: 4).

35 The heavy and light chain sequences of I-394 with human IgG1 constant regions, with L234A/L235E/G237A/A330S/P331S substitutions (retaining N297-linked glycosylation) are shown below:

## I-394 heavy chain sequence:

EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGRTEWIGYIVPLNGGSTFNQKFKGRA  
TLTVNTSSRTAYMELRSLTSEDSAAYYCARGGTRFAYWGQGTLVTVSAASTKGPSVFPLAPSS  
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC  
NVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTPREEQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTI  
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHTQKSLSLSPGK

(SEQ ID NO: 37).

## I-394 light chain sequence:

DIVLTQSPASLAVSLGQRATISCRASESVDNFGVSFMYWFQQKPGQPPNLLIYGASNQGSGVPARFRG  
SGSGTDFSLNIHPMEADDTAMYFCQQTKEVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT  
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSTTLSKADYEKHKVYACEVT  
HQGLSSPVTKSFNRGEC

(SEQ ID NO: 38).

Antibody I-394 was then tested for loss of binding to CD39 mutants defined by substitutions of amino acids exposed at the molecular surface over the surface of CD39. Mutants were transfected in Hek-293T cells, as shown in the table 1, using numbering of SEQ ID NO: 1. Dose-ranges of antibodies I-394 were tested on the 20 mutants by flow cytometry. As shown in **Figure 3B**, I-394 showed complete loss of binding to cells expressing mutant 19 of CD39. Mutant 19 includes substitutions at residues R138, M139 and E142. The core epitope of I-394 thus includes one or more (or all of) residues R138, M139 and E142.

Unlike prior antibody BY40 which loses binding to mutant 5 and has the ability to inhibit cellular CD39 but not soluble CD39, antibody I-394 loses binding to the adjacent mutant 19, with strongly reduced binding to mutant 5 (but with some residual binding to mutant 5). Interestingly, the residues of mutant 19 are in close proximity or adjacent to those of residue 5, such that I-394 may represent a shift in epitope compared to BY40. Antibody I-394 thus presents a valuable new epitope for anti-CD39 antibodies that permits inhibition of the ATPase activity of soluble CD39 protein. It also provides a specific positive control that permits the validation and testing of screening assays for detecting further antibodies that neutralize the ATPase activity of soluble CD39 protein.

25

30

35

**Example 5: A non-epitope directed screen for sCD39-neutralizing mAbs**

Based on the results for Example 4 indicating the antibody-mediated inhibition of soluble CD39 is possible, fusions from the different immunizations using different protocols from Example 3 were revisited in order to seek antibodies that neutralize the ATPase activity of sCD39.

Different approaches for screening for ATPase inhibition were then evaluated. In one experiment, I-394 antibody was used to spike supernatants from hybridomas of an immunization of Example 3 that were found negative for ability to inhibit the ATPase activity of soluble CD39. This addition of I-394 to supernatant did not restore the ability of negative supernatants to inhibit ATPase activity of CD39. Antibody I-394 was then purified from the negative supernatant using Protein A coated beads, and we observed the purified I-394 was again able to inhibit of ATPase activity was restored.

In view of the foregoing results, new immunization and screening protocols were developed in which growing clones from new and past immunizations were screened by flow cytometry using wild type CHO and CHO expressing huCD39 cell lines without assessment of inhibition of soluble CD39 or cellular CD39 ATPase activity, and without screening bias for epitopes. While data regarding loss of binding to mutant 5 or 19 was available for some hybridomas, such data was not used for clone selection but only retained for purposes of rescuing hybridomas for cloning in the event of negative results in the ATPase blocking assay. Hybridomas that bind CD39 were selected and cloned, and then purified using Protein A according to the following protocol:

- Add to 300 µl of hybridomas supernatant 10µl of protein A beads
- Add NaCl to be at a final concentration of 1,5M
- Rotate the tubes for 3-4h at 4°C
- Centrifuge 1 min at 1500 rpm
- Eliminate the supernatant and perform three washes with 1 ml of TBS
- Eliminate all the TBS after the third wash
- Add 50 µl of Citrate 0,1M pH3, homogenize and incubate at RT for 5 min
- Centrifuge the beads for 1 min at 1500 rpm
- Harvest the 50 µl of elution and add rapidly 450 µl of TBS and store at 4°C.

The antibodies obtained were then screened in a comparative assay for the ability to inhibit the ATPase activity of CD39 to a similar degree as I-394. Assays used for inhibition of the enzymatic activity of soluble and cellular CD39 were as described above (Methods). Surprisingly, among the exemplary antibodies produced in this way, several showed inhibition of soluble CD39 (as well as inhibition of cellular CD39). **Figure 1** shows a representative screening result, showing antibodies I-397, I-398 and I-399 compared to positive control I-394 antibody. Similarly, antibodies I-395 and I-396 from different

immunization inhibited the enzymatic activity of soluble CD39 protein. **Figures 2A and 2B** shows results for antibodies I-395 and I-396 for which greater quantities of antibodies were available for additional experiments for both soluble and cellular CD39 neutralization. **Figure 2A** shows that antibodies I-395 and I-396 both inhibit cell-membrane bound CD39 in comparison to BY40 and I-394 antibodies, with both I-394 and I-395 showing greater potency and maximal inhibition of cellular CD39 compared to BY40. **Figure 2B** shows that antibodies I-395 and I-396 both inhibit soluble CD39 in comparison to BY40 and I-394 antibodies. While BY40 does not inhibit soluble CD39 at any concentration, I-394, I-395 and I-396 all inhibit soluble CD39 with I-394 showing the greatest potency, followed by I-395 and then I-396 with lower potency.

The results obtained raise the possibility that factor(s) in hybridoma supernatants are rapidly hydrolyzing ATP in both cell culture and in the soluble CD39 assay, such that no signal for ATP is detected in screening of antibodies using conventional methods. The soluble factor may be CD39 or some other enzyme, for example produced by the fusion partner.

Antibodies were then cloned, with modification to have a human constant regions with an IgG1 Fc domain having the mutations L234A/L235E/G237A/A330S/P331S (Kabat EU numbering) which results in lack of binding to human Fc<sub>Y</sub> receptors CD16A, CD16B, CD32A, CD32B and CD64, in the same way as shown herein for I-394. The resulting antibodies can then be subjected to titrations and then more detailed activity assessment as shown in Example 7-9 (titration, inhibition of ATPase activity) to assess EC<sub>50</sub> and IC<sub>50</sub> determinations to rank antibodies according to potency.

#### **Example 6: Epitope mapping of sCD39 neutralizing mAbs**

As shown in Example 4, I-394 showed complete loss of binding to cells expressing mutant 19 of CD39, but did not lose binding to mutant 5. In order to define the epitopes of the further anti-CD39 antibodies of Example 5, they were tested for loss of binding to the panel of CD39 mutants as described in Example 1 and Table 1. Mutants were transfected in Hek-293T cells, as shown in the table 1, using numbering of SEQ ID NO: 1. Dose-ranges of test antibodies (10 – 2.5 – 0.625 – 0.1563 – 0.0391 – 0.0098 – 0.0024 – 0.0006 µg/ml) are tested on the 20 generated mutants by flow cytometry.

Results showed that the antibodies selected in Example 5 for ability to inhibit soluble CD39 represented several different epitopes. Among the antibodies that showed inhibition of soluble extracellular CD39 in Example 5, antibody I-395 is an example of an antibody that displayed loss of binding to mutant 5 having substitutions at residues Q96, N99, E143 and R147, and also loss of binding to mutant 19 having substitutions at residues R138, M139

and E142. Mutant 19 includes substitutions at residues R138, M139 and E142. The core epitope on CD39 of I-395 thus comprises one, two, three or four of residues Q96, N99, E143 and R147 as well as one, two or three of residues R138, M139 and E142.

Antibody I-398 on the other hand, is an example of an antibody that displayed loss of binding to mutant 19 having substitutions at residues R138, M139 and E142, but does not have decreased or loss of binding to mutant 5 having substitutions at residues Q96, N99, E143 and R147.

Other antibodies that showed inhibition of soluble extracellular CD39 in Example 5 had very different epitopes and did not show loss of binding to either of mutants 5 or 19, suggesting that soluble CD39 can also be inhibited by binding to other sites on sCD39. For some antibodies, loss of binding to one of the 20 mutants of Table 1 permitted the localization of binding site on CD39, while for others the binding site remained to be determined as they did not lose binding to any of the 20 mutants. Among the antibodies showing inhibition of ATPase activity of soluble CD39 in Example 5, antibody I-396 showed loss of binding to mutant 15 having substitutions K87A, E100A and D107A, without loss of binding to any of the other 20 mutants. The core epitope on CD39 of this antibody thus comprises one or more (or all of) residues K87, E100 and D107. Antibody I-399 showed loss of binding to mutant 11 having substitutions N371K, L372K, E375A, K376G, V377A and an insertion of a valine between K376 and V377 (referred to in Table 1 as "insertion 377V"), without loss of binding to any of the other 20 mutants. The core epitope on CD39 of this antibody thus comprises one or more (or all of) residues N371, L372, E375, K376 and V377.

**Figure 3A** shows the position of residues mutated in mutants 5 (M5), 15 (M15) and 19 (M19) on the surface of the CD39 protein. **Figure 3B** shows results of binding to mutants 5, 15 and 19 for different antibodies.

The results thus show that antibodies that inhibit soluble CD39 can be obtained against different epitopes. The epitopes include epitopes defined by one or more residues of mutant 19 which are located adjacent to the binding site of the BY40 or BY40-like antibodies that inhibit only cellular CD39 but not soluble CD39 (which lose binding to mutant 5), epitopes that are defined by one or more residues of mutant 19 but also partly by mutant 5, indicating possibly a smaller shift compared to BY40 or BY40-like antibodies, epitopes defined by one or more residues of mutant 19 and not by residues of mutant 5, as well as other epitopes such as those defined by one or more residues of mutant 11 or one or more residues of mutant 15, or further by other antibodies that do not have any reduced binding to any of mutants 5, 15 or 19 for which localization of epitopes remain to be determined.

**Example 7: Antibody titration on CD39 expressing cells by flow cytometry**

Antibody I-394 was tested in two repeated experiments for binding to CHO cells expressing human CD39, CHO cells expressing cynomolgus (*macaca fascicularis*) CD39, CHO cells expressing murine CD39, and human Ramos lymphoma cells (ATCC™, reference CRL-1596). Cells were incubated with various concentration of unlabeled anti-CD39 antibody from 30 µg/ml to 5x10<sup>-4</sup> µg/ml, for 30 minutes at 4°C. After washes, cells were incubated with Goat anti-mouse H+L labeled secondary antibody for 30min at 4°C.

Results are shown in **Figure 4**. Antibody I-394 bound to cells expressing human CD39 (CHO-huCD39), cells expressing cynomolgus CD39 (CHO-cyCD39) and to Ramos lymphoma cells, but not to cells expressing murine CD39 (CHO-moCD39). I-394 bound to Ramos cells with EC<sub>50</sub> values of 0.16 µg/ml and 0.19 µg/ml in the respective first and second set of experiments. Several other anti-CD39 antibodies showed comparable EC<sub>50</sub> values for binding to Ramos cells.

**Example 8: IC<sub>50</sub> determination for inhibition of cellular ATPase activity**

The inhibition by antibody I-394 of the ATPase activity of CD39 in CD39-expressing cells was evaluated using the assay used for inhibition of the enzymatic activity of cellular CD39 as described above (Methods).

Results are shown in **Figure 5**. I-394 is highly potent at blocking CD39 enzymatic activity in tumor (Ramos) cells, with greater potency compared to all other antibodies tested. I-394 also blocks CD39 enzymatic activity in cells expressing human CD39 (CHO-huCD39), and in cells expressing cynomolgus CD39 (CHO-cyCD39). Cells expressing murine CD39 (CHO-moCD39) are shown as a negative control. The calculated IC<sub>50</sub> (inhibition of 50% of the enzymatic activity of CD39 expressed by 50,000 Ramos cells) is 0.05 µg/ml. The maximum inhibition achieved is 81.6%. Isotype control had no effect.

**Example 9: IC<sub>50</sub> determination for inhibition of the ATPase activity of recombinant soluble CD39 protein**

The inhibition by antibody I-394 of the ATPase activity of soluble CD39 protein was evaluated using the assays used for inhibition of the enzymatic activity of soluble CD39 as described above (Methods). Results are shown in **Figure 6**. I-394 inhibits the enzymatic activity of soluble CD39 protein. Antibody BY40 in comparison did not inhibit the enzymatic activity of soluble CD39 protein. The calculated IC<sub>50</sub> is 0.003 µg/ml. The maximum inhibition achieved is 74.9%.

25

30

35

**Example 10: ELISA titration on CD39-L1, L2, L3, L4 isoforms**

Antibody I-394 was tested for binding to recombinant human CD39 isoforms (Rec-huCD39 isoforms) having amino acid sequences shown below were coated in 96-well plate in PBS 1X at 500ng/ml or 1µg/ml at 4°C overnight. Wells were washed in TBS Tween 20, and further saturated 2H at RT in TBS Blocking buffer. Dose range concentration of primary antibody was incubated in TBS blocking buffer for 2h at RT. Wells were washed in TBS Tween 20. Secondary Antibody (GAM-HRP or GAH-HRP in TBS blocking buffer) was incubated for 1H at RT, and was revealed with TMB. Optical density was measured on Enspire™ at OD=450.

*Amino acid sequence of the cloned huCD39 (vascular isoform):*

Human CD39-L1, also known as NTPDase2 or ENTPD2:

```

1 MAGKVRSLP PLLAAAGLA GLLLLCVPTR DVREPPALKY GIVLDAGSSH TSMFIYKWPA
61 DKENDTIVG QHSSCDVPGG GISSYADNPS GASQSLVGCL EQALQDVPKE RHAGTPLYLG
121 ATAGMRLLN L TNPEASTS VL MAVTHLTQY PFDFRGARIL SGQEEGVFGW VTANYLLENF
181 IKYGVWGRWF RPRKGTLGAM DLGGASTQIT FETTSPAEDR ASEVQLHLYG QHYRVYTHSF
241 LCYGRDQVLQ RLLASALQTH GFHPCWPRGF STQVLLGDVY QSPCTMAQRP QNFNSSARVS
301 LSGSSDPHLC RDLVSGLFSF SSCPFSRCSF NGVFQPPVAG NFVAFSAFFY TVDFLRTSMG
361 LPVATLQQLE AAAVNVCNQT WAQQLLSRGY GFDERAFGGV IFQKKAADTA VGWALGYMLN
421 LTNLIPADPP GLRKGTDFSS WVVL VLLFAS ALLAALVLL RQVHSAKLPS TI
(SEQ ID NO: 40).

```

Human CD39-L2, also known as NTPDase6 or ENTPD6:

```

1 MKKGIRYETS RKTSYIFQQP QHGPWQTRMR KISNHGSLRV AKVAYPLGLC VGVFIYVAYI
61 KWHRATATQA FFSITRAAPG ARWGQQAHSP LGTAADGHEV FYGIMFDAGS TGTRVHFQF
121 TRPPREPTPL THETFKALKP GLSAYADDVE KSAQGIRELL DVAKQDIPFD FWKATPLVLK
181 ATAGLRLLPKG EKAQKLLQKV KEVFKASPFL VGDDCVSIMN GTDEGVSAWI TINFLTGS
241 TPGGSSVGML DLGGGSTQIA FLPRVEGTLQ ASPPGYLTAL RMFNRTYKLY SYSYLGGLM
301 SARLA ILGGV EGQPAKDGKE LVSPCLSPSF KGEWEHAEVT YRVSGQAAA SLHELCAARV
361 SEVLQNRVHR TEEVKHVDFY AFSYYYDAA GVGLIDAEGK GSLVVGDFEI AAKYVCRTLE
421 TQPQSSPFSC MDLTYVSLLL QEEFGFPRSKV LKLTRKIDNV ETSWALGAIF HYIDSLNRQK
481 SPAS
(SEQ ID NO: 41).

```

Human CD39-L3, also known as NTPDase3 or ENTPD3:

```

1 MFTVLRQPC EQAGLKALYR TPTIIALVVL LVSIVVLVSI TVIQIHKQEV LPPGLKYGIV
61 LDAGSSRTTV YYVYQWPAEKE NNTGVVSQTF KCSVKGSGIS SYGNNPQDVP RAFEECMQKV
121 KGQVPSHLHG STPIHLGATA GMRLRLQNE TAANEVLESI QSYFKSQPF DFRGAQIISGQ
181 EEGVYGVITA NYLMGNFLEK NLWHMWVHPH GVETTGALDL GGASTQISFV AGEKMDLNTS
241 DIMQVSLYGY VYTLYTHSFQ CYGRNEAEKK FLAMLLQNSP TKNHLTNPY PRDYSISFTM
301 GHVFDSLCTV DQRPESYNP DNITFEGTGD PSLCKEKVAS IFDFKACHDQ ETCSFDGVYQ
361 PKIKGPFVAF AGFYYTASAL NLSGSFSLDT FNSSTWNFCS QNWSQLPLLL PKFDEVYARS
421 YCFSANYIYH LFVNGYKFT ETWPQIHFEK EVGNSSIAWS LGYMLSLTNQ IPAESPLIRL
481 PIEPPVFVGT LAFFTAAALL CLAFLAYLCS ATRRKRHSEH AFDHAVDSD
(SEQ ID NO: 42).

```

Human CD39-L4, also known as NTPDase5 or ENTPD5:

```

1 MATSWGTVFF MLVVSCVCSA VSHRNQQTWF EGIFLSSMCP INVSASTLYG IMFADGSTGT
61 RIHVYTFVQK MPGQLPILEG EVFDSVKPGL SAFVDQPKQG AETVQGLLEV AKDSIPRSHW
121 KKTPVVLKAT AGLRLLPEHK AKALLFEVKE IFRKSPFLVP KGSVSIMDGS DEGILAWVTV
181 NFLTGQLHGH RQETVGTLQI GGASTQITFL PQFEKTLEQT PRGYLTSFEM FNSTYKLYTH
241 SYLGFGLKAA RLATLGALET EGTDGHTFRS ACLPRWLEAE WIFGGVKYQY GGNQEGERVGF
301 EPCYAEVLRV VRGKLHQPEE VQRGSFYAFS YYYDRAVDTD MIDYEKGIL KVEDFERKAR

```

361 EVCDNLENFT SGSPFLCMDL SYITALLKDG FGFADSTVLQ LTKKVNNIET GWALGATFHL  
421 LQSLGISH  
(SEQ ID NO: 43).

I-394 bound to the CD39 but not to any of the isoforms CD39-L1, -L2, -L3 or -L4. Isotype control antibodies (IC) did not bind to any CD39 or CD39-L molecule. Results are shown in **Figure 7**.

#### **Example 11: Activation of dendritic cells**

While ATP has pro-inflammatory activity, CD39-mediated catabolism of ATP is believed to be able to impair dendritic cell (DC) activation, in turn altering a broader adaptive immune response against tumor antigen. In order to evaluate whether CD39 blockade using anti-CD39 antibodies could overcome CD39-mediated alteration of dendritic cell (DC) activation in the presence of ATP, we incubated monocyte-derived DC (moDC) with anti-CD39 antibodies in the presence of ATP.

Briefly, human monocytes were purified from human healthy blood and differentiated into MoDC in presence of GM-CSF and IL-4 during 6 days. Then MoDC were activated in presence of ATP (Sigma, 0.25 – 1 mM) during 24 hours and DC activation were assessed by analyzing CD80, CD83 and HLA-DR expression by flow cytometry. In some cases, MoDC were preincubated during 1 hours in presence of CD39 inhibitor: ARL6716 (Tocris, 250  $\mu$ M), CD73 inhibitor : APCP (Tocris 50  $\mu$ M), anti-CD39 blocking antibody I-394 or BY40 (for BY40 see WO2009/095478), or anti-CD73 blocking antibodies. LPS (Invivogen, 10 ng/ml) was used as positive control. To assess resulting effect of ATP-mediated DC activation on CD4 T cells activation, ATP-activated DC were washed and then incubated with allogenic CD4 T cells (ratio 1 MoDC / 4 T cells) for a mixed lymphocytes reaction (MLR) during 5 days. T cells activation and proliferation were analyzed through CD25 expression and Cell Trace Violet dilution by flow cytometry (**Figure 8**).

Results are shown in **Figures 9, 10 and 11**. In the presence of negative control (medium), moDC activation was observed in the presence of 1 mM ATP, however ATP at 0.125 mM, 0.25 mM or 0.5mM did not permit moDC activation. Addition of chemical inhibitors of CD39 which are believed to fully block CD39 enzymatic activity by binding to the active site lead to moDC activation at each of 0.125 mM, 0.25 mM or 0.5mM. However, anti-CD39 antibodies such as BY40 or anti-CD73 antibodies were not able to favor ATP-induced activation of dendritic cell (DC), suggesting that antibodies are not able to block enzymatic activity sufficiently to avoid ATP catabolism. Surprisingly, the anti-CD39 blocking antibody I-394 (shown in Figures at concentration 10  $\mu$ g/ml) which substantially fully blocks the ATPase activity of CD39 and can therefore permit accumulation of ATP, permitted moDC activation

as assessed by HLA-DR or CD83 expression at each of 0.125 mM, 0.25 mM or 0.5mM (**Figures 9 and 10**). Interestingly, the MoDC activated in presence of ATP were able to induce better T cells activation and proliferation in a MLR assay. Moreover, the enhancement of ATP-mediated MoDC activation by anti-CD39 blocking antibody I-394 resulted in higher T cells proliferation and activation (**Figure 11**).

Assessment of the ability to CD39 inhibitors to activate DC in the presence of ATP provides a method to identify and evaluate anti-CD39 antibodies that are able to achieve a high degree of inhibition of CD39. Furthermore, the possibility of using anti-CD39 antibodies to relieve the immunosuppressive effect exerted by CD39 upon DC can provide for enhancement of the adaptive immune response toward antigens, notably on tumors cells. Furthermore, such anti-CD39 antibodies may be of particular interest when used to enhance the immunogenic effect of chemotherapeutic agents. Numerous chemotherapeutic agents that cause necrosis of tumor cells are able to induce ATP; combined use with anti-CD39 antibodies can be particularly useful to enhance the anti-tumor response in these settings.

**Example 12: In vivo combination treatment with anti-CD39 antibodies of agents that induce ATP release**

1x10<sup>6</sup> MCA205 mouse tumor cells (sarcoma) were subcutaneously engrafted in the right flank of mice genetically modified to express human CD39 (CD39KI mice). Mice (n= 9 to 13) were either treated with controls, oxaliplatin (10 mg/kg, intraperitoneally, on days 5 and 12 or 14), murine anti-human CD39 antibody I-394 (20 mg/kg for the first injection and then 10 mg/kg, intra-venously, twice a week for 3 or 4 weeks from day 4) or combination of both. Tumors were measured twice a week with a caliper (L: length and w: width) and tumor volume was calculated with the formula (Lxw<sup>2</sup>)/2. Mice were sacrificed when tumor volume was above 1800 mm<sup>3</sup> or when tumors were highly necrosed. The human CD39 KI mice were engrafted with MCA205 tumor cells at day 0. The murine I-394 used was engineered with an aglycosylated mouse IgG1 isotype (substitution at Kabat heavy chain residue N297), in order to prevent mouse FcR and complement binding, such that the only effect observed is linked to the blocking property of the antibody, and not to ADCC or CDC lysis of CD39+ immune suppressor cells or CD39+ endothelial cells.

In a first experimental series, mice were treated at day 5 post tumor cell engraftment with either control (1 group) PBS, or oxaliplatin chemotherapy (2 groups). In parallel, one group of mice treated with oxaliplatin was injected twice a week with anti-CD39 antibody, with the anti-CD39 antibody treatment starting just one day before oxaliplatin treatment (at day 4). This ensured that oxaliplatin induced ATP release in a tumor environment where CD39 was already and fully inhibited, and thus providing optimal

prevention of ATP degradation by intratumoral CD39. In this experiment, a delay of tumor growth and mice survival could be observed in the combination of oxaliplatin and I-394 antibody group, however the delay was deemed relatively modest, even though one Complete Response (CR) was obtained in this group, whereas no CR was observed in the control or oxaliplatin single agent group. Survival median of control was 20 days, oxaliplatin was 25 days and I-394 antibody combined with oxaliplatin was 31 days. Results are shown in **Figure 12**.

In a second experimental series (one representative experiment out of 2 is shown), the oxaliplatin injection was repeated one week after the first oxaliplatin injection, again just one day after the treatment with I-394 antibody, to provide optimal inhibition of ATP degradation. I-394 Ab administered alone had only marginal effect on tumor growth and on mice survival. Oxaliplatin as single agent with repeated (twice) injections did induce some regression of tumor volume, and increase in mice survival. However, the combination of repeated injections of oxaliplatin combined with antibody I-394 administered before oxaliplatin induced tumor volume regression in all mice, with 3 CR compared with 2 with Oxaliplatin alone, and 6 partial responses (PR) versus 3 PR with Oxaliplatin alone. The combination also improved survival of mice, 40 days post tumor engraftment, with 4/13 tumor free mice versus 2/12 in the oxaliplatin alone group. Results are shown in **Figure 13**.

The second repeat injection of oxaliplatin in this setting is believed to allow ATP accumulation and adenosine (Ado) suppression in the presence of blocking anti-CD39 antibody to take place during the classical two week period required to mount an efficient anti-tumor immune response. Consequently, in humans an improved treatment regimen can involve repeating the chemotherapy administration at least twice, in order to see the strongest combination effect with anti-CD39 blocking antibody. Moreover, the anti-CD39 Ab can ideally be administered at least 1-48 h before chemotherapeutic agent inducing ATP release, in order to ensure full inhibition of intratumoral CD39, and full inhibition of ATP degradation into adenosine, at the moment when the chemotherapeutic agent induces ATP release.

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.

Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also provide a corresponding

approximate measurement, modified by "about," where appropriate). Where "about" is used in connection with a number, this can be specified as including values corresponding to +/- 10% of the specified number.

The description herein of any aspect or embodiment of the invention using terms such as "comprising", "having," "including," or "containing" with reference to an element or elements is intended to provide support for a similar aspect or embodiment of the invention that "consists of", "consists essentially of", or "substantially comprises" that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).

The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

**CLAIMS**

1. A method of treating a tumor in a human individual, the treatment comprising administering to the individual an effective amount of each of: (a) an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of ATP, wherein the antibody comprises a HCDR1 comprising an amino acid sequence DYNMH (SEQ ID NO: 5); a HCDR2 comprising an amino acid sequence YIVPLNGGSTFNQFKKG (SEQ ID NO: 6); a HCDR3 comprising an amino acid sequence GGTRFAY (SEQ ID NO: 7); a LCDR1 comprising an amino acid sequence RASESVDNFGVFSFMY (SEQ ID NO: 8); a LCDR2 region comprising an amino acid sequence GASNQGS (SEQ ID NO: 9); and a LCDR3 region comprising an amino acid sequence QQTKEVPYT (SEQ ID NO: 10), and (b) a platinum agent, wherein the antibody and the platinum agent are each administered for at least one administration cycle, the administration cycle comprising at least a first and second administrations of the antibody and the platinum agent.

2. The method of claim 1, wherein the individual has a poor response or prognostic for response to treatment with an agent that induces the extracellular release of ATP from tumor cells, in the absence of combined treatment with an antibody that is capable of binding and neutralizing the ATPase activity of human CD39.

3. The method of claims 1 or 2, wherein the antibody that neutralizes the ATPase activity of human CD39 and the platinum agent are formulated for separate administration and are administered concurrently or sequentially.

4. The method of any one of claims 1-3, wherein the platinum agent is administered 1 to 48 hours after the administration of the antibody that is capable of binding and inhibiting the ATPase activity of CD39.

25 5. The method of any one of claims 1-4, wherein the individual has a solid tumor.

6. The method of any one of claims 1-5, wherein the individual has an ovarian cancer, a gastric cancer, a colon cancer, an esophageal cancer, or a lung cancer.

30 7. The method of any one of claims 1-4, wherein the individual has a hematological tumor.

8. The method of any one of claims 1-7, wherein an antibody that neutralizes the ATPase activity of CD39 substantially lacks binding to human CD16, CD32a, CD32b and/or CD64 polypeptides.

35 9. The method of any one of claims 1-8, wherein said antibody is a chimeric, human or humanized antibody.

10. The method of any one of claims 1-9, wherein said antibody that neutralizes the activity of CD39 is a non-depleting antibody.

11. The method of any one of claims 1-10, wherein said antibody is an antibody fragment is selected from Fab, Fab', Fab'-SH, F(ab') 2, Fv, a diabody, a single-chain antibody fragment, or is a multispecific antibody comprising multiple different antibody fragments.

12. The method of any one of claims 1-11, wherein the antibody comprises a modified human IgG1 Fc domain comprising N-linked glycosylation at Kabat residue N297 and comprising an amino acid substitution at Kabat residue(s) 234 and 235, optionally further at Kabat residue 331, optionally at Kabat residues 234, 235, 237 and at Kabat residues 330 and/or 331, optionally wherein the Fc domain comprises L234A/L235E/P331S substitutions, L234F/L235E/P331S substitutions, L234A/L235E/G237A/P331S substitutions, or L234A/L235E/G237A/A330S/P331S substitutions.

13. The method of any one of claims 2-12, wherein the antibody is administered at least 24 hours or 48 hours prior to the administration of the agent or treatment that induces the extracellular release of ATP.

14. The method of any one of claims 2-13, wherein the agent or treatment that induces the extracellular release of ATP is administered at least twice within a period of two weeks following administration of the antibody.

15. Use of (a) an antibody that is capable of binding and inhibiting the ATPase activity of CD39 in the presence of ATP, wherein the antibody comprises a HCDR1 comprising an amino acid sequence DYNMH (SEQ ID NO: 5); a HCDR2 comprising an amino acid sequence YIVPLNGGSTFNQKFKG (SEQ ID NO: 6); a HCDR3 comprising an amino acid sequence GGTRFAY (SEQ ID NO: 7); a LCDR1 comprising an amino acid sequence RASESVDNFGVSMY (SEQ ID NO: 8); a LCDR2 region comprising an amino acid sequence GASNQGS (SEQ ID NO: 9); and a LCDR3 region comprising an amino acid sequence QQTKEVPYPT (SEQ ID NO: 10), and (b) a platinum agent, in the manufacture of a medicament for treating a tumor in a human individual, wherein the antibody and the platinum agent are each administered for at least one administration cycle, the administration cycle comprising at least a first and second administrations of the antibody and the platinum agent.

16. The use of claim 15 wherein the antibody that neutralizes the ATPase activity of human CD39 and the platinum agent are formulated for separate administration and are administered concurrently or sequentially.

17. The use of claim 15 or claim 16 wherein the individual has an ovarian cancer, a gastric cancer, a colon cancer, an esophageal cancer, or a lung cancer.

18. The use of any one of claims 15 to 17 wherein the antibody comprises a modified human IgG1 Fc domain comprising N-linked glycosylation at Kabat residue N297 and comprising an amino acid substitution at Kabat residue(s) 234 and 235, optionally further at Kabat residue 331, optionally at Kabat residues 234, 235, 237 and at Kabat residues 330 and/or 331, optionally wherein the Fc domain comprises L234A/L235E/P331S substitutions, L234F/L235E/P331S substitutions, L234A/L235E/G237A/P331S substitutions, or L234A/L235E/G237A/A330S/P331S substitutions.

19. The use of any one of claims 16 to 18 wherein the antibody is administered at least 24 hours or 48 hours prior to the administration of the agent or treatment that induces the extracellular release of ATP.

20. The use of any one of claims 16 to 19 wherein the agent or treatment that induces the extracellular release of ATP is administered at least twice within a period of two weeks following administration of the antibody.

Figure 1




Figure 2A




Figure 2B





Figure 3A



C








Figure 3B



	TUBE NAME	Count	Median: Comp-Alexa Fluor 647-A
■	I-396	2487	4343
■	I-395	2565	4237
■	I-394	2151	3716
■	US	1942	10.3

	TUBE NAME	Count	Median: Comp-Alexa Fluor 647-A
■	I-396	2152	8189
■	I-395	2281	52.6
■	I-394	2219	1459
■	US	1524	8.98



	TUBE NAME	Count	Median: Comp-Alexa Fluor 647-A
■	I-396	2186	35.9
■	I-395	2138	5750
■	I-394	2014	6363
■	US	1908	8.98

	TUBE NAME	Count	Median: Comp-Alexa Fluor 647-A
■	I-396	2375	8893
■	I-395	2698	15.4
■	I-394	2611	24.4
■	US	1879	8.98

Figure 4




Figure 5





Figure 6






Figure 8




Figure 9




Figure 10




Figure 11




Figure 12

## Oxa Single Injection day 5





Figure 13

## Oxa Repeated Injections d5, d12



eolf-othd-000002 (3).txt  
SEQUENCE LISTING

<110> INNATE PHARMA

<120> POTENTIATING THE EFFECT OF ATP RELEASE

<130> CD39-8

<150> US 62/586,224

<151> 2017-11-15

<150> US 62/733,175

<151> 2018-09-19

<150> US 62/686,149

<151> 2018-06-18

<160> 48

<170> PatentIn version 3.5

<210> 1

<211> 510

<212> PRT

<213> HOMO SAPIENS

<400> 1

Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn  
1 5 10 15

Ile Leu Ala Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu  
20 25 30

Leu Ala Val Gly Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys  
35 40 45

Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile  
50 55 60

Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln  
65 70 75 80

eolf-othd-000002 (3).txt

Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln  
85 90 95

Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala  
100 105 110

Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu  
115 120 125

Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu  
130 135 140

Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro  
145 150 155 160

Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala  
165 170 175

Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys  
180 185 190

Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr  
195 200 205

Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val  
210 215 220

Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg  
225 230 235 240

Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr  
245 250 255

Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val  
260 265 270

eof-othd-000002 (3).txt

Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys  
275 280 285

Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg  
290 295 300

Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly  
305 310 315 320

Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser  
325 330 335

Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro  
340 345 350

Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys  
355 360 365

Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu  
370 375 380

Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser  
385 390 395 400

Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly  
405 410 415

Thr Tyr Ile Leu Ser Leu Leu Gln Gly Tyr His Phe Thr Ala Asp  
420 425 430

Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala  
435 440 445

Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala  
450 455 460

eolf-othd-000002 (3).txt

Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Tyr Val Phe Leu  
465 470 475 480

Met Val Leu Phe Ser Leu Val Leu Phe Thr Val Ala Ile Ile Gly Leu  
485 490 495

Leu Ile Phe His Lys Pro Ser Tyr Phe Trp Lys Asp Met Val  
500 505 510

<210> 2  
<211> 478  
<212> PRT  
<213> HOMO SAPIENS

<400> 2

Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn  
1 5 10 15

Ile Leu Ala Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu  
20 25 30

Leu Ala Val Gly Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys  
35 40 45

Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile  
50 55 60

Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln  
65 70 75 80

Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln  
85 90 95

Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala  
100 105 110

Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu

eolf-othd-000002 (3).txt

115

120

125

Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu  
130 135 140

Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro  
145 150 155 160

Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala  
165 170 175

Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys  
180 185 190

Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr  
195 200 205

Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val  
210 215 220

Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg  
225 230 235 240

Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr  
245 250 255

Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val  
260 265 270

Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys  
275 280 285

Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg  
290 295 300

Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly

eolf-othd-000002 (3).txt

305 310 315 320

Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser  
325 330 335

Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro  
340 345 350

Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys  
355 360 365

Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu  
370 375 380

Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser  
385 390 395 400

Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly  
405 410 415

Thr Tyr Ile Leu Ser Leu Leu Gln Gly Tyr His Phe Thr Ala Asp  
420 425 430

Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala  
435 440 445

Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala  
450 455 460

Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Tyr Val  
465 470 475

<210> 3  
<211> 116  
<212> PRT  
<213> MUS MUSCULUS

eolf-othd-000002 (3).txt

<400> 3

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
20 25 30

Asn Met His Trp Val Lys Gln Ser His Gly Arg Thr Leu Glu Trp Ile  
35 40 45

Gly Tyr Ile Val Pro Leu Asn Gly Gly Ser Thr Phe Asn Gln Lys Phe  
50 55 60

Lys Gly Arg Ala Thr Leu Thr Val Asn Thr Ser Ser Arg Thr Ala Tyr  
65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Ala Tyr Tyr Cys  
85 90 95

Ala Arg Gly Gly Thr Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ala  
115

<210> 4  
<211> 111  
<212> PRT  
<213> MUS MUSCULUS

<400> 4

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Phe  
20 25 30

eolf-othd-000002 (3).txt

Gly Val Ser Phe Met Tyr Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro  
35 40 45

Asn Leu Leu Ile Tyr Gly Ala Ser Asn Gln Gly Ser Gly Val Pro Ala  
50 55 60

Arg Phe Arg Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His  
65 70 75 80

Pro Met Glu Ala Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Thr Lys  
85 90 95

Glu Val Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105 110

<210> 5  
<211> 5  
<212> PRT  
<213> MUS MUSCULUS

<400> 5

Asp Tyr Asn Met His  
1 5

<210> 6  
<211> 17  
<212> PRT  
<213> Mus musculus

<400> 6

Tyr Ile Val Pro Leu Asn Gly Gly Ser Thr Phe Asn Gln Lys Phe Lys  
1 5 10 15

Gly

<210> 7

eolf-othd-000002 (3).txt

<211> 7  
<212> PRT  
<213> Mus musculus

<400> 7

Gly Gly Thr Arg Phe Ala Tyr  
1 5

<210> 8  
<211> 15  
<212> PRT  
<213> Mus musculus

<400> 8

Arg Ala Ser Glu Ser Val Asp Asn Phe Gly Val Ser Phe Met Tyr  
1 5 10 15

<210> 9  
<211> 7  
<212> PRT  
<213> Mus musculus

<400> 9

Gly Ala Ser Asn Gln Gly Ser  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Mus musculus

<400> 10

Gln Gln Thr Lys Glu Val Pro Tyr Thr  
1 5

<210> 11  
<211> 116  
<212> PRT  
<213> Mus musculus

eolf-othd-000002 (3).txt

<400> 11

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Arg Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
20 25 30

Asn Met His Trp Val Lys Lys Asn His Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asn Thr Ser Ser Lys Thr Ala Tyr  
65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Thr Arg Gly Gly Thr Arg Phe Ala Ser Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ala  
115

<210> 12  
<211> 111  
<212> PRT  
<213> Mus musculus

<400> 12

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr  
20 25 30

eolf-othd-000002 (3).txt

Gly Ile Ser Phe Met Tyr Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro  
35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Thr Gln Gly Ser Gly Val Pro Ala  
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His  
65 70 75 80

Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Lys  
85 90 95

Glu Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
100 105 110

<210> 13

<211> 5

<212> PRT

<213> Mus musculus

<400> 13

Asp Tyr Asn Met His  
1 5

<210> 14

<211> 17

<212> PRT

<213> Mus musculus

<400> 14

Tyr Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys  
1 5 10 15

Gly

<210> 15

eolf-othd-000002 (3).txt

<211> 7  
<212> PRT  
<213> Mus musculus

<400> 15

Gly Gly Thr Arg Phe Ala Ser  
1 5

<210> 16  
<211> 15  
<212> PRT  
<213> Mus musculus

<400> 16

Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Tyr  
1 5 10 15

<210> 17  
<211> 7  
<212> PRT  
<213> Mus musculus

<400> 17

Ala Ala Ser Thr Gln Gly Ser  
1 5

<210> 18  
<211> 9  
<212> PRT  
<213> Mus musculus

<400> 18

Gln Gln Ser Lys Glu Val Pro Phe Thr  
1 5

<210> 19  
<211> 122  
<212> PRT  
<213> Mus musculus

eolf-othd-000002 (3).txt

<400> 19

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Ile Val Ser Gly Phe Asn Ile Lys Asp Thr  
20 25 30

Tyr Ile Asn Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Met Thr Ser Asp Thr Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Leu His Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Trp Gly Tyr Asp Asp Glu Glu Ala Asp Tyr Phe Asp Ser Trp  
100 105 110

Gly Gln Gly Thr Thr Leu Thr Val Ser Ser  
115 120

<210> 20

<211> 111

<212> PRT

<213> Mus musculus

<400> 20

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr  
20 25 30

eolf-othd-000002 (3).txt

Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro  
35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala  
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile Leu  
65 70 75 80

Pro Met Glu Glu Val Asp Ala Ala Met Tyr Phe Cys His Gln Ser Lys  
85 90 95

Glu Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105 110

<210> 21  
<211> 5  
<212> PRT  
<213> Mus musculus

<400> 21

Asp Thr Tyr Ile Asn  
1 5

<210> 22  
<211> 17  
<212> PRT  
<213> Mus musculus

<400> 22

Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln  
1 5 10 15

Gly

<210> 23

eolf-othd-000002 (3).txt

<211> 13  
<212> PRT  
<213> Mus musculus

<400> 23

Trp Gly Tyr Asp Asp Glu Glu Ala Asp Tyr Phe Asp Ser  
1 5 10

<210> 24  
<211> 15  
<212> PRT  
<213> Mus musculus

<400> 24

Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Asn  
1 5 10 15

<210> 25  
<211> 7  
<212> PRT  
<213> Mus musculus

<400> 25

Ala Ala Ser Asn Gln Gly Ser  
1 5

<210> 26  
<211> 9  
<212> PRT  
<213> Mus musculus

<400> 26

His Gln Ser Lys Glu Val Pro Trp Thr  
1 5

<210> 27  
<211> 118  
<212> PRT  
<213> Mus musculus

eolf-othd-000002 (3).txt

<400> 27

Pro Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Met Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Phe  
20 25 30

Trp Met Asn Trp Met Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp Pro Ser Asp Phe Tyr Thr Asn Ser Asn Gln Arg Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg Gly Asp Phe Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr  
100 105 110

Ser Val Thr Val Ser Ser  
115

<210> 28  
<211> 108  
<212> PRT  
<213> Mus musculus

<400> 28

Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Thr Ser Ser Pro Gly  
1 5 10 15

Glu Lys Ile Thr Phe Thr Cys Ser Ala Ser Ser Ser Ile Asn Ser Asn  
20 25 30

eolf-othd-000002 (3).txt

Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu  
35 40 45

Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser  
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu  
65 70 75 80

Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Leu Pro  
85 90 95

Arg Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 29  
<211> 5  
<212> PRT  
<213> Mus musculus

<400> 29

Ser Phe Trp Met Asn  
1 5

<210> 30  
<211> 17  
<212> PRT  
<213> Mus musculus

<400> 30

Glu Ile Asp Pro Ser Asp Phe Tyr Thr Asn Ser Asn Gln Arg Phe Lys  
1 5 10 15

Gly

<210> 31

eolf-othd-000002 (3).txt

<211> 9  
<212> PRT  
<213> Mus musculus

<400> 31

Gly Asp Phe Gly Trp Tyr Phe Asp Val  
1 5

<210> 32  
<211> 12  
<212> PRT  
<213> Mus musculus

<400> 32

Ser Ala Ser Ser Ser Ile Asn Ser Asn Tyr Leu His  
1 5 10

<210> 33  
<211> 7  
<212> PRT  
<213> Mus musculus

<400> 33

Arg Thr Ser Asn Leu Ala Ser  
1 5

<210> 34  
<211> 9  
<212> PRT  
<213> Mus musculus

<400> 34

Gln Gln Gly Ser Ser Leu Pro Arg Thr  
1 5

<210> 35  
<211> 45  
<212> DNA  
<213> HOMO SAPIENS

eolf-othd-000002 (3).txt

<400> 35  
tacgactcac aagcttgcg ccaccatgga agatacaaag gagtc 45

<210> 36  
<211> 64  
<212> DNA  
<213> HOMO SAPIENS

<400> 36  
ccgccccgac tctagatcac ttgtcatcgt catcttgta atcgacatag gtggagtggg 60

agag 64

<210> 37  
<211> 446  
<212> PRT  
<213> Artificial

<220>  
<223> Chimeric homo sapiens mus musculus

<400> 37

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
20 25 30

Asn Met His Trp Val Lys Gln Ser His Gly Arg Thr Leu Glu Trp Ile  
35 40 45

Gly Tyr Ile Val Pro Leu Asn Gly Gly Ser Thr Phe Asn Gln Lys Phe  
50 55 60

Lys Gly Arg Ala Thr Leu Thr Val Asn Thr Ser Ser Arg Thr Ala Tyr  
65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Ala Tyr Tyr Cys  
85 90 95

eolf-othd-000002 (3).txt

Ala Arg Gly Gly Thr Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala  
115 120 125

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu  
130 135 140

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly  
145 150 155 160

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser  
165 170 175

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu  
180 185 190

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr  
195 200 205

Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr  
210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe  
225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro  
245 250 255

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val  
260 265 270

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr  
275 280 285

eolf-othd-000002 (3).txt

Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val  
290 295 300

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys  
305 310 315 320

Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser  
325 330 335

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro  
340 345 350

Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val  
355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly  
370 375 380

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp  
385 390 395 400

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp  
405 410 415

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His  
420 425 430

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
435 440 445

<210> 38

<211> 218

<212> PRT

<213> Artificial

<220>

<223> Chimeric homo sapiens mus musculus

eolf-othd-000002 (3).txt

<400> 38

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Phe  
20 25 30

Gly Val Ser Phe Met Tyr Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro  
35 40 45

Asn Leu Leu Ile Tyr Gly Ala Ser Asn Gln Gly Ser Gly Val Pro Ala  
50 55 60

Arg Phe Arg Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His  
65 70 75 80

Pro Met Glu Ala Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Thr Lys  
85 90 95

Glu Val Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg  
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln  
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr  
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser  
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr  
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys

180

185

190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro  
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
 210 215

<210> 39  
 <211> 486  
 <212> PRT  
 <213> HOMO SAPIENS

<400> 39

Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn  
 1 5 10 15

Ile Leu Ala Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu  
 20 25 30

Leu Ala Val Gly Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys  
 35 40 45

Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile  
 50 55 60

Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln  
 65 70 75 80

Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln  
 85 90 95

Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala  
 100 105 110

Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu  
 115 120 125

eolf-othd-000002 (3).txt

Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu  
130 135 140

Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro  
145 150 155 160

Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala  
165 170 175

Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys  
180 185 190

Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr  
195 200 205

Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val  
210 215 220

Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg  
225 230 235 240

Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr  
245 250 255

Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val  
260 265 270

Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys  
275 280 285

Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg  
290 295 300

Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly  
305 310 315 320

eolf-othd-000002 (3).txt

Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser  
325 330 335

Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro  
340 345 350

Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys  
355 360 365

Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu  
370 375 380

Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser  
385 390 395 400

Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly  
405 410 415

Thr Tyr Ile Leu Ser Leu Leu Gln Gly Tyr His Phe Thr Ala Asp  
420 425 430

Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala  
435 440 445

Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala  
450 455 460

Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Tyr Val Asp Tyr  
465 470 475 480

Lys Asp Asp Asp Asp Lys  
485

<210> 40  
<211> 472

eolf-othd-000002 (3).txt

<212> PRT  
<213> HOMO SAPIENS

<400> 40

Met Ala Gly Lys Val Arg Ser Leu Leu Pro Pro Leu Leu Leu Ala Ala  
1 5 10 15

Ala Gly Leu Ala Gly Leu Leu Leu Cys Val Pro Thr Arg Asp Val  
20 25 30

Arg Glu Pro Pro Ala Leu Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser  
35 40 45

Ser His Thr Ser Met Phe Ile Tyr Lys Trp Pro Ala Asp Lys Glu Asn  
50 55 60

Asp Thr Gly Ile Val Gly Gln His Ser Ser Cys Asp Val Pro Gly Gly  
65 70 75 80

Gly Ile Ser Ser Tyr Ala Asp Asn Pro Ser Gly Ala Ser Gln Ser Leu  
85 90 95

Val Gly Cys Leu Glu Gln Ala Leu Gln Asp Val Pro Lys Glu Arg His  
100 105 110

Ala Gly Thr Pro Leu Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu  
115 120 125

Asn Leu Thr Asn Pro Glu Ala Ser Thr Ser Val Leu Met Ala Val Thr  
130 135 140

His Thr Leu Thr Gln Tyr Pro Phe Asp Phe Arg Gly Ala Arg Ile Leu  
145 150 155 160

Ser Gly Gln Glu Glu Gly Val Phe Gly Trp Val Thr Ala Asn Tyr Leu  
165 170 175

eolf-othd-000002 (3).txt

Leu Glu Asn Phe Ile Lys Tyr Gly Trp Val Gly Arg Trp Phe Arg Pro  
180 185 190

Arg Lys Gly Thr Leu Gly Ala Met Asp Leu Gly Gly Ala Ser Thr Gln  
195 200 205

Ile Thr Phe Glu Thr Thr Ser Pro Ala Glu Asp Arg Ala Ser Glu Val  
210 215 220

Gln Leu His Leu Tyr Gly Gln His Tyr Arg Val Tyr Thr His Ser Phe  
225 230 235 240

Leu Cys Tyr Gly Arg Asp Gln Val Leu Gln Arg Leu Leu Ala Ser Ala  
245 250 255

Leu Gln Thr His Gly Phe His Pro Cys Trp Pro Arg Gly Phe Ser Thr  
260 265 270

Gln Val Leu Leu Gly Asp Val Tyr Gln Ser Pro Cys Thr Met Ala Gln  
275 280 285

Arg Pro Gln Asn Phe Asn Ser Ser Ala Arg Val Ser Leu Ser Gly Ser  
290 295 300

Ser Asp Pro His Leu Cys Arg Asp Leu Val Ser Gly Leu Phe Ser Phe  
305 310 315 320

Ser Ser Cys Pro Phe Ser Arg Cys Ser Phe Asn Gly Val Phe Gln Pro  
325 330 335

Pro Val Ala Gly Asn Phe Val Ala Phe Ser Ala Phe Phe Tyr Thr Val  
340 345 350

Asp Phe Leu Arg Thr Ser Met Gly Leu Pro Val Ala Thr Leu Gln Gln  
355 360 365

eolf-othd-000002 (3).txt

Leu Glu Ala Ala Ala Val Asn Val Cys Asn Gln Thr Trp Ala Gln Gln  
370 375 380

Leu Leu Ser Arg Gly Tyr Gly Phe Asp Glu Arg Ala Phe Gly Gly Val  
385 390 395 400

Ile Phe Gln Lys Lys Ala Ala Asp Thr Ala Val Gly Trp Ala Leu Gly  
405 410 415

Tyr Met Leu Asn Leu Thr Asn Leu Ile Pro Ala Asp Pro Pro Gly Leu  
420 425 430

Arg Lys Gly Thr Asp Phe Ser Ser Trp Val Val Leu Leu Leu Leu Phe  
435 440 445

Ala Ser Ala Leu Leu Ala Ala Leu Val Leu Leu Leu Arg Gln Val His  
450 455 460

Ser Ala Lys Leu Pro Ser Thr Ile  
465 470

<210> 41  
<211> 484  
<212> PRT  
<213> HOMO SAPIENS

<400> 41

Met Lys Lys Gly Ile Arg Tyr Glu Thr Ser Arg Lys Thr Ser Tyr Ile  
1 5 10 15

Phe Gln Gln Pro Gln His Gly Pro Trp Gln Thr Arg Met Arg Lys Ile  
20 25 30

Ser Asn His Gly Ser Leu Arg Val Ala Lys Val Ala Tyr Pro Leu Gly  
35 40 45

eof-othd-000002 (3).txt

Leu Cys Val Gly Val Phe Ile Tyr Val Ala Tyr Ile Lys Trp His Arg  
50 55 60

Ala Thr Ala Thr Gln Ala Phe Phe Ser Ile Thr Arg Ala Ala Pro Gly  
65 70 75 80

Ala Arg Trp Gly Gln Gln Ala His Ser Pro Leu Gly Thr Ala Ala Asp  
85 90 95

Gly His Glu Val Phe Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr Gly  
100 105 110

Thr Arg Val His Val Phe Gln Phe Thr Arg Pro Pro Arg Glu Thr Pro  
115 120 125

Thr Leu Thr His Glu Thr Phe Lys Ala Leu Lys Pro Gly Leu Ser Ala  
130 135 140

Tyr Ala Asp Asp Val Glu Lys Ser Ala Gln Gly Ile Arg Glu Leu Leu  
145 150 155 160

Asp Val Ala Lys Gln Asp Ile Pro Phe Asp Phe Trp Lys Ala Thr Pro  
165 170 175

Leu Val Leu Lys Ala Thr Ala Gly Leu Arg Leu Leu Pro Gly Glu Lys  
180 185 190

Ala Gln Lys Leu Leu Gln Lys Val Lys Glu Val Phe Lys Ala Ser Pro  
195 200 205

Phe Leu Val Gly Asp Asp Cys Val Ser Ile Met Asn Gly Thr Asp Glu  
210 215 220

Gly Val Ser Ala Trp Ile Thr Ile Asn Phe Leu Thr Gly Ser Leu Lys  
225 230 235 240

eolf-othd-000002 (3).txt

Thr Pro Gly Gly Ser Ser Val Gly Met Leu Asp Leu Gly Gly Gly Ser  
245 250 255

Thr Gln Ile Ala Phe Leu Pro Arg Val Glu Gly Thr Leu Gln Ala Ser  
260 265 270

Pro Pro Gly Tyr Leu Thr Ala Leu Arg Met Phe Asn Arg Thr Tyr Lys  
275 280 285

Leu Tyr Ser Tyr Ser Tyr Leu Gly Leu Gly Leu Met Ser Ala Arg Leu  
290 295 300

Ala Ile Leu Gly Gly Val Glu Gly Gln Pro Ala Lys Asp Gly Lys Glu  
305 310 315 320

Leu Val Ser Pro Cys Leu Ser Pro Ser Phe Lys Gly Glu Trp Glu His  
325 330 335

Ala Glu Val Thr Tyr Arg Val Ser Gly Gln Lys Ala Ala Ala Ser Leu  
340 345 350

His Glu Leu Cys Ala Ala Arg Val Ser Glu Val Leu Gln Asn Arg Val  
355 360 365

His Arg Thr Glu Glu Val Lys His Val Asp Phe Tyr Ala Phe Ser Tyr  
370 375 380

Tyr Tyr Asp Leu Ala Ala Gly Val Gly Leu Ile Asp Ala Glu Lys Gly  
385 390 395 400

Gly Ser Leu Val Val Gly Asp Phe Glu Ile Ala Ala Lys Tyr Val Cys  
405 410 415

Arg Thr Leu Glu Thr Gln Pro Gln Ser Ser Pro Phe Ser Cys Met Asp  
420 425 430

eolf-othd-000002 (3).txt

Leu Thr Tyr Val Ser Leu Leu Leu Gln Glu Phe Gly Phe Pro Arg Ser  
435 440 445

Lys Val Leu Lys Leu Thr Arg Lys Ile Asp Asn Val Glu Thr Ser Trp  
450 455 460

Ala Leu Gly Ala Ile Phe His Tyr Ile Asp Ser Leu Asn Arg Gln Lys  
465 470 475 480

Ser Pro Ala Ser

<210> 42  
<211> 529  
<212> PRT  
<213> HOMO SAPIENS  
  
<400> 42

Met Phe Thr Val Leu Thr Arg Gln Pro Cys Glu Gln Ala Gly Leu Lys  
1 5 10 15

Ala Leu Tyr Arg Thr Pro Thr Ile Ile Ala Leu Val Val Leu Leu Val  
20 25 30

Ser Ile Val Val Leu Val Ser Ile Thr Val Ile Gln Ile His Lys Gln  
35 40 45

Glu Val Leu Pro Pro Gly Leu Lys Tyr Gly Ile Val Leu Asp Ala Gly  
50 55 60

Ser Ser Arg Thr Thr Val Tyr Val Tyr Gln Trp Pro Ala Glu Lys Glu  
65 70 75 80

Asn Asn Thr Gly Val Val Ser Gln Thr Phe Lys Cys Ser Val Lys Gly  
85 90 95

Ser Gly Ile Ser Ser Tyr Gly Asn Asn Pro Gln Asp Val Pro Arg Ala

100

105

110

Phe Glu Glu Cys Met Gln Lys Val Lys Gly Gln Val Pro Ser His Leu  
 115 120 125

His Gly Ser Thr Pro Ile His Leu Gly Ala Thr Ala Gly Met Arg Leu  
 130 135 140

Leu Arg Leu Gln Asn Glu Thr Ala Ala Asn Glu Val Leu Glu Ser Ile  
 145 150 155 160

Gln Ser Tyr Phe Lys Ser Gln Pro Phe Asp Phe Arg Gly Ala Gln Ile  
 165 170 175

Ile Ser Gly Gln Glu Glu Gly Val Tyr Gly Trp Ile Thr Ala Asn Tyr  
 180 185 190

Leu Met Gly Asn Phe Leu Glu Lys Asn Leu Trp His Met Trp Val His  
 195 200 205

Pro His Gly Val Glu Thr Thr Gly Ala Leu Asp Leu Gly Gly Ala Ser  
 210 215 220

Thr Gln Ile Ser Phe Val Ala Gly Glu Lys Met Asp Leu Asn Thr Ser  
 225 230 235 240

Asp Ile Met Gln Val Ser Leu Tyr Gly Tyr Val Tyr Thr Leu Tyr Thr  
 245 250 255

His Ser Phe Gln Cys Tyr Gly Arg Asn Glu Ala Glu Lys Lys Phe Leu  
 260 265 270

Ala Met Leu Leu Gln Asn Ser Pro Thr Lys Asn His Leu Thr Asn Pro  
 275 280 285

Cys Tyr Pro Arg Asp Tyr Ser Ile Ser Phe Thr Met Gly His Val Phe

eolf-othd-000002 (3).txt

290

295

300

Asp Ser Leu Cys Thr Val Asp Gln Arg Pro Glu Ser Tyr Asn Pro Asn  
305 310 315 320

Asp Val Ile Thr Phe Glu Gly Thr Gly Asp Pro Ser Leu Cys Lys Glu  
325 330 335

Lys Val Ala Ser Ile Phe Asp Phe Lys Ala Cys His Asp Gln Glu Thr  
340 345 350

Cys Ser Phe Asp Gly Val Tyr Gln Pro Lys Ile Lys Gly Pro Phe Val  
355 360 365

Ala Phe Ala Gly Phe Tyr Tyr Thr Ala Ser Ala Leu Asn Leu Ser Gly  
370 375 380

Ser Phe Ser Leu Asp Thr Phe Asn Ser Ser Thr Trp Asn Phe Cys Ser  
385 390 395 400

Gln Asn Trp Ser Gln Leu Pro Leu Leu Pro Lys Phe Asp Glu Val  
405 410 415

Tyr Ala Arg Ser Tyr Cys Phe Ser Ala Asn Tyr Ile Tyr His Leu Phe  
420 425 430

Val Asn Gly Tyr Lys Phe Thr Glu Glu Thr Trp Pro Gln Ile His Phe  
435 440 445

Glu Lys Glu Val Gly Asn Ser Ser Ile Ala Trp Ser Leu Gly Tyr Met  
450 455 460

Leu Ser Leu Thr Asn Gln Ile Pro Ala Glu Ser Pro Leu Ile Arg Leu  
465 470 475 480

Pro Ile Glu Pro Pro Val Phe Val Gly Thr Leu Ala Phe Phe Thr Ala

Ala Ala Leu Leu Cys Leu Ala Phe Leu Ala Tyr Leu Cys Ser Ala Thr  
 500 505 510

Arg Arg Lys Arg His Ser Glu His Ala Phe Asp His Ala Val Asp Ser  
 515 520 525

Asp

<210> 43  
 <211> 428  
 <212> PRT  
 <213> HOMO SAPIENS

<400> 43

Met Ala Thr Ser Trp Gly Thr Val Phe Phe Met Leu Val Val Ser Cys  
 1 5 10 15

Val Cys Ser Ala Val Ser His Arg Asn Gln Gln Thr Trp Phe Glu Gly  
 20 25 30

Ile Phe Leu Ser Ser Met Cys Pro Ile Asn Val Ser Ala Ser Thr Leu  
 35 40 45

Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr Gly Thr Arg Ile His Val  
 50 55 60

Tyr Thr Phe Val Gln Lys Met Pro Gly Gln Leu Pro Ile Leu Glu Gly  
 65 70 75 80

Glu Val Phe Asp Ser Val Lys Pro Gly Leu Ser Ala Phe Val Asp Gln  
 85 90 95

Pro Lys Gln Gly Ala Glu Thr Val Gln Gly Leu Leu Glu Val Ala Lys  
 100 105 110

eolf-othd-000002 (3).txt

Asp Ser Ile Pro Arg Ser His Trp Lys Lys Thr Pro Val Val Leu Lys  
115 120 125

Ala Thr Ala Gly Leu Arg Leu Leu Pro Glu His Lys Ala Lys Ala Leu  
130 135 140

Leu Phe Glu Val Lys Glu Ile Phe Arg Lys Ser Pro Phe Leu Val Pro  
145 150 155 160

Lys Gly Ser Val Ser Ile Met Asp Gly Ser Asp Glu Gly Ile Leu Ala  
165 170 175

Trp Val Thr Val Asn Phe Leu Thr Gly Gln Leu His Gly His Arg Gln  
180 185 190

Glu Thr Val Gly Thr Leu Asp Leu Gly Gly Ala Ser Thr Gln Ile Thr  
195 200 205

Phe Leu Pro Gln Phe Glu Lys Thr Leu Glu Gln Thr Pro Arg Gly Tyr  
210 215 220

Leu Thr Ser Phe Glu Met Phe Asn Ser Thr Tyr Lys Leu Tyr Thr His  
225 230 235 240

Ser Tyr Leu Gly Phe Gly Leu Lys Ala Ala Arg Leu Ala Thr Leu Gly  
245 250 255

Ala Leu Glu Thr Glu Gly Thr Asp Gly His Thr Phe Arg Ser Ala Cys  
260 265 270

Leu Pro Arg Trp Leu Glu Ala Glu Trp Ile Phe Gly Gly Val Lys Tyr  
275 280 285

Gln Tyr Gly Gly Asn Gln Glu Gly Glu Val Gly Phe Glu Pro Cys Tyr  
290 295 300

eolf-othd-000002 (3).txt

Ala Glu Val Leu Arg Val Val Arg Gly Lys Leu His Gln Pro Glu Glu  
305 310 315 320

Val Gln Arg Gly Ser Phe Tyr Ala Phe Ser Tyr Tyr Tyr Asp Arg Ala  
325 330 335

Val Asp Thr Asp Met Ile Asp Tyr Glu Lys Gly Gly Ile Leu Lys Val  
340 345 350

Glu Asp Phe Glu Arg Lys Ala Arg Glu Val Cys Asp Asn Leu Glu Asn  
355 360 365

Phe Thr Ser Gly Ser Pro Phe Leu Cys Met Asp Leu Ser Tyr Ile Thr  
370 375 380

Ala Leu Leu Lys Asp Gly Phe Gly Phe Ala Asp Ser Thr Val Leu Gln  
385 390 395 400

Leu Thr Lys Lys Val Asn Asn Ile Glu Thr Gly Trp Ala Leu Gly Ala  
405 410 415

Thr Phe His Leu Leu Gln Ser Leu Gly Ile Ser His  
420 425

<210> 44  
<211> 330  
<212> PRT  
<213> HOMO SAPIENS

<400> 44

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
20 25 30

eolf-othd-000002 (3).txt

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
100 105 110

Pro Ala Pro Glu Ala Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro  
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
195 200 205

Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
210 215 220

eolf-othd-000002 (3).txt

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu  
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn  
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
325 330

<210> 45

<211> 330

<212> PRT

<213> HOMO SAPIENS

<400> 45

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
35 40 45

eolf-othd-000002 (3).txt

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
100 105 110

Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro  
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
195 200 205

Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu  
225 230 235 240

eolf-othd-000002 (3).txt

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn  
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
325 330

<210> 46  
<211> 330  
<212> PRT  
<213> HOMO SAPIENS

<400> 46

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

eolf-othd-000002 (3).txt

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
100 105 110

Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro  
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
195 200 205

Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu  
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

eolf-othd-000002 (3).txt

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
325 330

<210> 47

<211> 330

<212> PRT

<213> HOMO SAPIENS

<400> 47

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
85 90 95

eolf-othd-000002 (3).txt

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
100 105 110

Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro  
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
195 200 205

Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu  
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn  
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
275 280 285

eolf-othd-000002 (3).txt

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
325 330

<210> 48  
<211> 574  
<212> PRT  
<213> homo sapiens

<400> 48

Met Cys Pro Arg Ala Ala Arg Ala Pro Ala Thr Leu Leu Leu Ala Leu  
1 5 10 15

Gly Ala Val Leu Trp Pro Ala Ala Gly Ala Trp Glu Leu Thr Ile Leu  
20 25 30

His Thr Asn Asp Val His Ser Arg Leu Glu Gln Thr Ser Glu Asp Ser  
35 40 45

Ser Lys Cys Val Asn Ala Ser Arg Cys Met Gly Gly Val Ala Arg Leu  
50 55 60

Phe Thr Lys Val Gln Gln Ile Arg Arg Ala Glu Pro Asn Val Leu Leu  
65 70 75 80

Leu Asp Ala Gly Asp Gln Tyr Gln Gly Thr Ile Trp Phe Thr Val Tyr  
85 90 95

Lys Gly Ala Glu Val Ala His Phe Met Asn Ala Leu Arg Tyr Asp Ala  
100 105 110

eolf-othd-000002 (3).txt

Met Ala Leu Gly Asn His Glu Phe Asp Asn Gly Val Glu Gly Leu Ile  
115 120 125

Glu Pro Leu Leu Lys Glu Ala Lys Phe Pro Ile Leu Ser Ala Asn Ile  
130 135 140

Lys Ala Lys Gly Pro Leu Ala Ser Gln Ile Ser Gly Leu Tyr Leu Pro  
145 150 155 160

Tyr Lys Val Leu Pro Val Gly Asp Glu Val Val Gly Ile Val Gly Tyr  
165 170 175

Thr Ser Lys Glu Thr Pro Phe Leu Ser Asn Pro Gly Thr Asn Leu Val  
180 185 190

Phe Glu Asp Glu Ile Thr Ala Leu Gln Pro Glu Val Asp Lys Leu Lys  
195 200 205

Thr Leu Asn Val Asn Lys Ile Ile Ala Leu Gly His Ser Gly Phe Glu  
210 215 220

Met Asp Lys Leu Ile Ala Gln Lys Val Arg Gly Val Asp Val Val Val  
225 230 235 240

Gly Gly His Ser Asn Thr Phe Leu Tyr Thr Gly Asn Pro Pro Ser Lys  
245 250 255

Glu Val Pro Ala Gly Lys Tyr Pro Phe Ile Val Thr Ser Asp Asp Gly  
260 265 270

Arg Lys Val Pro Val Val Gln Ala Tyr Ala Phe Gly Lys Tyr Leu Gly  
275 280 285

Tyr Leu Lys Ile Glu Phe Asp Glu Arg Gly Asn Val Ile Ser Ser His  
290 295 300

eolf-othd-000002 (3).txt

Gly Asn Pro Ile Leu Leu Asn Ser Ser Ile Pro Glu Asp Pro Ser Ile  
305 310 315 320

Lys Ala Asp Ile Asn Lys Trp Arg Ile Lys Leu Asp Asn Tyr Ser Thr  
325 330 335

Gln Glu Leu Gly Lys Thr Ile Val Tyr Leu Asp Gly Ser Ser Gln Ser  
340 345 350

Cys Arg Phe Arg Glu Cys Asn Met Gly Asn Leu Ile Cys Asp Ala Met  
355 360 365

Ile Asn Asn Asn Leu Arg His Thr Asp Glu Met Phe Trp Asn His Val  
370 375 380

Ser Met Cys Ile Leu Asn Gly Gly Ile Arg Ser Pro Ile Asp Glu  
385 390 395 400

Arg Asn Asn Gly Thr Ile Thr Trp Glu Asn Leu Ala Ala Val Leu Pro  
405 410 415

Phe Gly Gly Thr Phe Asp Leu Val Gln Leu Lys Gly Ser Thr Leu Lys  
420 425 430

Lys Ala Phe Glu His Ser Val His Arg Tyr Gly Gln Ser Thr Gly Glu  
435 440 445

Phe Leu Gln Val Gly Gly Ile His Val Val Tyr Asp Leu Ser Arg Lys  
450 455 460

Pro Gly Asp Arg Val Val Lys Leu Asp Val Leu Cys Thr Lys Cys Arg  
465 470 475 480

Val Pro Ser Tyr Asp Pro Leu Lys Met Asp Glu Val Tyr Lys Val Ile  
485 490 495

eolf-othd-000002 (3).txt

Leu Pro Asn Phe Leu Ala Asn Gly Gly Asp Gly Phe Gln Met Ile Lys  
500 505 510

Asp Glu Leu Leu Arg His Asp Ser Gly Asp Gln Asp Ile Asn Val Val  
515 520 525

Ser Thr Tyr Ile Ser Lys Met Lys Val Ile Tyr Pro Ala Val Glu Gly  
530 535 540

Arg Ile Lys Phe Ser Thr Gly Ser His Cys His Gly Ser Phe Ser Leu  
545 550 555 560

Ile Phe Leu Ser Leu Trp Ala Val Ile Phe Val Leu Tyr Gln  
565 570